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ABSTRACT
Type 1 diabetes (T1D) is one of the most frequently diagnosed chronic illnesses
among youth, and has many long-term complications, including retinopathy, neuropathy,
and cardiovascular disease. The risk of these complications may be reduced through
maintaining glycemic control and one potential risk factor for failure to achieve optimal
glycemic control is elevated depressive symptoms among youth and young adults (YYA)
with T1D. YYA with T1D are at increased risk of depression, which has been associated
with adverse outcomes such as poor adherence to self-management and poor glycemic
control. Although a robust body of research exists on the association between comorbid
depression and glycemic control among persons with T1D, little research has been
conducted on the change in depressive symptoms over time among YYA with T1D. Of
interest in the current investigation is whether there are subgroups of individuals among
YYA with T1D who demonstrate distinct trajectories of depressive symptoms over time,
whether there are baseline predictors of these trajectory groups, and whether trajectory
groups predict two health outcomes: glycemic control and arterial stiffness, a precursor to
cardiovascular disease.
Using data from YYA recently diagnosed with T1D who were enrolled in the
SEARCH for Diabetes in Youth Study between 2002-2005, we identified five depressive
symptom trajectories with group-based trajectory modeling based on Center for
Epidemiologic Studies - Depression (CES-D) scores collected at up to four timepoints
iv

over a five-year period. Most of the sample reported little to no or minimal depressive
symptoms at any timepoint, whereas a small proportion of the sample reported potentially
clinically significant symptoms – either decreasing from mild to minimal, increasing
from mild to moderate, or chronic, moderate symptoms. The baseline predictors that
differentiated between those who report little to no symptoms and those who report
clinically significant symptoms include female sex, experiencing at least one severe
hypoglycemic and/or diabetic ketoacidosis episode, living in a single-parent home, using
psychiatric medications, and cigarette use. We found that depressive symptom trajectory
groups were associated with glycemic control, such that those who report stable minimal
and decreasing mild to minimal depressive symptoms were more likely to demonstrate
high-risk glycemic control compared to those who reported little to no depressive
symptoms. There were no significant differences in arterial stiffness among the
depressive symptom trajectory groups.
This dissertation has implications for improving the understanding of the course,
predictors, and health outcomes of depressive symptoms among YYA with T1D. We
found that most YYA with T1D do not experience clinically significant depressive
symptoms during the first five years following diabetes diagnosis; however, around 8%
reported either increasing mild to moderate symptoms or chronic moderate symptoms
during this timeframe. Therefore, it is important that YYA with T1D are screened for
depression during visits with their health provider and that appropriate resources are
available to treat depression in this population. Further research is needed to clarify the
association between depressive symptom trajectories and health outcomes, as our results
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showed that high-risk glycemic control and arterial stiffness were not elevated among
those with the greatest burden of depressive symptoms.
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CHAPTER 1
INTRODUCTION
Type 1 diabetes (T1D) is one of the most frequently diagnosed chronic illnesses
among adolescents, with approximately 1 in 518 youths younger than 20 years of age
being affected as of 2009.1 Incidence among adolescents has also been increasing over
time.2 T1D has many potentially serious short-term and long-term complications,
including severe hypoglycemia, potentially resulting in loss of consciousness and severe
hyperglycemia, resulting in the potentially life-threatening condition of diabetic
ketoacidosis, retinopathy, neuropathy, nephropathy, cardiovascular disease, and
amputation.3 One potential risk factor for failure to achieve and maintain glycemic
control and for increased risk of these complications is elevated depressive symptoms
among adolescents with T1D.4
Research has shown that those living with T1D are often at increased risk of
depression and subclinical levels of depressive symptomology.5 Depression and
depressive symptomology among adolescents with T1D has been associated with poor
adherence to self-management, poor glycemic control and increased hospital and
emergency room visits.4,6–8 Although a body of research has been conducted on the
effects of comorbid depression on health outcomes among people with type 1 diabetes,
little research has been conducted on the change in depressive symptoms over time
among youth and young adults (YYA) with T1D.
1

Previous research has examined longitudinal trajectories of depression and
depressive symptoms among adults9,10 and adolescents11,12 and their effects on physical
and mental health; however, no studies have examined these trajectories among YYA with
T1D. Depressive symptom trajectories among YYA with T1D have implications for the
management and control of T1D, and the prevention of diabetes complications.
Understanding the composition of the distinct trajectories of depressive symptoms, and
their effects on health outcomes will further clarify the role of depressive symptoms in
diabetes care and outcomes among YYA with T1D.
The outcomes of focus in this study are glycemic control and macrovascular
complications of T1D, measured by arterial stiffness. Glycemic control is a frequently
used indicator to assess the success of diabetes management, and thus provides a good
measure of adequate management of blood glucose. Glycemic control is also predictive
of future occurrence of complications,13 and is thus often used as an intermediate
outcome to indicate the degree of risk for complications.
Macrovascular outcomes have been associated with both T1D and with
depression, independently. Particularly, arterial stiffness, as measured by Pulse Wave
Velocity (PWV), is an indicator of future risk for cardiovascular disease and
mortality.14,15 Previous research has shown that arterial stiffness is increased in YYA
with T1D,16 and in YYA with increased depressive symptoms.17 This study will address
whether longitudinal trajectories of depressive symptoms are associated with arterial
stiffness, a marker of cardiovascular risk.
The aims of this study are to 1) identify the longitudinal trajectories, or patterns,
of depressive symptoms experienced by YYA with T1D ranging in age from 10 – 30
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years, 2) understand the baseline characteristics associated with depressive symptom
trajectory groups, and 3) to assess the effects of depressive symptom trajectory groups on
glycemic control and arterial stiffness.
Specific Aims
Aim 1: To define longitudinal trajectories of depressive symptoms, as measured by the
Center for Epidemiologic Studies – Depression (CES-D) scale occurring among YYA
ranging in age from 10-30 years with T1D.
Hypothesis: The change in depressive symptoms over time in YYA with T1D
will fall into distinctive trajectories. Hypothesized trajectories included increasing
depressive symptoms over time, decreasing depressive symptoms over time, stable – little
to no depressive symptoms, and stable – mild-moderate depressive symptoms.
Implications: Depression, and elevated depressive symptoms, pose threats to
public health in that they are associated with increased reports of physical symptoms,
risky behaviors, physical inactivity, suicide, and other poor health outcomes.18,19 Among
YYA with T1D, depressive symptoms have also been associated with diabetes
complications, posing potential increased risks for poor health outcomes among this
population compared to YYA without T1D.20,21 Understanding how depressive symptoms
change over time among YYA with T1D helps to characterize the burden of depressive
symptoms in this population over time to improve understanding of the potential health
risks posed by depressive symptomology in YYA with T1D.
Aim 2: To identify baseline correlates of longitudinal depressive symptom trajectory
groups among YYA ranging in age from 10-30 years with T1D.
Hypothesis: Baseline measurements of demographic and socioeconomic
characteristics (age at diagnosis, sex, race/ethnicity, parental education, household
3

income, family structure, insurance status), diabetes self-care (insulin regimen,
hypoglycemic episodes, diabetic ketoacidosis episodes, frequency of blood glucose
monitoring), and other clinical and behavioral characteristics (BMI, tobacco use, physical
activity, and use of antidepressant medications) will be correlated with depressive
symptom trajectory groups.
Implications: By identifying baseline predictors of longitudinal depressive
symptom trajectories, we are able to identify groups who are at greater risk of
experiencing a high burden of depressive symptoms over time. This analysis provides
insight into both the identification of high-risk groups and potential targets for prevention
of persistent depressive symptoms.
Aim 3: To determine whether depressive symptom trajectory group predicts glycemic
control (as measured by hemoglobin A1c; HbA1C) among YYA ranging in age from 1030 years with T1D.
Hypothesis: Depressive symptom trajectory groups will predict glycemic control
(HbA1C), such that trajectories indicating a greater burden of depressive symptoms over
time will be associated with poor glycemic control.
Implications: Although most of the literature examining the association between
depressive symptoms and glycemic control suggests that increased depressive symptoms
are associated with poor glycemic control, there are some inconsistencies.21 Because
most prior research into this association has been cross-sectional in nature with relatively
small sample size, this analysis adds to the literature by utilizing longitudinal data
examining trajectories of depressive symptoms rather than symptoms measured at a
single timepoint.
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Aim 4: To determine whether depressive symptom trajectory group predicts arterial
stiffness, as measured by Pulse Wave Velocity (PWV) among YYA ranging in age from
10-30 years with T1D.
Hypothesis: Depressive symptom trajectory groups will predict increased arterial
stiffness, as measured by PWV, such that trajectories indicating a greater burden of
depressive symptoms over time will be associated with increased PWV.
Implications: Arterial stiffness is a predictor of future cardiovascular disease
among YYA,22 and YYA with T1D typically have elevated arterial stiffness compared to
their healthy peers.23 No previous research has examined whether depressive symptoms
are associated with elevated arterial stiffness among YYA with T1D. If this analysis
demonstrates increased risk of elevated arterial stiffness among those with persistently
high depressive symptoms, this will contribute to the literature on risk factors of
cardiovascular disease in YYA with T1D and suggest an area for potential intervention to
prevent or slow the development of arterial stiffness in this population.
Conceptual Framework
Figure 1.1 provides an overview of the conceptual framework which describes the
impact of depressive symptoms on diabetes care and outcomes, adopted from work
conducted by Piette et al.24 and Snoek et al.25 summarizing the mechanisms through
which depression affects diabetes management and outcomes. According to this
framework, demographic, socioeconomic, and behavioral characteristics influence the
occurrence of depressive symptoms. Depressive symptoms, in turn, influence behavioral
as well as clinical characteristics, such as performance of self-care behaviors and
occurrence of hypo- and hyperglycemia. These clinical and behavioral characteristics
influence the occurrence of physiologic outcomes, such as glycemic control and arterial
5

stiffness. Depressive symptoms may also directly influence the occurrence of these
physiologic outcomes, which may in turn influence the development of depressive
symptoms.

6
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Figure 1.1: Conceptual Framework

CHAPTER 2
LITERATURE REVIEW
Type 1 Diabetes
Definition
T1D is an autoimmune disorder characterized by a lack of insulin production
caused by destruction of pancreatic β – cells.26 The progression of T1D has been divided
into three stages - in the first stage, there are signs of autoimmunity, however glycemic
control is within range and the patient does not present with symptoms of T1D.26 In the
second stage, glycemic control becomes abnormal and in the third stage, hyperglycemia
occurs along with clinical symptoms.26 The destruction of pancreatic β – cells eventually
results in an absolute deficiency in insulin production.26 Diagnosis of T1D is confirmed
by a random plasma glucose ≥ 200 mg/dl accompanying symptoms of hyperglycemia.26
Epidemiology
T1D is primarily diagnosed in youth less than 18 years of age, and is one of the
most commonly diagnosed chronic illnesses in youth.27 Incidence and prevalence of T1D
in youth have been increasing over the past decade around the world.28 The estimated
prevalence of T1D in the United States among youth less than 20 years of age in the year
2009 was 1.93 per 1,000 compared to 1.48 per 1,000 in 2001, representing an increase of
21.1%.1 Prevalence of T1D varies by race/ethnic groups, with the highest prevalence seen
in non-Hispanic white youth (2.55 per 1,000) and the lowest prevalence seen in American
Indian/Alaskan Native youth (0.35 per 1,000) in 2009.29 Prevalence has been increasing
8

in most age and ethnic groups, with the greatest increases seen in the youth aged 15 to 19
years.1
Incidence of T1D in youth in the United States has also been increasing in recent
years.30 Between the years 2002 and 2009, incidence of T1D in youth less than 20 years
increased from 19.5 cases per 100,000 to 21.7 per 100,000, or by an average of 1.4% per
year.30 The change in incidence over this time period differed by age, sex, and race/ethnic
group. Incidence statistically significantly increased between 2002 and 2009 among those
ages 5 to 9 and 15 to 19, among Hispanic youth, and among boys, whereas incidence
significantly decreased among those ages 0 to 4.30
A more recent study using the same study population examined trends in T1D
incidence between 2002 and 2012.30 Using these additional data, significant increases in
incidence were seen across all race/ethnic groups except Asian or Pacific Islanders and
Native Americans, in both boys and girls, and in all age groups except for those 0-4 years
of age.30 On average, the adjusted annual increase in incidence was 1.8%.30 Additionally,
adjusted incidence of T1D increased at a greater rate among Hispanic youth compared to
Non-Hispanic white youth (increase of 4.2% per year compared to 1.2%).30 Among nonHispanic black youth, adjusted incidence of T1D increased at a rate of 2.2% per year.30
Treatment and Management
T1D is a chronic disease and requires intensive management of blood glucose
levels throughout the lifetime of individuals living with the disease.31 Management of
blood glucose levels is primarily achieved through subcutaneous injection of insulin and
monitoring of blood glucose levels.31 Insulin therapy may be administered through
multiple daily injections or through subcutaneous insulin infusion (insulin pump
therapy).32 There are several different types of insulin that may be used to manage blood
9

glucose levels, all of which act to influence blood glucose over different durations.33
Rapid-acting formulations, such as insulin lispro (Humalog) and insulin aspart (Novolog)
act within 10-30 minutes to influence blood glucose levels, whereas long-acting
formulations such as insulin glargine (Lantus) and insulin detemir (Levemir) act over a
period of 24 hours.33 Those patients on multiple daily injections typically inject rapidacting insulin at mealtime to correct for carbohydrate intake and inject long-acting insulin
once a day to maintain blood glucose levels, while those using insulin pump therapy
typically use only rapid-acting insulin, which is released throughout the day as well as
dosed at mealtimes to correct for carbohydrate intake.34
In order to administer the proper dose of insulin, blood glucose levels must be
monitored throughout the day. There are several methods used for monitoring blood
glucose. Traditionally, blood glucose is monitored using a blood glucose meter, checking
blood sugars 5-7 times or more per day, including before meals, at bedtime, before
driving, and before exercise.35 More recently, continuous glucose monitoring has become
more common. Continuous glucose monitoring measures interstitial glucose using a
sensor that is inserted beneath the skin.32 Interstitial glucose is measured continuously,
and an alarm sounds when blood glucose falls above or below the target range. Recently
approved devices combine insulin pump therapy with continuous glucose monitoring
technology to automatically adjust insulin administration based on blood glucose levels
in certain situations.35
Diabetes self-management includes blood glucose monitoring and insulin therapy
in combination with additional considerations such as carbohydrate counting, nutrition,
and physical activity.36 Carbohydrate counting is essential for determining appropriate
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insulin dosage for meals and snacks.32 Additionally, understanding how different types of
food impact blood glucose levels assists in adjusting insulin dosage appropriately.
Physical activity is also an important component of diabetes self-management.36 Physical
activity recommendations for youth with T1D do not differ from recommendations for
youth without a T1D diagnosis – it is recommended that children and adolescents with
T1D engage in 60 minutes or more of moderate or vigorous physical activity per day;36
however, physical activity increases risk for hypoglycemia.32 Therefore, individuals with
T1D must monitor blood glucose levels prior to, during, and after physical activity and
adjust insulin administration and/or carbohydrate consumption accordingly.32
Adherence to diabetes self-management is associated with improved glycemic
control;37 however, estimates of adherence to recommendations suggest that the majority
of adolescents with T1D are not fully adherent to recommendations.38–40 Estimates of
adherence to blood glucose monitoring recommendations vary. One study, relying on
caregiver reports of blood glucose monitoring frequency among participants aged 10 to
17 years in the SEARCH study, reported that 78% of children and adolescents monitored
their blood glucose as often as recommended by their healthcare provider.41 However,
studies using more objective measures of blood glucose monitoring report even lower
rates of adherence in adolescents, with 39% to 44% YYA between the ages of 7 and 16
years and over the age of 18 years, respectively monitoring their blood glucose at least 4
times per day.38,42
Glycemic Control
Glycemic control is the most common metric used to measure the success of
diabetes self-management and to assess the risk of developing future complications of
T1D and is measured routinely at diabetes follow-up visits with healthcare providers
11

using Hemoglobin A1c (HbA1c), a measure that indirectly measures the average blood
glucose level over the previous three months.31 HbA1c may range between around 5.5%
(indicating an average blood glucose of around 122 mg/dL) to over 12 (indicating an
average blood glucose of around 298 mg/dL) among individuals with T1D.31 In youth
and adolescents under the age of 18 with T1D, the target HbA1c is less than 7.5%.43 In
individuals over the age of 18, the target HbA1c is less than 7.0%.31 Glycemic control is
an important factor in determining the risk of future complications of T1D, as discussed
below.
Most children and adolescents with T1D do not meet recommendations regarding
glycemic control – according to one study using data from the SEARCH study among,
56% do not meet recommendations, and 17% have HbA1c greater than 9.5%, which is
considered high risk glycemic control.39 Because glycemic control is often less than ideal,
it is important to understand predictors and outcomes of poor glycemic control.39,40
Predictors of HbA1c. Glycemic control, as measured by HbA1c, is
associated with demographic, behavioral, clinical, socioeconomic and mental health
factors.4,39 Demographic and socioeconomic factors associated with glycemic control
include age, sex, race/ethnicity, living in a two-parent home, household income, and
parental education.39 A cross-sectional analysis from the SEARCH study of participants
between the ages of 0 and around 30 years found that younger age, living in a non-twoparent household, race/ethnicity other than non-Hispanic white, being female, having
lower household income and lower parental education are all significantly associated
with poor glycemic control, as indicated by HbA1c > 9.5%.39
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Behavioral factors associated with glycemic control include adherence to diabetes
self-management, such as frequency of blood glucose monitoring, carbohydrate counting,
and insulin dosing.38 Adherence to diabetes self-management is one of the primary
predictors of glycemic control, particularly frequency of blood glucose monitoring.38 A
meta-analysis conducted in 2009 assessing the association between adherence and
glycemic control among youth under the age of 19 found that there is a negative
association between adherence and glycemic control, such that those who are more
adherent to self-management guidelines typically have better glycemic control.37 This
study loosely defined adherence as frequency of blood glucose monitoring along with
patient and physician surveys assessing adherence by frequency of blood glucose
monitoring in addition to other self-management components such as carbohydrate
counting, and insulin dosing.
Clinical factors associated with glycemic control include method of insulin
administration, diabetes duration, and weight status.39,44 Children and adolescents with
T1D between the ages of 13 and 18 years who use insulin pumps have better glycemic
control compared to their peers using multiple daily injections.44 Additionally, those who
switch from using an insulin pump to performing multiple daily injections show an
increase in HbA1c, indicating worsening glycemic control.44 Papers utilizing data from
the SEARCH study have found that longer diabetes duration and being underweight have
been associated with poorer glycemic control among youth with an average age of around
14 years.39,45
Mental health factors, such as depression and anxiety have also been associated
with glycemic control among YYA with T1D. Depressive symptoms are associated with
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poorer glycemic control among children and youth with T1D aged 10 – 21 years.4,7
Additionally, anxiety symptoms are associated with poorer glycemic control among
adolescents with T1D between the ages of 13 and 18.8
Complications associated with HbA1c. Approximately 32% of individuals with
T1D experience at least one complication of diabetes by the age of 21 years, and most of
these complications are associated with poor glycemic control.40 Glycemic control is
associated with a number of health outcomes among those with T1D, and is the primary
predictor of developing long-term microvascular and macrovascular complications of
T1D.46–48 Higher HbA1c is predictive of microvascular complications, such as
retinopathy, neuropathy, and diabetic kidney disease.31 Intensive glycemic control
(HbA1c < 7%) has been shown to reduce the risk of cardiovascular morbidity and
mortality among those with T1D.31
One such complication associated with glycemic control among YYA with T1D
is arterial stiffness, a precursor to cardiovascular disease that often begins in childhood
and adolescence, particularly among youth with type 1 and type 2 diabetes.49
Arterial Stiffness
Definition and Measures
Arterial stiffness is commonly measured as an indicator of vascular dysfunction
and a marker of future cardiovascular disease morbidity and mortality.22 Vascular
dysfunction includes dysfunction in large arteries, microvasculature, and the
endothelium.50 Arterial stiffness is a measure of vascular dysfunction in the large arteries
and is conceptualized as the speed with which a pulse pressure wave moves through a
segment of an artery.22,51 Faster speed indicates increased stiffness of the artery, which is
detrimental to vascular health.22
14

Although the causal pathway between arterial stiffness and cardiovascular disease
is not fully understood, several mechanisms have been attributed to the increased risk of
cardiovascular disease associated with increased arterial stiffness.51 As arteries stiffen,
more force is required to circulate blood throughout the body.52 This increases the
workload of the heart, eventually leading to structural damage to the heart.52
Many non-invasive measures are available to quantify arterial stiffness, and these
measures can be applied in different parts of the arterial tree with measures of both
central and peripheral stiffness. The carotid-femoral pulse wave velocity (PWV) is
considered the “gold standard” measure of arterial stiffness as it is simple and
reproducible and has been assessed most often in relation to cardiovascular outcomes.22
Carotid-femoral PWV measures the speed for the pressure wave generated by cardiac
ejection to reach the periphery and is a measure of central stiffness. Higher carotidfemoral PWV indicates increased arterial stiffness.49 According to results of a metaanalysis of published literature on the association between carotid-femoral PWV and
cardiovascular events, a 1 m/s increase in carotid-femoral PWV is associated with a 14%
increased risk of cardiovascular events (including cardiovascular death, myocardial
infarction, stroke, revascularization, and aortic syndromes) overall.53
Arterial stiffness is a particularly useful measure in adolescent populations
because although cardiovascular disease is rare in this population, changes in arterial
stiffness begin to occur as young as the adolescent years.54
Type 1 Diabetes and Arterial Stiffness
Although cardiovascular disease is typically not present in YYA, arterial stiffness
has been proposed as a marker of future cardiovascular disease morbidity and mortality.53
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Arterial stiffness is increased in youth55 and adults56 with T1D. Of seven identified
studies that utilized PWV to measure arterial stiffness in individuals with T1D compared
to healthy controls, six studies demonstrated that arterial stiffness was significantly
greater among those with T1D57–62 and one study indicated that there was no difference in
arterial stiffness between those with T1D and healthy controls.63 There are multiple
mechanisms through which T1D may lead to increased arterial stiffness, and subsequent
increased risk for cardiovascular and renal disease. These potential mechanisms include
increased insulin sensitivity64 and chronic low-grade inflammation.65 Among patients
with T1D, increased arterial stiffness predicts incidence of cardiovascular disease and
end-stage renal disease.66
Predictors of Arterial Stiffness in Youth and Young Adults with Type 1 Diabetes
Among YYA with T1D with a mean age of 14 years, older age, poorer glycemic
control, greater waist circumference, higher LDL and lower HDL cholesterol, and
increased systolic and diastolic blood pressure are all cross-sectionally and independently
associated with increased arterial stiffness.49 Additionally, decreased insulin sensitivity
has been shown to predict increasing arterial stiffness over time in youth with T1D.64 A
longitudinal examination of the association between cardiovascular risk factors and
arterial stiffness among YYA with T1D with a mean age of 14.5 years found a significant
association between both waist circumference and blood pressure and PWV, adjusting for
age, sex, race/ethnicity, and duration of diabetes.67 Another longitudinal study found that
HDL cholesterol, smoking history, and HbA1c were associated with measures of arterial
stiffness after 18 years, adjusting for current age, heart rate, sex, height, and medication
use.68
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Depression, Depressive Symptoms and Type 1 Diabetes
Definition and Measurement
Depression is characterized by feelings of sadness, emptiness, and hopelessness
and loss of interest or pleasure in most activities.69 These symptoms may be accompanied
by other clinical indications, including weight loss or gain, insomnia or hypersomnia,
fatigue, indecisiveness, and suicidal ideation.69 In order for a diagnosis of major
depressive disorder to be made, five symptoms must be present, including depressed
mood and/or loss of interest or pleasure.69 In epidemiologic studies, often rather than
examining the presence vs. absence of major depressive disorder, the presence and
severity of depressive symptoms is of primary focus, particularly in cases where even
subclinical presence of depressive symptoms are associated with the outcome of interest.
Depressive symptoms are typically measured using self-report surveys in
epidemiologic studies. There are many validated surveys which assess frequency and/or
severity of depressive symptoms, however, the most common surveys used to measure
depression in research involving individuals with type 1 or type 2 diabetes are the Beck
Depression Inventory (BDI)70 and the Center for Epidemiologic Studies Depression Scale
(CES-D).71,72 The CES-D scale was designed for self-report of current levels of
depressive symptoms in the general population, focusing on depressed mood.72 The
CES-D includes 20 items including, “I felt depressed,” “I felt lonely,” and “I felt sad,”
and asks participants to report the frequency of experiencing these symptoms during the
past week, from less than 1 day, 1-2 days, 3-4 days, or 5-7 days.73 Scores range from zero
to 60, with a higher score indicating more and/or a greater frequency of depressive
symptoms. This scale has been validated in adults (Cronbach’s alpha = 0.85)72 and
adolescents (Cronbach’s alpha = 0.85-0.87).73 In adolescents, the survey was validated
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using five samples: a community sample consisting of subsamples of young adults aged
18-25, adults aged 26 and over, and adults with no emotional problems requiring
assistance in the previous month, a patient sample diagnosed with acute depression, a
convenience sample of college students, a convenience sample of high school students,
and a sample of junior high school students.73 These samples were compared to to
identify whether measures of reliability and validity differed among the adolescent
compared to the adult samples. The internal consistency of the scale did not differ
between the community sample and the school samples and was considered high.73
Internal consistency was lower among the acutely depressed sample.73 The samples
consisting of youth tended to have higher scores on the CES-D compared to the well
adults and lower scores compared to the acutely depressed patients.73 Results suggest that
scores for younger adolescents may be elevated due to transient depressive symptoms
that are less likely to persist over time.73
The CES-D has also been examined in terms of its utility in diagnosing
depression. Among a sample of adolescents with an average age of 14 years, the CES-D
was a moderately strong predictor of diagnosed depression among females, with an area
under the curve (AUC) of 0.73.74
Epidemiology in Youth and Young Adults
According to data from the National Survey on Drug Use and Health,
approximately 12.8% of adolescents aged 12-17 and 10.9% of young adults aged 18 to 25
experienced a major depressive episode, defined as 2 weeks or longer of experiencing
symptoms which qualify for diagnosis of major depressive disorder, in the past year.75
Data from the National Health and Nutrition Examination Survey (NHANES) indicate
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that between the years 2009 and 2012, the prevalence of moderate to severe depressive
symptoms among adolescents aged 12-17 was 5.7%, and that this figure was much higher
among females (7.4%) compared to males (4.0%).76 Moderate to severe depressive
symptoms were more common among those living below the poverty level and among
Hispanic and non-Hispanic black persons.76
Depressive Symptom Trajectories/Course in Youth and Young Adults
In addition to the presence or absence of clinical depression at a single point in
time, the course of depression is also significant in understanding the etiology of
depression as well as its consequences.77 Depressive symptoms within individuals may
display varying patterns over time.78 For some individuals, depressive symptoms persist
stably over time, for other individuals, symptoms may increase or decrease over time.78 A
systematic review of depressive symptom trajectories in the general population found that
trajectories of depressive symptoms vary in terms of the severity and stability of
symptoms over time.78 Typically, most of the population belongs to a group characterized
by stable, mild symptoms of depression.78 Another common pattern consists of
individuals with stable high depressive symptoms.78 Although this pattern was seen in
most studies, the number of individuals characterized by this pattern was small.78
Additionally, many studies identified classes consisting of moderate, stable symptoms
and those with either increasing or decreasing symptoms over time.78
Among children and adolescents, Musliner et al. identified seven studies
examining trajectories of depressive symptoms using group-based trajectory modeling,
covering participants with an average age of around 6 to 17 years.78 Of these, two
measured depressive symptoms using the 20-item CES-D.79,80 One study, following only

19

males who were 14-15 years of age at baseline over ten years, identified four classes:
very low, moderate-decreasing, high-decreasing, and high-persistent.80 The other study,
following males and females with an average age of 17 years, identified three classes
over 14 years of follow-up: high stable, moderate decreasing, and low decreasing.79 In
both of these studies, the class representing low/few depressive symptoms was used as
the reference group when examining various predictors of class membership. In one
study, the low depressive symptom class demonstrated a mean CES-D score of around 10
at baseline, which steadily declined to a mean of about 3 over 14 years.79 In the other
study, which included only males, a “very low” depressive symptom class served as the
reference group.80 The mean CES-D score for this class remained less than 5 throughout
the duration of follow-up.80
Studies included in this systematic review also identified predictors of trajectory
group membership. Females, those with lower education and lower income were more
likely to be characterized by stable high depressive symptoms compared to stable, low
depressive symptoms.78 Among adolescents, alcohol use, tobacco smoking, peer
rejection, family conflict, and lack of self-esteem were all associated with higher
depressive symptom trajectories compared to those trajectories reflecting stable, low
depressive symptoms.78
Studies also examined various outcomes associated with trajectory group
membership. Adolescents who had stable moderate or severe depressive symptoms were
less likely at age 30 to be married, and have a high school or college degree and were
more likely to be of lower socioeconomic status and have low self-esteem compared to
those with stable, low depressive symptoms.78,79
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These studies suggest that the severity and stability of depressive symptoms over
time often have distinct predictors and outcomes among various populations. Of interest
in the present study is the trajectory group composition of depressive symptoms among
YYA with T1D.
Predictors of Depressive Symptom Trajectories
Demographic and socioeconomic characteristics are associated with depressive
symptoms among YYA.81 Previous research has demonstrated that the risk of developing
depressive symptoms increases throughout adolescence and early adulthood.81 Females in
this age range are also at increased risk for experiencing depressive symptoms compared
to males.81 Lower socioeconomic status, as measured by income and education, has also
been shown to increase risk for depression in YYA.81 Among studies examining
trajectories of depressive symptoms over time among children and adolescents, lower
education, lower income, being female, alcohol use, tobacco use, peer rejection, family
conflict, and lack of self-esteem have all been associated with depressive symptom
trajectories indicating more severe, stable symptoms compared to stable, low symptom
trajectories.78
Behavioral factors, such as physical activity have also been shown to predict
depressive symptoms in adolescents and young adults across cultures, such that increased
moderate to vigorous physical activity is associated with fewer depressive symptoms.82–87
This inverse association between physical activity has been demonstrated in both crosssectional84,86,88 and longitudinal18,83,85 studies in populations ranging in age from 9 to 29
years. One study examining depressive symptom trajectories among YYA between the
ages of 12 and 29 years found that physical activity levels were highest among those with
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stable, low depressive symptoms over time compared to those with increasing,
decreasing, or persistently high depressive symptoms.18 Although many studies have
demonstrated an association between physical activity and depressive symptoms, others
suggest a negligible effect of physical activity on lowering depressive symptoms.89
Another behavioral predictor of depressive symptoms in adolescence and young
adulthood is the use of tobacco products.90 A systematic review of longitudinal studies
examining the association between smoking tobacco and depressive symptoms including
participants ranging in age from 13 to 19 years found that tobacco smoking is
consistently associated with an increased risk of depression.90 Another review of research
among adolescents aged 12 to 18 years found a small and significant effect of tobacco
use on depressive symptoms, such that tobacco use is associated with elevated risk of
depression.89
A potential protective factor against developing depression among YYA is type of
diet consumed. Previous research among adolescents between the ages of 12 and 18
suggests that healthy eating is associated with a decreased risk of depressive symptoms.89
Research conducted among adolescent females between the ages of 12 and 18 found that
adherence to the DASH diet is significantly associated with a lower burden of depressive
symptoms.91
Another potential predictor of depressive symptoms in YYA is body weight, or
BMI. A review of the literature including participants between the ages of 12 and 18
found that increased weight is associated with increasing depressive symptoms across
this age range.89

22

Depression and Type 1 Diabetes
According to data from the SEARCH study, approximately 14% of youth with
type 1 and type 2 diabetes between the ages of 10 and 21 years have mildly depressed
mood and 8.6% have moderate to severely depressed mood.4 Another cross-sectional
study estimates that 11.3% of adolescents and young adults with T1D between the ages
of 11 and 25 years experience depression.92 Although varied, most research suggests that
the prevalence of depression among YYA with T1D is much higher than the prevalence
among their healthy counterparts.93 One meta-analysis examined studies comparing
reports of depressive symptoms in children and adolescents between the ages of 6 and 19
with and without T1D, and found that on average, children and adolescents with T1D
experienced greater depressive symptoms than their healthy peers.94 Additionally, several
systematic reviews have concluded that adults with T1D have greater odds of
experiencing comorbid depression compared to their healthy peers.21,95–97
Most literature examining the prevalence of depression and depressive symptoms
among individuals with T1D has utilized cross-sectional data to assess the presence of
depression or depressive symptoms at a particular point in time.4,92,98,99 This information
is useful for understanding the burden of depression in the T1D population, but provides
no information on the course of depressive symptoms following the diagnosis of T1D and
the relationship between the course of depressive symptoms and clinical outcomes of
diabetes, such as glycemic control and other diabetes complications.
Several studies have examined changes in depressive symptoms over time in
YYA with T1D. One study assessed the course of major depressive disorder in youth
with T1D between the ages of eight and thirteen years compared to matched controls who
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experienced major depressive disorder but did not have diabetes over a median follow-up
period of around 10 years.100 In this study, the likelihood of recovering from a first
depressive episode and the risk of experiencing a second episode did not differ between
those with and without T1D. However, those with T1D had depressive episodes that
lasted longer compared to controls. Depression was more likely to recur among females
with T1D compared to males with T1D.100 These results suggest that individuals with
T1D who also experience depression may be at greater risk of prolonged depression due
to the increased stress of living with a chronic disease.100 Another study, utilizing
SEARCH data, examined mean change in depressive symptoms in a sample of youth
with T1D with a mean age of 14 yeras.45 In this study, the mean number and frequency of
depressive symptoms, as quantified by the CES-D scale,72 remained stably mild over
several years with a mean CES-D score of around 9 at each study visit.45
One study has examined trajectories of depressive symptoms, and predictors of
trajectory group membership, in German adults (mean age of 28 years) with T1D over a 5
year period, with yearly measures of depressive symptoms.101 This study utilized the
Symptom Checklist 90-R to measure depressive symptoms. On this scale, scores less than
60 indicate no depression, scores between 60 and 70 indicated moderate depression and
scores greater than or equal to 70 indicate severe depression.101 Three unique trajectories
were identified in this study using growth mixture modeling: those with no depressive
symptoms throughout the course of follow-up (with a mean score of around 50
throughout follow-up), those with worsening depressive symptoms, and those with
worsening depressive symptoms that improved after two years.101
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Another study has examined stability and change in depressive symptoms over
time among young adults with an average age of 23 years with T1D, using two
timepoints of depressive symptom assessment, taken five years apart.102 Rather than
using statistical models to distinguish between depressive symptom trajectory classes,
however, this study employed hard coding to impose a definition of stable vs. changing
depressive symptoms over time. Four categories were created: no/minimal depression
(65%), recovering depression (6%), increasing depression (12%), and persistent
depression (16%).102 The no/minimal depression group had a mean CES-D score of
around 5 at both time points.102
Depressive Symptoms and Glycemic Control
Previous research on the association between depressive symptoms and glycemic
control among YYA with T1D has shown mixed results. Three systematic reviews have
been conducted examining this issue.21,103,104 Roy and Lloyd (2012)21 reviewed the
literature examining the association between depression and glycemic control in adults
with diabetes, and found that only one identified study out of nine utilized longitudinal
data to examine this association among people with T1D.96 This study found a significant
association, such that individuals with T1D and a history of depression had greater mean
HbA1c values compared to those without a history of depression.96 A cross-sectional
study included in this review found that depressed mood was associated with poor
glycemic control among adults with T1D.105 These were the only two studies in the
review which assessed this association in adults with T1D.
Another review identified fifteen studies assessing the association between
depressive symptoms and glycemic control in individuals with T1D under the age of
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25.103 Of these fifteen studies, ten were cross-sectional and five were longitudinal. Of the
ten cross-sectional studies, eight identified a significant association between depressive
symptoms and glycemic control such that increased depressive symptoms were
associated with worse glycemic control, whereas two studies did not find a significant
association between depressive symptoms and glycemic control.103 Of the five
longitudinal studies, three identified a significant association between depressive
symptoms measured at baseline and glycemic control assessed at 6 months106, 1 year107,
and 2 years.108 Two longitudinal studies found no significant association between
baseline depressive symptoms and glycemic control assessed at 6 months109 and 1
year.110 Of the fifteen studies included in this review, three measured depressive
symptoms using the CES-D scale and all of these studies demonstrated an association
between elevated depressive symptoms and glycemic control.103
The third systematic review to examine this association identified eleven studies
assessing the association between depressive symptoms and glycemic control among
youth with T1D with mean ages between around 13 and 17 years.104 All eleven of these
studies demonstrated a significant, positive association between depressive symptoms
and glycemic control.104 This association was seen in both cross-sectional and
longitudinal analyses with measures of HbA1c at six, nine, and twelve months of followup.104 One of the eleven studies found an association between depressive symptoms as
measured by the Children’s Depression Inventory (CDI) and HbA1c in a cross-sectional
analysis among adolescents aged 13-18 years (r = .26), but no association between
depressive symptoms and HbA1c measured six months later (r = .12).109 Another crosssectional study of adolescents and young adults aged 11 – 21 years with T1D included in
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this review examined the association between individual depressive symptoms (measured
by the PHQ-9) and HbA1c and found that the two primary symptoms of depression
(anhedonia and dysphoria) were not associated with HbA1c; however, other symptoms
including sleep difficulty, lethargy, and overeating/poor appetite were associated with
elevated HbA1c.111 In models adjusted for age, sex, socioeconomic status, family
structure, frequency of insulin injection, smoking, and body mass index, the total PHQ-9
score was also associated with elevated HbA1c.111 In one of the only studies examining
longitudinal changes in depressive symptoms as predictors of glycemic control, 145
adolescents ages 13-18 were recruited to join a prospective cohort study.106 Two study
visits took place – a baseline visit and a second visit 6 months later. At both of these
visits, participants completed the CDI to measure depressive symptoms and gave blood
samples to measure HbA1c.106 Results of this study suggest that as depressive symptoms
increase over time, HbA1c also increases, independent of age, gender, ethnicity, diabetes
duration, mode of insulin delivery, caregiver education, caregiver marital status, and
health insurance status.106
Several small-scale studies, not included in the above reviews, have also
examined the association between depressive symptoms and glycemic control among
adolescents with T1D. In a cross-sectional study of 51 adults ages 18-70 with T1D,
having ongoing and/or previous depressive disorders was non-significantly associated
with elevated HbA1c (p = 0.08), adjusting for age, sex, and diabetes duration.98 The mean
HbA1c among participants with previous and/or ongoing depressive disorders was 8.5%
compared to 7.9% among those with no depressive disorder.98 In a cross-sectional study
of 150 adolescents and young adults ages 11 – 25 years, screening positive for depression
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on the BDI was not associated with elevated HbA1c; however, those who screened
positive on at least one mental health screen (including depression, disordered eating, and
anxiety disorders) were more likely to have HbA1c greater than 8.5%.92 In another crosssectional study of 145 youth between the ages of 10 and 18, those with elevated
depressive symptoms as measured by the CDI had greater mean HbA1c (9.3%) compared
to those without elevated depressive symptoms (8.6%).112
In a cross-sectional studying using data from the SEARCH study including
participants with type 1 and type 2 diabetes (n=2672) between the ages of 10 and 21
years, Hba1c was associated with depressed mood in males and females, with a greater
mean HbA1c in those with increased depressed mood.4 Among males, the mean HbA1c
was 8.98 among those with moderate to severe depressive symptoms compared to 8.28
among those with minimal depressive symptoms.4 Among females, the mean HbA1c was
8.73 among those with moderate to severe depressive symptoms compared to 8.40 among
those with minimal depressive symptoms.4 In another study utilizing longitudinal data
from the SEARCH study (n=1,026 with T1D), mean CES-D score and change in mean
CES-D over time did not predict HbA1c in a multilevel model in which baseline
psychosocial characteristics, demographic, and clinical characteristics were included.45
To our knowledge, only one study has examined the association between
depressive symptom trajectories and glycemic control among individuals with T1D.101 In
this study, described in more detail above, three depressive symptom trajectories were
identified among adults between the ages of 17 and 40 years: no depression, improving
depressive symptoms over time, and worsening depressive symptoms over time.
Compared to the group with no depressive symptoms, those with worsening depressive
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symptoms had significantly higher mean HbA1c (8.2%) compared to those with no
depressive symptoms (7.2%) after five years of follow-up.101
Most available research suggests that increased depressive symptoms are
associated with worse glycemic control among YYA with T1D. However, most research
has been conducted using cross-sectional data, and little research has been conducted
using longitudinal data. Thus, it is unclear whether depressive symptoms precede poor
glycemic control in time. It is possible that this relationship is bidirectional, such that
depressive symptoms increase risk for poor glycemic control, and poor glycemic control
increases risk for experiencing depressive symptoms. Additionally, most previous
research has examined the association between mean depressive symptoms and mean
HbA1c. The goal of the present study is to identify subgroups of participants who
experience similar patterns of depressive symptoms over time and to assess whether these
patterns are associated with glycemic control.
Depression and Arterial Stiffness
Depression among patients with T1D has been associated with a number of
diabetes complications, including retinopathy, nephropathy, neuropathy, and
macrovascular complications.20 Of particular interest in this study is the association
between depression and macrovascular complications, as conceptualized by increased
arterial stiffness. To our knowledge, no existing research examines the association
between depression and arterial stiffness among YYA with T1D. However, prior research
supports an association between depression and arterial stiffness in the general population
of YYA.113
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Depression has been associated with increased risk of cardiovascular disease
incidence and mortality.114 Several mechanisms have been implicated in this pathway
from depression to cardiovascular disease, including immune activation, HPA axis
hyperactivity, and endothelial dysfunction.114 One of the proposed mechanisms through
which depression increases this risk is arterial stiffness, which is of particular interest in
examining this association in YYA, as arterial stiffness is a subclinical marker of
cardiovascular disease that often begins to change during adolescence.114
The association between depressive symptoms and arterial stiffness has been
documented cross-sectionally in adult populations.115 A recent systematic review and
meta-analysis identified eight studies which examined this association and found that
seven of the eight studies, including a total of 913 individuals with depressive symptoms
and 4648 controls with no depressive symptoms indicated increased arterial stiffness
among those with depressive symptoms, as measured by pulse wave velocity. The overall
standard mean difference (Cohen’s d) in pulse wave velocity between those with
depressive symptoms and controls with no depressive symptoms was 0.216 (p < 0.001),
suggesting a small effect size.115 Raw differences in PWV between depressed participants
and controls ranged from 0.3 to 1.8 m/s in the seven studies which demonstrated
increased arterial stiffness in depressed participants.115 Previous research indicates that an
increase in PWV of 1 m/s corresponds to a 14% increased risk of cardiovascular events.53
At least one study has assessed the effect of treating depressive symptoms on
changes in arterial stiffness among women with severe depression.116 In this study of 20
women with major depressive disorder matched to twenty health controls, the baseline
arterial stiffness, as measured by pulse wave velocity, was significantly higher among
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women with depression compared to controls.116 Following treatment for depression
using antidepressants, there was no statistically significant difference in pulse wave
velocity between the depressed patients and controls.116 This suggests that depressive
symptoms may cause increases in arterial stiffness among adult women with severe
depression.116
Additional research among otherwise healthy adult populations also supports the
positive association between depressive symptoms and arterial stiffness.117 One crosssectional study with 449 adults with a lifetime diagnosis of major depression compared to
169 controls found that arterial stiffness, as measured by augmentation index, was
increased in those with current depression compared to controls after adjusting for age,
sex, education, BMI, physical activity, smoking status, mean arterial pressure, use of
antihypertensive medication, use of lipid-modifying medication, diabetes, and
cardiovascular disease.117
Previous research has demonstrated an association between depressive symptoms
and arterial stiffness in otherwise healthy adolescents.113 In a sample of 157 adolescents
aged 16 – 21, Dietz and Matthews (2011) found a positive association between increased
depressive symptoms, as measured by the CES-D and arterial stiffness, as measured by
pulse wave velocity, adjusting for age, race, sex, BMI, parent education, smoking status,
physical activity, systolic blood pressure, and heart rate.113
Although the association between depressive symptoms and arterial stiffness has
been evaluated in both adult and adolescent populations, this association has not been
evaluated in YYA with T1D and has not been evaluated longitudinally. Thus, whether

31

depressive symptoms precede arterial stiffness in time is unclear, as is the influence of
longitudinal patterns of depressive symptoms on changes in arterial stiffness.
Implications of Examining Youth and Young Adults
The population of interest in this examination is focused on YYA with T1D.
Studying depressive symptom trajectories in this population is of particular importance
because adolescence and emerging adulthood are times of transition in physical,
emotional, social, and educational development. Depressive symptoms experienced
during this period of development may have consequences that last long after
adolescence and emerging adulthood has passed.18,19 Additionally, previous research has
shown that depression experienced during adolescence is more likely to be transitory in
nature compared to that experienced in adulthood.73 Thus, examining trajectories of
depressive symptoms is particularly informative in this population as this allows for the
identification of YYA who are truly experiencing persistently high depressive symptoms
and to determine whether these YYA are at an increased risk for poor health outcomes
compared to those youth who either have persistently low or transitory depressive
symptoms.
Research Gaps
Although previous research has documented elevated depressive symptoms
among those with T1D compared to their healthy counterparts,5 and past research
supports an association between depressive symptoms and poor glycemic control,4 the
research conducted to date has been predominantly cross-sectional in nature, and thus
unable to capture changes in depressive symptoms over time or the direction of the
association between clinical outcomes and depressive symptoms among adolescents with
T1D. Additionally, the findings from research concerning the association between
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depressive symptoms and glycemic control in this population have been mixed, with
most supporting an association between increased depressive symptoms and poor
glycemic control.21,103,104
The little longitudinal research that has been conducted has largely examined
mean changes of depressive symptoms over time, which does not capture individual
trajectories of symptoms over time.45 Thus, previous research has largely been unable to
describe patterns of change in depressive symptoms over time and how these different
courses of depressive symptoms may influence clinical outcomes, such as glycemic
control and arterial stiffness in YYA with T1D. Thus far, only one known study has
examined depressive symptom trajectories in individuals with T1D and the association
between these trajectories and glycemic control, and this study examined an adult
population with a relatively small sample size (n=313).101
Additionally, to our knowledge, no research has been conducted on the
association between depressive symptoms and arterial stiffness in individuals with T1D.
Thus, the present research contributes to the literature by examining longitudinal
trajectories of depressive symptoms in YYA with T1D and assesses the association
between trajectory group membership and glycemic control and arterial stiffness. This is
one of the first examinations of the association between depressive symptom trajectories
and glycemic control and the first known examination of the association between
depressive symptoms and arterial stiffness in this population.
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CHAPTER 3
METHODS
Specific Aims and Hypotheses
The goals of this research were to identify subgroups of YYA (YYA), between
the ages of 10 and 30 years, with T1D with similar longitudinal trajectories, or patterns,
of depressive symptoms, to assess baseline characteristics associated with these trajectory
groups, and to evaluate whether trajectory groups are related to glycemic control and
arterial stiffness.
In Specific Aim 1, group-based trajectory modeling (GBTM) was used to identify
longitudinal trajectories of depressive symptoms among YYA between the ages of 10 and
30 with T1D, using the Center for Epidemiologic Studies – Depression (CES-D) scale72
as a measure of depressive symptoms. Based on previous research modeling trajectories
of depressive symptoms in YYA, it was hypothesized that changes in depressive
symptoms over time in youth with T1D would fall into distinctive trajectories, including
increasing depressive symptoms over time, stable – little to no depressive symptoms, and
stable – moderate/high depressive symptoms.
In Specific Aim 2, to identify baseline correlates of belonging to longitudinal
depressive symptom trajectory groups among YYA ranging in age from 10-30 years with
T1D, bivariate associations between baseline measurements of demographic and
socioeconomic characteristics (age at diagnosis, sex, race, parental education, household
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income, family structure, insurance status), diabetes self-care (insulin regimen,
hypoglycemic episodes, diabetic ketoacidosis episodes, frequency of blood glucose
monitoring), and other clinical and behavioral characteristics (BMI, tobacco use, physical
activity, diet quality, and use of antidepressant medications) and depressive symptom
trajectory groups were assessed. Next, these variables were entered as predictors in a
multivariable model predicting trajectory group membership.
In Specific Aims 3 and 4, depressive symptom trajectory groups among YYA
ranging in age from 10-30 years with T1D were used to predict glycemic control and
arterial stiffness. It was hypothesized that trajectory groups indicating stable high or
worsening depressive symptoms would be associated with worse glycemic control and
increased arterial stiffness.
Table 3.1: Overview of potential predictors, correlates for depression trajectories
and outcomes at follow-up
Baseline potential Baseline potential correlates
Outcomes at most recent
predictors
study visit
Age at diagnosis
Hypoglycemic Episodes
HbA1c
Sex
Diabetic Ketoacidosis
Arterial stiffness (PWV)
Episodes
Race/Ethnicity
Frequency of blood glucose
monitoring
Parental Education
BMI
Household Income
Use of antidepressant
medications
Family Structure
Insulin regimen
Insurance Status
Tobacco Use
Physical Activity

SEARCH Study
Design
The SEARCH for Diabetes in Youth (SEARCH) study is an observational, multicenter, population-based study that has identified incident cases of non-gestational
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diabetes diagnosed among youth less than 20 years of age since 2002.118 Phases 1 (20002005) and 2 (2005-2010) of SEARCH identified prevalent and incident cases of
diagnosed diabetes. Phase 3 (2010-2015) added a cohort component, recruiting
participants with incident diabetes from 2002-2006, and 2008 who had a baseline visit
and had a duration of diabetes at least five years at the cohort visit.119 Five clinical
centers in the United States contributed participants for the cohort study: South Carolina
(all counties), Ohio (Cincinnati and eight surrounding counties), Colorado (all counties),
Southern California (members of Kaiser Permanente Medical Care Program Health Plan
in Southern California, except San Diego), and Washington (four counties surrounding
Seattle).119
Population
Approximately 2,316 participants with T1D are included in the SEARCH 3 cohort
study, with ages ranging from 8 – 32 years. All participants are between the ages of 10
and 20 years at the baseline visit. For the purposes of this analysis, only individuals with
physician-diagnosed T1D diagnosed between the years 2002-2005 were included. These
participants completed up to five visits: baseline, 12-month, 24-month, 60-month, and an
additional visit for inclusion in the cohort. All participants less than 10 years of age were
excluded because these participants did not complete the depressive symptom
questionnaire. Participants with fewer than two measurements of depressive symptoms
were excluded to reduce the likelihood of misclassification using GBTM.120 Although
this reduced the likelihood of misclassification using GBTM, limiting the sample to those
with at least two measures of depressive symptoms may have introduced the potential for
selection bias. It is possible that those who completed only one measure of depressive
symptoms differed from those who completed either two, three, or four measures.
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CES-D
HbA1c
PWV

Table 3.2 Data collected at each study visit in SEARCH used in analyses
Baseline
12 Month
24 Month
60 Month
Cohort
X
X
X
X
X
X
X

Data Collection
IRB approval was obtained for data collection at each study site prior to the
initiation of study procedures. Participants attended in-person study visits, in which they
completed questionnaires, physical exams, and laboratory tests. Questionnaires included
data on demographics, medical history, and physical and mental health. Physical exams
and laboratory tests assessed chronic complications of diabetes, glycemic control, and
other relevant risk factors associated with diabetes. Questionnaires involving information
on age, sex, age at diagnosis, history of diabetic ketoacidosis, insulin use, prescription
medications, and race/ethnicity were filled out by either the participant or his/her legal
guardian, depending on the age of the participant. All information about depressive
symptoms and health behaviors was provided by the participant, regardless of age.
Measures
Depressive Symptoms
Depressive symptoms were assessed at each study visit in participants ≥ 10 years
of age using the Center for Epidemiologic Studies Depression (CES-D) scale.72 The CESD scale is a 20-item scale which was designed to measure the current level of depressive
symptomatology in members of the general population.72 Items on the scale reflect
symptoms assessed in the diagnosis of depression, focusing on depressed mood.72 Items
include “I felt depressed,” “I felt that everything I did was an effort,” and “I thought my
life had been a failure.”72 Participants chose on a scale of 0 (Rarely or none of the time)
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to three (Most or all of the time) the frequency with which the symptom occurred in the
past week.72 The sum of all item responses was taken to get a total score, which ranges
from 0 to 60, with higher scores indicating more depressive symptoms.72 Traditionally, a
cut-off of 16 is used to distinguish between depressed and non-depressed individuals in
adult populations.72,73 In adolescent populations, at cut-off of 24 has been found to be
more appropriate for identifying depressed mood as defined by the DSM.121 The accepted
categories for assessing depressed mood in adolescents are as follows: minimal (0-15),
mild (16-23), and moderate/severe (24-60).121 The main analysis was conducted using
the continuous CES-D score, thus these cutoffs were used for interpretation only. The
CES-D was initially validated in an adult sample (Cronbach’s alpha = 0.85) and was
subsequently validated in an adolescent population (Cronbach’s alpha = 0.84-0.87 in
various samples).72,73 The CES-D has also been validated against other measures of
depression and depressive symptoms in children, adolescents, and adults.122,123 A
systematic review of the validity of the CES-D scale among children and adolescents
found that the CES-D has poor positive predictive value, good negative predictive value,
and moderate diagnostic ability.122 This review also evaluated the Beck Depression
Inventory, the Children’s Depression Inventory, and the Reynolds Adolescent Depression
Scale and found that there were no key differences between depression scales on
measures of reliability or validity.122 Another systematic review conducted among adult
populations compared the CES-D, the Zung Depression Rating Scale, the Major
Depression Inventory, the Beck Depression Inventory, and the Kellner Symptom
Questionnaire.123 This review also found that there were no major differences in
reliability or validity among the examined depression scales.123
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Glycemic Control
Glycemic control was assessed by Hemoglobin A1c (HbA1C), which is the
standard measure of glycemic control over the past three months. Whole blood samples
collected during the study visit were analyzed for HbA1C by the Northwest Lipid
Metabolism and Diabetes Research Laboratories in Seattle, WA, using an automated
nonporous ion-exchange high-performance liquid chromatography system (model G-7;
Tosoh Bioscience, Montgomeryville, Pennsylvania).39 Glycemic control was assessed
both as a continuous measure of HbA1c (%) and as a categorical variable based on the
ADA and International Society for Pediatric and Adolescent Diabetes (ISPAD) 2014
Guidelines for HbA1c to categorize participants’ glycemic control: for ages <18 years, 1)
<7.5% is optimal, 2) 7.5-9.0% is suboptimal, and (3) >9.0% is high risk 32,124; for ages
≥18 years, 1) <7.0% is optimal, 2) 7.0-9.0% is suboptimal, and 3) >9.0% is high risk
32,39,124

.

Arterial Stiffness
The measure of arterial stiffness used in this analysis was Pulse Wave Velocity
(PWV), which was assessed on all participants at the SEARCH cohort visit. The
SEARCH study has collected data on three measures of PWV which reflect difference
segments of the arterial tree: carotid-femoral, carotid-radial, and carotid-foot, and all
three were examined as outcomes in this study. PWV was measured using the
SphygmoCor CPVH System from AtCor Medical (Lisle, IL). All measurements were
performed three times and the average of the three measures was recorded. First, the
participant laid down in a comfortable position. Then, using a tape measure, the distance
between the suprasternal notch to the umbilicus was measured to obtain the distal
distance between those two points. Next, the distance between the umbilicus and the
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strongest pulse at the femoral artery was measured to obtain the distal femoral distance.
Next, the distance between the femoral artery and the point with the strongest pulse on
the top of the foot was measured to obtain the distal foot distance. Next, the distance
between the suprasternal notch to the radial artery on the thumb’s side of the patient’s
wrist was measured to obtain the distal distance between these two points. Finally, the
distance between the carotid and the suprasternal notch was obtained as a measure of the
proximal distance for all measures. Using a tonometer, which is a device used to obtain
arterial blood pressure waveforms, the waveform from the proximal site (carotid) and
waveforms from each of the distal sites (femoral, radial, and foot) were obtained. The
PWV was calculated as the difference between the carotid-to-distal path length divided
by the difference in R-wave-to-waveform foot times. The R wave-to-waveform foot time
is a measure of the duration of one cardiac cycle. This process was repeated ten times to
obtain one measure of PWV. For each PWV measure (femoral, radial, and foot) an
average of three measures was recorded. According to the SEARCH protocol this
measure of PWV has demonstrated excellent reproducibility in the targeted age group.
PWV was considered as a continuous variable in all analyses.
Although, the carotid-femoral measure is considered the “gold standard” measure
of arterial stiffness and is the only measure of PWW with extensive validation and
demonstration of an association with increased risk of future cardiovascular events,22 all
three measures of PWV were considered as outcomes in this study to evaluate whether
there were differences in the association between depressive symptom trajectories and the
three measures of PWV.
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Demographic and Socioeconomic Variables
Age at diagnosis was determined by calculating the difference between date of
birth and date of diabetes diagnosis. Self-reported sex was collected from the initial
patient questionnaire. Self-reported race/ethnicity was categorized as non-Hispanic white,
non-Hispanic black, Hispanic, and other, with non-Hispanic white serving as the
reference group. Parental education was defined as the highest education level achieved
by either parent/guardian and categorized as less than high school, high school graduate,
some college, and college graduate, with less than high school as the reference group.
Household income was categorized as less than $25,000, $25,000-49,999, $50,00074,999, and $75,000 and greater, with less than $25,000 as the reference group. Insurance
type was categorized as private, government-funded, and other/none, with private as the
reference group. Family structure was categorized as two-parent household or singleparent household/ other structure, with two-parent household as the reference group.
These categorizations have been utilized in previous publications using SEARCH data
and were used in the present research to maintain consistency with these previous
publciations.4,40,45
Diabetes Self-Care and other Clinical Variables
Insulin regimen was categorized as insulin pump, basal/bolus injections,
and other regimen, with insulin pump as the reference category. Self-reported frequency
of blood glucose monitoring was categorized as ≤ 2 times per day, 3 times per day, and ≥
4 times per day with ≥ 4 times per day as the reference. Participants self-reported whether
they had experienced severe hypoglycemic episodes requiring assistance and/or episodes
of diabetic ketoacidosis in the previous six months. Body mass index (BMI) was
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calculated based on the weight and height of the participant collected during the physical
exam at the study visit as kg/m2, was converted to a z-score to standardize the
interpretation of BMI at different ages, and compared to the 2000 Centers for Disease
Control and Prevention standards.125 Participants reported all medication they were
currently taking, and any medications that belonged to antidepressant, antianxiety, or
antipsychotic/antimanic classes were categorized as psychiatric medications.4
Lifestyle Variables
Physical activity was assessed by the number of days of exercise reported in the
past seven days. Participants were asked to report the number of days in the previous
week in which they exercised for at least 20 minutes. Number of days with physical
activity per week was used as a continuous variable. Tobacco use was assessed by
whether the participant reported ever trying cigarette smoking. Diet quality was assessed
using the DASH diet score, as calculated from a one-week food frequency questionnaire,
in which participants indicated whether they had consumed and the frequency with which
they consumed 85 listed food items.126 These 85 food items were divided into eight food
groups: grains, vegetables, fruits, dairy, meats, nuts/seeds/legumes, fats/oils, and sweets
which were used to create the DASH diet score, which ranges from 0 to 80. Higher scores
indicated greater adherence to the DASH diet.126
Statistical Analysis
Descriptive Statistics
Descriptive statistics were calculated for baseline demographic, clinical, and
lifestyle characteristics for the study sample. Missing data were assessed to determine
whether those who were excluded from analyses (those with fewer than two CES-D
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responses) differed with regard to key variables of interest measured at baseline,
including baseline demographics.
Aim 1
Group-based trajectory modeling (GBTM) was used to identify latent trajectories
of depressive symptoms among YYA with T1D, utilizing the CES-D scale total score as
the measure of depressive symptoms, measured at the baseline, 12-month, 24-month, and
60-month visits. Duration of diabetes in months was used as the time scale to model
depressive symptom trajectories. GBTM is a statistical approach which allows for the
identification of subgroups of individuals within a population that follow approximately
the same trajectory on a particular outcome over time.127–129 This analysis was conducted
using the PROC TRAJ procedure in SAS (v.9.4, Cary, NC), which was developed to
conduct GBTM as developed by Nagin.130–132 This procedure applies a semi-parametric,
group-based modeling strategy using mixture models.131
GBTM is one of several approaches that may be used to model trajectories of
particular outcomes over time; other approaches include hierarchical modeling and latent
curve analysis.133 Each approach makes different assumptions about trajectory
distributions in the population, and the assumptions made by GBTM are arguably most
suited for this particular analysis. Both hierarchical modeling and latent curve analysis
assume that the mean and covariance structure of the trajectories are continuously
distributed across individuals and are explainable by the multivariate normal
distribution.133 These methods are used to estimate individual variability around the mean
trend in the population of interest.127 GBTM, on the other hand, does not assume that the
mean and covariance of the trajectory is continuously distributed, but rather assumes that
there are groups of distinct trajectories that approximate underlying patterns.133 Due to
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these differences, GBTM may be used to identify distinct groups of individuals with
similar trajectories, and to determine predictors of membership in each trajectory group
as well as outcomes associated with trajectory group membership.133 Hierarchical
modeling and latent curve analysis are better suited when it is safe to make an assumption
that most individuals in a population experience similar growth, but at different rates.133
GBTM, however, is best for processes that differ among individuals. In the case of
depression, it is typically not assumed that everyone will follow a similar pattern – for
example, not everyone will experience an increase in depression, or demonstrate
chronically elevated depressive symptoms.133 Rather, some groups of individuals may
experience increasing depressive symptoms over time, some decreasing, etc. GBTM can
capture these group differences within the study population.
Model selection was performed based on the recommendations of Nagin and
Odgers (2014)129. The Bayesian information criteria (BIC) was the primary statistical
criteria used to determine the appropriate number of trajectory groups. We used a twostage process for model selection, as described by Nagin.133 In the first stage, the
appropriate number of trajectory groups was assessed by running models for two through
six trajectory groups. The model with the highest BIC value was be chosen at this stage.
In the next stage, the appropriate order of polynomial to model the shape of trajectories
was chosen, with the model with the highest BIC value chosen. Although BIC was the
primary statistical criteria, a subjective assessment was also considered during this
process. Often, the BIC will increase as the number of groups increase even if these
additional groups add little to no value in understanding the underlying patterns of
depressive symptoms across time.133 Thus, in addition to considering BIC in choosing the
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appropriate model, we also considered the purpose of this analysis as identifying
distinctive trajectories of depressive symptoms over time in choosing the appropriate
model.
Previous research has demonstrated that sample size has a modest impact on the
model selection process for GBTM.134 Specifically, above a sample size of 200, the
model selection process typically does not change or improve with the addition of
additional participants.134 Thus, with the expected sample size of more than 800 for this
study, there should be no limitations associated with the model selection process due to
the sample size utilized.
Once the appropriate model was selected, posterior probabilities of group
membership were calculated for each participant. These probabilities describe the
likelihood that an individual belongs to each trajectory group.133 Each participant was
assigned to the trajectory group with the highest posterior probability of membership for
subsequent analyses. Two diagnostics were computed to assess the accuracy of the model
in terms of group assignment, as described by Nagin.133 The first diagnostic was the
average posterior probability for each trajectory group. Ideally, the average posterior
probability should be greater than 0.7 for each group.133 The second diagnostic was the
odds of correct classification, which is the odds of correct classification into each group
divided by the odds of correct classification based on random assignment.133 This value
should ideally be greater than 5.0 for each group for the model to demonstrate accurate
group assignment.133 Had the above diagnostics demonstrated that assignment to
trajectory groups performed poorly based on the selected model, it may have been
necessary to conduct growth mixture modeling as opposed to GBTM. Using this method,
45

it would be possible to allow parameters, such as means and variances, to vary within
each trajectory class in addition to across classes.135 This is in contrast to GBTM, in
which the variance is fixed to zero within classes and only varies between classes.135
Following classification of participants, each identified trajectory group was
plotted and summarized with regard to the burden of depressive symptoms and the shape
of the trajectory over time.
Additionally, we examined whether trajectory group membership was modified by age at
diagnosis or age at baseline visit.
Aim 2
In order to assess baseline correlates of depressive symptom trajectory groups, the
bivariate associations between the following baseline measures and trajectory groups
were assessed using multinomial logistic regression, with the trajectory group
representing little to no depressive symptoms across time as the reference group:
demographic characteristics (age at diagnosis, sex, race, parental education, household
income, family structure, insurance status), diabetes self-care measures (insulin regimen,
hypoglycemic episodes, diabetic ketoacidosis episodes, frequency of blood glucose
monitoring), and other clinical and behavioral characteristics (use of antidepressant
medications, body mass index, tobacco use, and physical activity). Next, all variables
were entered into a multivariable, multinomial logistic regression model predicting
trajectory group membership.
Aim 3
In order to assess the association between trajectory group membership and
glycemic control, two primary analyses were performed. First, an ANCOVA model was
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assessed, with trajectory group membership predicting a continuous measure of HbA1c
% assessed at the cohort visit. A crude model was assessed, followed by adjusted models:
Adjustment 1 included demographic characteristics: age at diagnosis, sex, race/ethnicity,
and study site. Adjustment 2 included the previous covariates in addition to
socioeconomic and behavioral characteristics assessed at baseline: parental education,
household income, family structure, health insurance status, BMI, tobacco use, and
physical activity. Adjustment 3 included the previous covariates in addition to and insulin
regimen, and adjustment 4 additionally included use of antidepressant medications. This
process was repeated to assess the association between depressive symptom trajectory
group and categorical glycemic control, using logistic regression to predict levels of
glycemic control. Glycemic control was categorized into two levels: optimal/suboptimal,
and high-risk, as described above, with optimal/suboptimal as the reference group. The
directed acyclic graph (DAG), presented below depicts the association between trajectory
group membership, glycemic control, and covariates. The DAG was created using
DAGitty v2.3.

Figure 3.1: Directed Acyclic Graph Depicting the Association between Depressive
Symptom Trajectory Groups and Glycemic Control
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Aim 4
In order to assess the association between trajectory group membership and
arterial stiffness, an ANCOVA was assessed, with trajectory group membership
predicting each of the continuous measures of PWV assessed at the cohort visit (carotidfemoral, carotid-radial, and carotid-foot). A crude model was assessed, followed by
adjusted models: Adjustment 1 included demographic characteristics: age at diagnosis,
sex, race/ethnicity, and study site. Adjustment 2 included the previous covariates in
addition to socioeconomic and behavioral characteristics assessed at baseline: parental
education, household income, family structure, health insurance status, BMI, tobacco use,
and physical activity. Adjustment 3 included the previous covariates in addition to and
insulin regimen, and adjustment 4 additionally included use of antidepressant
medications. The DAG below depicts the association between trajectory group
membership, arterial stiffness, and covariates.

Figure 3.2: Directed Acyclic Graph Depicting the Association between Depressive
Symptom Trajectory Groups and Arterial Stiffness
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CHAPTER 4
DEPRESSIVE SYMPTOM TRAJECTORIES AMONG YOUTH AND YOUNG
ADULTS WITH TYPE 1 DIABETES IN THE SEARCH FOR DIABETES IN YOUTH
STUDY1

Melanie W. Sutherland, Angela D. Liese, Matthew Lohman, Kate Flory, Monique
Brown. Not yet submitted.
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Abstract
Background: Type 1 diabetes (T1D) is one of the most frequently diagnosed chronic
illnesses among youth, and YYA with T1D are at increased risk of depression, which has
been associated with adverse outcomes such as poor adherence to self-management and
poor glycemic control, which increase the risk of diabetes complications. Although a
robust body of research exists on the association between comorbid depression and
glycemic control among persons with T1D, little research has been conducted on the
change in depressive symptoms over time among YYA with T1D. The purpose of this
study is to characterize the burden of depressive symptoms over time in youth and young
adults (YYA) with type 1 diabetes (T1D) by identifying subgroups that have similar
trajectories of depressive symptoms and assessing baseline predictors of these
trajectories.
Methods: YYA diagnosed with T1D between 2002-2005, ages 10 to 21 years, who were
enrolled in the SEARCH for Diabetes in Youth Study baseline were included (n = 879,
47.6% female, 76.3% non-Hispanic white). Participants provided a baseline and at least
one follow-up measure of depressive symptoms using the Center for Epidemiologic
Studies – Depression (CES-D) scale over a five-year period. Group-based trajectory
modeling was used to assign individuals to the most likely depressive symptom trajectory
class, and multinomial logistic regression was used to assess predictors of trajectories.
Depressive symptoms were interpreted based on established CES-D cut-offs for
adolescents: minimal (0-15), mild (16-23), and moderate/severe (24-60).
Results: Five depressive symptom trajectory classes were identified: little to no
symptoms (63.2%), persistent minimal (22.2%), increasing from mild to moderate
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(4.6%), decreasing from mild to minimal (6.7%), and chronic moderate (3.3%). After
adjustment for all covariates, female gender, experiencing at least one severe
hypoglycemic and/or diabetic ketoacidosis episode, and living in a single-parent home
distinguished those who experienced clinically significant depressive symptoms from
those who experienced little to no depressive symptoms.
Conclusion: Among YYA with T1D, unique trajectories of depressive symptoms show
meaningful differences in demographic, socioeconomic, clinical, and lifestyle
characteristics. These results provide insight into the identification of high-risk groups
and potential target populations for prevention of chronic depressive symptoms.
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Introduction
Type 1 diabetes (T1D) is one of the most frequently diagnosed chronic illnesses
among adolescents, with approximately 1 in 518 youths younger than 20 years of age
being affected, as of 2009.1 Incidence among adolescents has also been increasing over
time.2 T1D has many potentially serious short-term and long-term complications. These
conditions include severe hypoglycemia, potentially resulting in loss of consciousness,
and severe hyperglycemia, resulting in the potentially life-threatening illnesses including
diabetic ketoacidosis, retinopathy, neuropathy, nephropathy, cardiovascular disease, and
amputation.3 One potential risk factor for failure to achieve and maintain glycemic
control which increases the risk of these complications is elevated depressive symptoms
among youth and young adults with T1D.4
Research has shown that those living with T1D are often at increased risk of
depression and subclinical levels of depressive symptomology5 which in turn have been
associated with poor adherence to self-management, poor glycemic control, and increased
hospital and emergency room visits.4,6–8 Although a robust body of research exists on the
effects of comorbid depression on health outcomes among persons with T1D, little
research has been conducted on the change in depressive symptoms over time among
youth and young adults (YYA) with T1D. What is known to date is that the overall level
of depressive symptoms typically remains stable over time in a group of youth and young
adults with T1D.45 However, this research captures only changes in the overall mean
level of symptoms in this sample but does not describe individual trajectories. Of interest
in the current investigation is whether there are subgroups of individuals among youth
and young adults with T1D who demonstrate distinct trajectories, or patterns in changes
or stability, of depressive symptoms over time.
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Studies of individuals free of diabetes have shown that there are typically between
three and six unique depressive symptom-related trajectory groups among those aged 15
– 25 and there are consistently groups reflecting little to no depressive symptoms and
chronically elevated symptoms across studies.136 The majority of adolescents and young
adults typically follow a trajectory of no depressive symptoms and a small proportion,
usually around 5%, report chronically elevated symptoms.136 Additional groups vary by
study, but typically reflect increasing or decreasing symptoms over time.136
Because they are dealing with a lifelong, incurable chronic health condition that is
usually diagnosed in adolescence, the population of YYA with T1D may exhibit different
depressive symptom trajectories compared to the general population, and these
trajectories potentially have implications for the management and control of T1D and the
prevention of diabetes complications. Understanding the composition of the distinct
trajectories of depressive symptoms and their predictors will further clarify the role of
depressive symptoms in diabetes care and outcomes among YYA with T1D. The goals of
this study are to 1) identify longitudinal trajectories, or patterns, of depressive symptoms
among youth and young adults with T1D and 2) identify baseline demographic,
socioeconomic, clinical, and lifestyle characteristics associated with membership in these
depressive symptom trajectory groups.
Methods
Design
The SEARCH for Diabetes in Youth (SEARCH) study is an observational, multicenter, population-based study that has identified incident cases of non-gestational
diabetes diagnosed among youth less than 20 years of age since 2002.118 SEARCH 1
(2000-2005) identified prevalent and incident cases of diagnosed diabetes and included
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baseline study visits. SEARCH 2 (2005-2010) included 12-, 24-, and 60-month follow-up
visits among incident cases diagnosed 2002-2005. SEARCH 3 continued to collect
incident cases and established a cohort, which included incident cases diagnosed between
2002-2005 with a minimum of a baseline visit and 5 years of diabetes duration as well as
incident cases from 2008 and 2012. The present analysis only includes incident cases
between 2002-2005 because these are the only participants who completed the 12-, 24-,
and 60-month follow-up visits (Figure 4.1a). Five clinical centers in the United States
contributed participants for the cohort study: South Carolina (all counties), Ohio
(Cincinnati and eight surrounding counties), Colorado (all counties), Southern California
(members of Kaiser Permanente Medical Care Program Health Plan in Southern
California, except San Diego), and Washington (four counties surrounding Seattle).119
Population
The present analysis was limited to participants with T1D diagnosed by a
physician between the years 2002-2005, were at least ten years old at baseline, and were
included in the SEARCH cohort. This sample included the 1,203 participants with T1D
who were between the ages of 10 and 21 years at the baseline visit. For the purposes of
this analysis, only individuals with physician-diagnosed T1D diagnosed between the
years 2002-2005 were included. These participants completed up to four visits: baseline,
12-month, 24-month, and 60-months. All participants less than 10 years of age were
excluded because these participants did not complete the Center for Epidemiologic
Studies – Depression (CES-D) questionnaire. Initially, participants with a minimum of
three CES-D measures, including a baseline measure, were included to reduce the
likelihood of misclassification using group-based trajectory modeling (GBTM).120 This
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reduced the eligible sample size to 586. To retain a greater proportion of the sample, we
tested whether it was feasible to include participants with a minimum of two CES-D
measures, including a baseline measure, and maintain a suitable GBTM. After
performing the model selection procedure for both samples, we found that there were no
differences between the sample with a minimum of two and the sample with a minimum
of three CES-D measures. Thus, we used the resulting sample size of 879 YYA with T1D
and at least two CES-D measures included in the final GBTM analysis (Figure 4.1b).
Data Collection
IRB approval was obtained for data collection at each study site prior to the
initiation of study procedures. Participants provided informed consent (if ≥18 years old)
or assent (if <18 years old) along with parental consent before data collection.
Participants attended in-person study visits, in which they completed questionnaires,
physical exams, and laboratory tests. Questionnaires included data on demographics,
medical history, and physical and mental health. Physical exams and laboratory tests
assessed chronic complications of diabetes, glycemic control, and other relevant risk
factors associated with diabetes. Questionnaires involving information on age, sex, age at
diagnosis, history of diabetic ketoacidosis, insulin use, prescription medications, and
race/ethnicity were filled out by either the participant or his/her legal guardian, depending
on the age of the participant. A parent or guardian completed these questionnaires on
behalf of participants under the age of 18. All information about depressive symptoms
and health behaviors was provided by the participant, regardless of age.
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Measures
Depressive symptoms. Depressive symptoms were assessed at each study visit in
participants ≥ 10 years of age using the Center for Epidemiologic Studies Depression
(CES-D) scale.72 The CES-D is a 20-item scale which was designed to measure the
current level of depressive symptomatology in the general population.72 Items on the
scale reflect symptoms assessed in the diagnosis of depression, focusing on depressed
mood,72 including statements such as “I felt depressed,” “I felt that everything I did was
an effort,” and “I thought my life had been a failure.”72 Participants reported the
frequency with which symptoms occurred in the past week, with responses ranging from
0 (rarely or none of the time) to 3 (most or all of the time).72 The sum of all item
responses ranges from 0 to 60, with higher scores indicating more depressive
symptoms.72 Traditionally, a cut-off of 16 is used to distinguish between depressed and
non-depressed individuals in adult populations.72,73 In adolescent populations, a cut-off
of 24 was found to be more appropriate for identifying depressed mood as defined by the
DSM.121 The accepted categories for assessing depressed mood in adolescents ages 14-18
based on CES-D score are as follows: minimal (0-15), mild (16-23), and moderate/severe
(24-60).121 The main analyses were conducted using the continuous CES-D score, thus
these cutoffs were used for interpretation only. The CES-D was initially validated in an
adult sample (Cronbach’s alpha = 0.85) and was subsequently validated in an adolescent
population (Cronbach’s alpha = 0.84-0.87 in various samples).72,73 In the present sample,
the Cronbach’s alpha = 0.86.
Baseline Demographic and Socioeconomic Variables. Age at diagnosis was
determined by calculating the difference between date of birth and date of diabetes
56

diagnosis. Self- or parent-reported sex was collected from the initial patient
questionnaire. Self- or parent reported race/ethnicity was categorized as non-Hispanic
black, Hispanic, and other vs. non-Hispanic white. Parental education was defined as the
highest education level achieved by either parent/guardian and categorized as high school
degree or less, some college vs. college graduate. Household income was categorized as
less than $25,000, $25,000-49,999, $50,000- 74,999, and $75,000 and greater, with less
than $25,000 as the reference group. Insurance type was categorized as governmentfunded or other/none vs. private. Family structure was categorized as single-parent
household or other structure vs. two-parent household.
Baseline Diabetes Self-Care and other Clinical Variables. Hemoglobin A1c
(HbA1C) was used as the standard measure of glycemic control over the past three
months. Whole blood samples collected during the study visit were analyzed for HbA1C
by the Northwest Lipid Metabolism and Diabetes Research Laboratories in Seattle, WA,
using an automated nonporous ion-exchange high-performance liquid chromatography
system (model G-7; Tosoh Bioscience, Montgomeryville, Pennsylvania).39 Glycemic
control was then characterized both using the continuous measure (%) and as a
categorical variable based on the ADA and International Society for Pediatric and
Adolescent Diabetes (ISPAD) 2014 Guidelines for HbA1c : for ages <18 years, 1) <7.5%
is optimal, 2) 7.5-9.0% is suboptimal, and (3) >9.0% is high risk;32,124 for ages ≥18 years,
1) <7.0% is optimal, 2) 7.0-9.0% is suboptimal, and 3) >9.0% is high risk.32,39,124
Insulin regimen was categorized as insulin pump, basal/bolus injections, and
other regimen, with insulin pump as the reference category. Self-reported frequency of
blood glucose monitoring was categorized as ≤2 times per day, 3 times per day, and ≥ 4
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times per day, with ≥ 4 times per day as the reference group. Participants self-reported
whether they had experienced severe hypoglycemic episodes which required assistance
from another person and episodes of diabetic ketoacidosis within the previous six
months. Body mass index (BMI) was calculated based on the weight and height of the
participant collected during the physical exam at the study visit as kg/m2, was converted
to a z-score to standardize the interpretation of BMI at different ages, and compared to
the 2000 Centers for Disease Control and Prevention standards.125 Participants reported
all medication they were currently taking, and any medications that belonged to
antidepressant, antianxiety, or antipsychotic/antimanic classes were categorized as
psychiatric medications.4
Lifestyle variables. Physical activity was assessed by the number of days of
exercise reported in the past seven days. Participants were asked to report the number of
days in the previous week in which they exercised for at least 20 minutes. Number of
days with physical activity per week was used as a continuous variable. Tobacco use was
assessed by whether the participant reported ever trying cigarette smoking.
Statistical Analysis
Descriptive Statistics. Descriptive statistics were calculated for baseline
demographic, clinical, and lifestyle characteristics for the study sample. Missing data
were also assessed to determine whether those who were excluded from analyses (those
with fewer than two CES-D responses) differed with regard to key variables of interest
measured at baseline, including baseline demographics. Additionally, we examined
missing data patterns to determine whether different patterns were associated with
different mean scores on the CES-D.
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Group-Based Trajectory Modeling. Group-based trajectory modeling (GBTM),
was used to identify latent trajectories of depressive symptoms among YYA with T1D,
utilizing the CES-D scale total score as the measure of depressive symptoms, measured at
the baseline, 12-month, 24-month, and 60-month visits. Duration of diabetes in months
was used as the time scale to model depressive symptom trajectories. GBTM is a
statistical approach which allows for the identification of subgroups of individuals within
a population that follow approximately the same trajectory on a particular outcome over
time.127–129 This analysis was conducted using the PROC TRAJ procedure in SAS (v.9.4,
Cary, NC), which was developed to conduct GBTM as described by Nagin.130–132 This
procedure applies a semi-parametric, group-based modeling strategy using mixture
models.131
Model selection was performed based on the recommendations of Nagin and
Odgers (2014)129. This process was first conducted separately among participants who
provided a minimum of three CES-D measures and those who provided a minimum of
two CES-D measures. This process was completed separately for both samples to
determine whether it would be appropriate to utilize the larger sample including those
with fewer CES-D measures. Because the results of the model selection procedure were
similar for both samples, the larger sample size was selected for all subsequent analyses.
The results of the model selection procedure for only those participants with a minimum
of three CES-D measures are presented in Appendix A.
A total of 26.9% of otherwise eligible participants were excluded due to missing
CES-D data, leaving a final sample size of 879. Those excluded from the GBTM were on
average older, had lower parental education and household income, and were more likely
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to use government-funded health insurance compared to those who were included (see
Table B1). Missing data patterns were also examined (see Table B2). Mean CES-D
scores were similar at each visit across patterns of missingness.
We used a two-stage process for model selection, as described by Nagin.133 In the
first stage, the appropriate number of trajectory groups was assessed by fitting models for
two through six trajectory groups. Nagin suggests selecting the model with the highest
BIC value at this stage. In the next stage, the appropriate order of polynomial to model
the shape of trajectories was chosen, based on the model with the highest Bayesian
information criterion (BIC) value. Often, the BIC will increase as the number of groups
increase even if these additional groups add little to no value in understanding the
underlying patterns of depressive symptoms across time.133 Thus, in addition to
considering BIC in choosing the appropriate model, we also subjectively considered the
purpose of this analysis as identifying distinctive, meaningful trajectories of depressive
symptoms over time in choosing the appropriate model. Thus, although the BIC was
slightly higher for the six-class model (-8424.70 vs. -8425.67 for the five-class model)
(see Table B3), the five-class model was selected because the additional class added in
the six-class model did not add any meaningful value in terms of depressive symptom
interpretation.
Once the appropriate model was selected, posterior probabilities of group
membership were calculated for each participant. These probabilities describe the
likelihood that an individual belongs to each trajectory group.133 Each participant was
assigned to the trajectory group with the highest posterior probability of membership for
subsequent analyses. Two diagnostics, presented in Table B4, were computed to assess
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the accuracy of the model in terms of group assignment, as described by Nagin.133 The
first diagnostic was the average posterior probability for each trajectory group. Ideally,
the average posterior probability should be greater than 0.7 for each group.133 Average
posterior probabilities ranged from 0.74-0.92. The second diagnostic was the odds of
correct classification, which is the odds of correct classification into each group divided
by the odds of correct classification based on random assignment.133 This value should
ideally be greater than 5.0 for each group for the model to demonstrate accurate group
assignment.133 The odds of correct classification ranged from 6.7 – 336.
In order to assess baseline correlates of trajectory group membership, the bivariate
associations between the following baseline measures and trajectory group membership
were assessed using multinomial logistic regression, with the trajectory group
representing minimal depressive symptoms across time as the reference group:
demographic and socioeconomic characteristics (age at baseline visit, age at diagnosis,
sex, race, parental education, household income, family structure, insurance status),
diabetes self-care measures (insulin regimen, severe hypoglycemic episodes, diabetic
ketoacidosis episodes, frequency of blood glucose monitoring), and other clinical and
behavioral characteristics (glycemic control, use of psychiatric medications, BMI,
tobacco use, and physical activity). Next, all variables were entered into a multivariable,
multinomial logistic regression model predicting trajectory group membership.
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Results
Depressive Symptoms
The mean CES-D score in the overall study sample was similar at all study visits
(baseline mean (SD) = 9.72 (8.17), 12-month = 9.46 (8.30), 24-month = 9.13 (7.70), and
60-month = 9.72 (8.66), p = 0.54).
Figure 4.2 displays the predicted depressive symptom trajectories based on the
five-class GBTM. The majority of the participants (63.2%) fell into a trajectory that
indicated little to no depressive symptoms throughout the follow-up period, with a mean
CES-D score of around 5 at each visit. The second largest trajectory group (22.2%)
indicated stable, minimal symptoms across time, with mean CES-D scores ranging from
around 12-16 at each visit. Three smaller trajectory groups were characterized by varying
degrees of clinically significant depressive symptoms. One of these trajectories (6.7%)
identified those who first reported mild depressive symptoms, which decreased to
minimal symptoms over time, with a baseline mean CES-D score of around 25
decreasing to around 9 at the final follow-up visit. Another trajectory (4.6%) identified
participants who reported mild symptoms at baseline, with a mean CES-D score of
around 15 at baseline increasing to around 35 at the final follow-up visit. Finally, the
smallest trajectory group (3.3%) identified participants who reported chronically elevated
depressive symptoms with mean CES-D scores ranging from 33 to 25 across follow-up.
Baseline Characteristics
Participant characteristics at baseline for the sample and by depressive symptom
trajectory group are displayed in Table 4.1. The average age at the baseline visit was 13.6
years and the average age at diabetes diagnosis was 12.7 years. The sample was 47.6%
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female, 76.3% non-Hispanic white, 10.7% non-Hispanic black, and 10.7% Hispanic. On
average, the sample had a relatively high socioeconomic status: 47.3% reported parental
education of bachelor’s degree or higher, 39.8% had a household income of ≥$75,000,
81.4% used private health insurance, and 66.6% lived in a two-parent household. The
mean HbA1c was 7.6%, and 16.9% had high-risk glycemic control. Additionally, 6.7%
experienced at least one severe hypoglycemic episode and 17.8% experienced at least one
episode of diabetic ketoacidosis in the previous 6 months. The majority of participants
did not use an insulin pump (90.8%) and only 3.6% were taking psychiatric medications.
The mean (SD) BMI z-score was 0.6 (0.9), 14.1% had tried cigarette smoking at least one
time, and participants reported exercising on average 3.6 days per week.
Baseline Predictors of Trajectory Group Membership
There were no statistically significant differences in age at baseline visit across
the trajectory groups, although, the chronic moderate group had a non-significantly
higher age, with a mean age of 14.4 years compared to a mean age ranging from 13.1 to
13.7 among the other trajectory groups (see Table 4.1). In unadjusted models, statistically
significant predictors of trajectory group membership included sex, race/ethnicity,
parental education, family income, health insurance status and family structure. Table B5
displays unadjusted odds ratios for baseline characteristics predicting depressive
symptom trajectory group.
In a model adjusted for all baseline characteristics, age at baseline visit, parental
education, family income, health insurance status, family structure, baseline HbA1c,
severe hypoglycemic events, episodes of diabetic ketoacidosis, frequency of blood
glucose monitoring, use of psychiatric medications, BMI, having ever tried cigarette
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smoking, and exercise were significantly associated with trajectory group membership
(see Table 4.2). Compared to those in the little to no symptoms group, those in all other
groups were more likely to have tried smoking cigarettes. Those in the stable minimal
group were younger, less likely to have parents with a bachelor’s degree or more and
were more likely to have non-government, non-private, or no health insurance, had a
lower frequency of blood glucose monitoring, and higher BMI z-scores compared to
those in the little to no symptoms group. Those in the decreasing mild to minimal group
were younger, had a lower family income, were more likely to use non-government, nonprivate, or no health insurance, and had a higher HbA1c on average compared to the little
to no symptom group. Those in the increasing mild to moderate group were more likely
to live in a single-parent household, more likely to use psychiatric medications and less
likely to participate in physical activity compared to the little to no symptom group.
Those in the chronic moderate group were more likely to be female, more likely to have
parent with a high school degree or less, more likely to have to have experienced at least
one severe hypoglycemic event and/or to have experienced at least one episode of
diabetic ketoacidosis in the previous six months, and to use psychiatric medications
compared to the little to no symptom group.
Discussion
Five unique depressive symptom trajectory groups were identified in this sample
of YYA with T1D who were followed for up to five years between 2002-2010. The
majority of the sample reported little to no or minimal depressive symptoms at any
timepoint (63.2%) or minimal depressive symptoms (22.2%), whereas a small proportion
of the sample reported potentially clinically significant symptoms - decreasing from mild
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to minimal over time (6.7%), increasing from mild to moderate over time (4.6%) or
chronic, moderate symptoms (3.3%). The five depressive symptom trajectory groups
differed with regard to demographic, socioeconomic, clinical, and behavioral
characteristics, providing potential means of identifying those who have an increased
likelihood of experiencing the most severe depressive symptoms and thus to monitor
these groups more closely and potentially intervene earlier.
Our study revealed that the different depressive symptom trajectory groups
differed with regard to several demographic, socioeconomic, clinical, and lifestyle
characteristics. The chronic moderate symptom group, which reported the highest levels
of depressive symptoms of the four groups, was demographically unique in that it was
composed of participants who were more likely to be female. These findings are
consistent with the majority of previous research demonstrating that females typically
experience greater rates of depression and more depressive symptoms during adolescence
compared to males.137 Additionally, this group differed from the stable little to no
symptom group on several key clinical and behavioral characteristics, including increased
odds of experiencing severe hypoglycemic and/or diabetic ketoacidosis episodes and use
of psychiatric medications. These results differ from previous research using crosssectional data from the SEARCH study that did not show significant differences in these
clinical variables by depressive symptom severity measured at baseline.4 However, this
cross-sectional analysis included both type 1 and type 2 diabetes, making it difficult to
directly compare the results. One strength of this analysis is the longitudinal collection of
CES-D scores, demonstrating that although clinical diabetes events may not be related to
a cross-sectional measure of depressive symptoms, those who experience at least one
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episode of severe hypoglycemia and/or diabetic ketoacidosis have a greater likelihood of
experiencing chronic, clinically significant depressive symptoms. Thus, YYA with T1D
who are female, and/or have experienced severe hypoglycemia and/or diabetic
ketoacidosis should be closely monitored with regard to depressive symptoms in clinical
practice.
Although experiencing only mild symptoms at baseline, those in the increasing
mild to moderate symptom group reported the highest level of depressive symptoms
compared to all other groups at their last follow-up visit. This group differed from the
little to no symptom group on several baseline characteristics: increased likelihood of
living in a single-parent home, use of psychiatric medications, and behavioral factors
including having tried cigarette smoking, and lower frequency of exercising. The more
frequent use of psychiatric medications suggests that although CES-D symptoms were
not elevated at baseline in this group, at least 13.5% of participants were receiving
psychiatric care of some sort, which may have influenced reports of baseline depressive
symptoms. This group reported a greater likelihood of less healthy behavioral
characteristics, including cigarette smoking and relatively low levels of physical activity.
Previous research has demonstrated that both physical activity and use of tobacco
products are risk factors for depression in adolescents. The inverse association between
physical activity and depressive symptoms has been demonstrated in both crosssectional84,86,88 and longitudinal18,83,85 studies in populations ranging in age from 9 to 29
years. One study examining depressive symptom trajectories among YYA between the
ages of 12 and 29 years found that physical activity levels were highest among those with
stable, low depressive symptoms over time compared to those with increasing,
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decreasing, or persistently high depressive symptoms.18 A systematic review of
longitudinal studies examining the association between smoking tobacco and depressive
symptoms including participants ranging in age from 13 to 19 years found that tobacco
smoking is consistently associated with an increased risk of depression.90 The current
investigation adds to this literature by demonstrating that reduced physical activity and
increased frequency of having tried cigarettes at baseline predicts an increase in reports
of depressive symptoms over time. Thus, although these individuals do not report
clinically significant depressive symptoms soon after T1D diagnosis, those who live in
single-parent homes, who have tried smoking cigarettes, and/or do not exercise often
have an increased likelihood of developing clinically significant depressive symptoms in
the future and should be monitored closely for depression in clinical practice.
The stable minimal and decreasing mild to minimal symptom groups were similar
in several respects. They both differed from the little to no symptom group by age and
socioeconomic characteristics. After adjustment for covariates, these groups had a greater
likelihood of younger age compared to the little to no symptom group. These findings are
unexpected, as previous research has shown that the prevalence of depression typically
increases with age during childhood and adolescence.138 Thus, we might expect the little
to no symptom group to have the youngest age at baseline compared to all groups who
reported non-clinically relevant depressive symptoms at baseline. One implication of
these findings is that reports of mild depressive symptoms among younger ages may be
more likely to be transient in nature and not persist throughout adolescence. This aligns
with previous research showing that depressive symptoms reported at younger ages are
more likely to be situationally-dependent rather than chronic.139
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Additionally, the stable minimal and decreasing mild to minimal symptom
groups were more likely to have lower parental education (stable minimal) or lower
family income (decreasing mild to minimal) and to not have health insurance compared
to the little to no symptom group (although health insurance was not statistically
significant for the stable minimal group). Thus, although these groups did not report
potentially clinically significant depressive symptoms for the majority of follow-up, they
still differed from the little to no symptom group on these key baseline socioeconomic
characteristics. Thus, measures reflecting lower socioeconomic status predict minimal to
mild depressive symptoms that likely do not have clinical implications.
Strengths of this study include the longitudinal design with multiple measures of
depressive symptoms across up to five years of follow-up. The SEARCH study is a
diverse cohort of youth with T1D, with a relatively large sample size. Additionally, the
SEARCH study has collected measures of depressive symptoms longitudinally, with up
to four measures contributing to trajectories in the present study. Another strength of this
study is the use of GBTM, an advanced statistical method, which provides a data-driven
approach to model depressive symptom trajectories. This method allows for the
identification of meaningful subgroups within a population, rather than examining the
mean change in an outcome over time. The use of simply the mean number of depressive
symptoms over time may mask meaningful differences within the study population,
whereas the use of GBTM allows for the identification of distinct patterns, which are
differentially associated with baseline characteristics.
This study also has several limitations. There is no available information on
diagnoses of clinical depression or whether participants received any type of therapy for
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mental health conditions. This limits our conception of depressive symptoms to the CESD scale, which only provides an estimate of potentially clinically significant depressive
symptoms. Additionally, the sample size was limited, particularly in the increasing mild
to moderate and chronic moderate symptom groups. This limits the power of the analysis
to identify statistically significant differences in baseline characteristics among these
groups. Additionally, because there is no measure of alcohol consumption at the baseline
visit, we were unable to examine this characteristic in the analyses. Another potential
limitation is the rate of loss to follow-up in this sample, as 27% of the sample did not
contribute at least two CES-D scale measures. Additionally, those participants who were
included had on average higher family income and parental education and were more
likely to use private health insurance. This limits our inferences to those participants who
were willing and able to consistently participate in follow-up visits, and therefore may
not be generalizable to the general population of YYA with T1D.
One of the main limitations of this study is a lack of information about levels of
depressive symptoms prior to diabetes diagnosis. It is possible that some individuals
experienced depressive symptoms prior to diagnosis, and these symptoms either
remained chronic, increased following diagnosis, or decreased following diagnosis. It is
also possible that some individuals did not experience clinically significant depressive
symptoms prior to diagnosis, but began to experience symptoms following diagnosis,
which may have remained chronic, increased, or decreased over time. Because we do not
have this information, it is difficult to consider etiologic origins of the five identified
depressive symptom trajectories. If future research obtains measures of depressive
symptoms prior to T1D diagnosis, etiology of the different trajectories could be further
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examined. Knowing the CES-D score prior to diagnosis would provide insight into
whether clinically significant symptoms are situational, resulting from the experience of
being diagnosed with a chronic illness, or reflect pre-existing, chronic depression. Thus,
we could more fully consider whether any of the trajectory groups reflect depressive
symptoms resulting from a diabetes diagnosis and whether they are similar in etiology to
depressive symptom trajectories identified in non-diabetic populations.
In conclusion, we identified five unique depressive symptom trajectories in a
sample of YYA with T1D. Although the majority of our sample did not experience
depressive symptoms at any time, 14.6% of the sample experienced mild or moderate
symptoms during at least one baseline or follow-up CES-D assessment. Thus, these data
provide insight on the best time to screen for depressive symptoms and to start treatment.
Although most participants who did not report clinically significant levels of depressive
symptoms recently following diagnosis of T1D did not become depressed, 4.6% reported
moderate depressive symptoms after five years of follow-up, and 3.3% reported moderate
symptoms both recently following diagnosis and throughout follow-up. The baseline
predictors that most clearly differentiated between those who report little to no symptoms
and those who report chronic, moderate symptoms are female sex and experiencing at
least one severe hypoglycemic and/or diabetic ketoacidosis episode. The predictors that
most clearly differentiated between those who report little to no symptoms and those who
report increasing depressive symptoms over time are living in a single-parent home, use
of psychiatric medications, cigarette use, and less participation in physical activity. Thus,
it is important for clinicians treating YYA with T1D to regularly screen for depressive
symptoms among their patients, and in recently diagnosed female patients, those who
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have experienced at least one severe hypoglycemic and/or diabetic ketoacidosis episode,
and who live in single-parent homes. These groups have the greatest likelihood of
experiencing potentially clinically significant depressive symptoms. Among YYA with
T1D, unique trajectories of depressive symptoms show meaningful differences in
demographic, socioeconomic, clinical, and behavioral characteristics. These results
provide insight into the identification of high-risk groups and potential target populations
for prevention of chronic depressive symptoms and support the inclusion of regular
depression screening into clinical practice of providers treating YYA with T1D. Future
research should consider the relationship between depressive symptom trajectories and
clinical outcomes, such as glycemic control, adherence to diabetes self-management, and
diabetes complications.
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Table 4.1: Baseline Characteristics for the Study Sample and by Depressive Symptom Trajectory Group
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Baseline CES-D* score
Age at baseline visit (years), mean (SD)
Age at diagnosis, mean (SD)
Female, n (%)
Race/Ethnicity, n (%)
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Parental Education, n (%)
High school degree or less
Some college
Bachelor’s degree or more
Family Income, n (%)
<$25,000
$25,000-$49,000
$50,000-$74,999
≥$75,000
Not Reported/Don’t Know
Health Insurance, n (%)

Total
(n= 879)
9.7 (8.2)
13.6 (2.4)
12.7 (2.4)
418 (47.6)

Little to
None
(n= 577)
6.0 (4.2)
13.6 (2.5)
12.8 (2.5)
251 (43.5)

Stable
Minimal
(n= 186)
12.3 (4.7)
13.4 (2.2)
12.6 (2.3)
97 (52.2)

Decreasing
Mild to
Minimal
(n= 49)
25.4 (7.5)
13.1 (2.2)
12.3 (2.2)
30 (61.2)

Increasing
Mild to
Moderate
(n= 37)
15.1 (6.3)
13.7 (2.2)
12.8 (2.3)
20 (54.1)

Chronic
Moderate
(n= 30)
33.2 (6.5)
14.4 (2.4)
13.5 (2.3)
20 (66.7)

671 (76.3)
94 (10.7)
94 (10.7)
20 (2.3)

463 (80.2)
49 (8.5)
51 (8.8)
14 (2.4)

128 (68.8)
27 (14.5)
27 (14.5)
4 (2.2)

33 (67.4)
12 (24.5)
3 (6.1)
1 (2.0)

26 (70.3)
3 (8.1)
7 (18.9)
1 (2.7)

21 (70.0)
3 (10.0)
6 (20.0)
0 (0.0)

157 (17.9)
304 (34.7)
414 (47.3)

85 (14.8)
175 (30.5)
314 (54.7)

43 (23.2)
83 (44.9)
59 (31.9)

11 (22.5)
17 (34.7)
21 (42.9)

10 (27.0)
17 (46.0)
10 (27.0)

8 (26.7)
12 (40.0)
10 (33.3)

112 (12.8)
176 (20.1)
184 (21.1)
348 (39.8)
54 (6.2)

54 (9.4)
99 (17.3)
122 (21.3)
264 (46.0)
35 (6.1)

30 (16.3)
49 (26.6)
37 (20.1)
60 (32.6)
8 (4.4)

17 (34.7)
8 (16.3)
11 (22.5)
8 (16.3)
5 (10.2)

7 (18.9)
14 (37.8)
6 (16.2)
8 (21.6)
2 (5.4)

4 (13.3)
6 (20.0)
8 (26.7)
8 (26.7)
4 (13.3)
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Private
Government-funded
Other/None
Family Structure, n (%)
Two-parent
Single-parent or Other
Baseline Diabetes Duration (months), mean
(SD)
Baseline HbA1c** (%), mean (SD)
Baseline Glycemic Control***, n (%)
Optimal
Suboptimal
High Risk
Severe hypoglycemic episode in past 6 months
DKA**** episode in past 6 months
Frequency of blood glucose monitoring, n (%)
≤ 2 times per day
3 times per day
≥4 times per day
Insulin Regimen, n (%)
Insulin Pump
Basal/bolus injections
Other regimen
Use of psychiatric medications, n (%)
BMI z-score, mean (SD)
Ever tried cigarette smoking, n (%)

710 (81.4)
134 (15.4)
28 (3.2)

491 (85.8)
70 (12.2)
11 (1.9)

140 (76.1)
34 (18.5)
10 (5.4)

30 (61.2)
14 (28.6)
5 (10.2)

25 (67.6)
11 (29.7)
1 (2.7)

24 (80.0)
5 (16.7)
1 (3.3)

583 (66.6)
292 (33.4)
9.6 (6.4)
7.6 (1.7)

407 (70.8)
168 (29.2)
9.5 (6.4)
7.5 (1.6)

123 (66.5)
62 (33.5)
9.4 (6.1)
7.8 (1.8)

22 (44.9)
27 (55.1)
9.8 (6.5)
8.4 (2.1)

14 (38.9)
22 (61.1)
11.2 (7.0)
8.0 (1.5)

17 (56.7)
13 (43.3)
10.4 (7.2)
7.8 (1.7)

426 (51.9)
256 (31.2)
139 (16.9)
59 (6.7)
156 (17.8)

299 (55.7)
168 (31.3)
70 (13.0)
31 (5.4)
94 (16.4)

81 (46.0)
56 (31.8)
39 (22.2)
16 (8.7)
34 (18.4)

17 (37.0)
15 (32.6)
14 (30.4)
3 (6.1)
10 (20.4)

16 (43.2)
11 (29.7)
10 (27.0)
2 (5.4)
6 (16.2)

13 (52.0)
6 (24.0)
6 (24.0)
7 (23.3)
12 (40.0)

64 (7.4)
91 (10.5)
708 (82.0)

43 (7.6)
50 (8.9)
472 (83.5)

12 (6.5)
26 (14.1)
146 (79.4)

5 (10.2)
4 (8.2)
40 (81.6)

3 (8.1)
4 (10.8)
30 (81.1)

1 (3.6)
7 (25.0)
020
(71.4
20 (71.4)

79 (9.2)
293 (34.1)
487 (56.7)
32 (3.6)
0.6 (0.9)
123 (14.1)

53 (9.4)
185 (32.8)
326 (57.8)
13 (2.3)
0.5 (0.9)
58 (10.1)

18 (9.9)
71 (39.2)
92 (50.8)
6 (3.2)
0.7 (1.0)
31 (16.8)

4 (8.2)
20 (40.8)
25 (51.0)
2 (4.1)
0.8 (1.1)
13 (26.5)

1 (2.8)
9 (25.0)
26 (72.2)
5 (13.5)
0.5 (1.0)
10 (27.8)

3 (10.3)
8 (27.6)
18 (62.1)
6 (20.0)
0.8 (0.9)
11 (36.7)

Number of days exercised in past week, mean
3.6 (2.3)
3.6 (2.2)
3.6 (2.4)
3.8 (2.4)
2.5 (2.0)
2.6 (2.1)
(SD)
*Center for Epidemiologic Studies – Depression, **Hemoglobin A1c, ***1) for ages < 18 years, <7.5% is optimal, 2) 7.5-9.0% is
suboptimal, and (3) >9.0% is high risk; for ages ≥18 years, 1) <7.0% is optimal, 2) 7.0-9.0% is suboptimal, and 3) >9.0% is high risk,
****Diabetic Ketoacidosis
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Table 4.2: Adjusted odds ratios and 95% confidence intervals from multinomial logistic regression of baseline characteristics
predicting depressive symptom trajectory group

Age at baseline visit
Sex (Female vs. Male)
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Race/Ethnicity (ref = NonHispanic White)
Non-Hispanic Black
Hispanic
Other
Parental Education (ref =
college graduate)
High School or Less
Some College
Family Income (ref =
<$25,000)
$25,000-$49,000
$50,000-$74,999
≥$75,000
Not Reported/Don’t Know
Health Insurance (ref =
private)
Government-funded
Other/None

Little to
None
(ref)
1.00
1.00

Stable
Minimal
0.88 (0.80 – 0.97)
1.38 (0.94 – 2.03)

Decreasing Mild
to Minimal
0.75 (0.62 – 0.91)
1.53 (0.77 – 3.03)

Increasing Mild to
Moderate
0.94 (0.76 – 1.15)
1.60 (0.73 – 3.50)

Chronic Moderate
0.92 (0.69 – 1.23)
4.42 (1.27 – 15.38)

1.00
1.00
1.00

1.67 (0.83 – 3.34)
1.82 (0.99 – 3.37)
0.91 (0.25 – 3.28)

1.68 (0.59 – 4.80)
0.62 (0.15 – 2.48)
0.57 (0.05 – 6.65)

0.56 (0.13 – 2.30)
1.02 (0.29 – 3.59)
0.95 (0.10 – 9.49)

1.48 (0.23 – 9.41)
2.58 (0.54 – 12.38)
-----

1.00
1.00

2.13 (1.15 – 3.93)
2.12 (1.33 - 3.37)

0.54 (0.18 – 1.55)
0.64 (0.28 -1.46)

1.59 (0.46 – 5.45)
2.01 (0.73 – 5.50)

5.68 (1.05 – 30.75)
2.13 (0.54 – 8.49)

1.00
1.00
1.00
1.00

1.50 (0.70 – 3.25)
1.10 (0.45 – 2.69)
1.24 (0.51 – 3.04)
0.52 (0.16 - 1.68)

0.26 (0.08 - 0.86)
0.38 (0.11 – 1.33)
0.15 (0.04 - 0.57)
0.67 (0.17 – 2.65)

2.00 (0.57 – 7.01)
1.37 (0.28 – 6.76)
0.77 (0.15 – 3.92)
1.01 (0.15 – 6.91)

0.64 (0.08 – 5.25)
1.41 (0.17 – 11.80)
0.46 (0.05 – 4.57)
1.01 (0.10 – 10.31)

1.00
1.00

1.16 (0.57 – 2.36)
2.54 (0.92 – 7.04)

0.84 (0.26 – 2.66) 1.80 (0.58 – 5.56)
5.25 (1.32 – 20.90) 0.90 (0.09 – 9.44)

0.55 (0.08 – 3.79)
------
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Family Structure (ref = twoparent)
Single-Parent/Other
1.00
Baseline HbA1c* (%)
1.00
Severe hypoglycemic episode
1.00
in past 6 months (ref = no)
DKA** episodes in past 6
1.00
months (ref = no)
Frequency of blood glucose
monitoring (ref = ≥4 times per
day)
<2 times per day
1.00
3 times per day
1.00
Insulin Regimen (ref = pump)
Basal/bolus injections
1.00
Other regimen
1.00
Use of psychiatric
1.00
medications (ref = no)
BMI z-score
1.00
Ever tried cigarette smoking
1.00
(ref = no)
Number of days exercised in
1.00
past week
*Hemoglobin A1c, **Diabetic Ketoacidosis

0.80 (0.51 - 1.25)
1.12 (0.99 - 1.25)
1.66 (0.78 – 3.54)

1.43 (0.66 – 3.10)
1.21 (1.01 - 1.45)
1.29 (0.35 – 4.78)

3.71 (1.58 – 8.72)
1.03 (0.83 - 1.29)
1.40 (0.28 – 6.86)

0.69 (0.20 – 2.45)
1.16 (0.87 - 1.55)
7.79 (2.03 – 29.91)

1.18 (0.72 - 1.94)

1.45 (0.64 – 3.32)

0.47 (0.13 – 1.69)

3.39 (1.09 – 10.55)

0.63 (0.26 – 1.54)
1.89 (1.01 – 3.55)

1.14 (0.32 – 4.05)
0.99 (0.28 – 3.54)

0.75 (0.17 – 3.25)
1.19 (0.30 – 4.72)

0.38 (0.03 – 4.32)
3.81 (0.96 – 15.16)

0.87 (0.44 – 1.71)
0.65 (0.33 - 1.26)
1.46 (0.47 – 4.53)

1.12 (0.33 – 3.78) 1.71 (0.20 – 14.85) 0.39 (0.04 – 3.61)
0.60 (0.18 – 2.03) 2.93 (0.37 – 2.56) 1.47 (0.20 – 10.71)
2.43 (0.41 – 14.36) 9.34 (2.49 – 35.09) 24.56 (4.52–133.5)

1.24 (1.01 - 1.52)
3.64 (1.95 – 6.81)

1.28 (0.88 - 1.86)
0.92 (0.61 - 1.36)
1.46 (0.81 - 2.66)
5.92 (2.15 – 16.28) 3.33 (1.04 – 10.64) 5.85 (1.23 – 27.78)

0.99 (0.91 - 1.08)

1.05 (0.91 - 1.22)

0.84 (0.70 - 0.99)

0.87 (0.69 – 1.10)

a. Design of the SEARCH cohort study:
Incident cases:
2001

2002

2003

2004

2005

Baseline Baseline Baseline Baseline
Visit
Visit
Visit
Visit

2006
Baseline
Visit

2007

2008
Baseline
Visit

12-, 24, and 60-month follow-up visits

Minimum of baseline visit and 5 years
diabetes duration

Cohort
Visit

b. Sample Selection
1,203 Registered incident cases ages 10 and up at
the baseline visit (2002-2005) diagnosed with
type 1 diabetes and completed baseline visit

305 excluded (completed < 2 CES-D measures)

898 with type 1 diabetes, baseline visit, and ≥2
CES-D measures
19 excluded (did not complete baseline CES-D)

879 with type 1 diabetes, baseline visit, and ≥2
CES-D measures including baseline included in
present analysis
Figure 4.1: SEARCH Study Design and Sample Recruitment
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Diabetes Duration (Months)
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Chronic Moderate (3.3%)

Mild Cutoff

Moderate/Severe Cutoff

Figure 4.2: Predicted Depressive Symptom Trajectories by Diabetes Duration
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CHAPTER 5
LONGITUDINAL TRAJECTORIES OF DEPRESSIVE SYMPTOMS PREDICT
GLYCEMIC CONTROL AMONG YOUTH AND YOUNG ADULTS WITH TYPE 1
DIABETES IN THE SEARCH FOR DIABETES IN YOUTH STUDY2

Melanie W. Sutherland, Angela D. Liese, Matthew Lohman, Kate Flory, Monique
Brown. Not yet submitted.
2
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Abstract
Background: Most youth and young adults (YYA) with type 1 diabetes (T1D) do not
meet recommendations regarding glycemic control, which places them at increased risk
of diabetes complications. One potential risk factor for high-risk glycemic control is
depression. Previous research has shown that depressive symptoms among YYA with
T1D are often associated with poor glycemic control; however, little research has been
conducted to examine how changes in depressive symptoms over time in this population
relate to glycemic control. In a previous study, we identified five distinct trajectories, or
patterns of depressive symptoms over time among YYA with T1D enrolled in the
SEARCH for Diabetes in Youth (SEARCH) study: little to no symptoms (63.2%),
persistent minimal (22.2%), increasing from mild to moderate (4.6%), decreasing from
mild to minimal (6.7%), and chronic moderate (3.3%). The purpose of this study is to
assess whether these depressive symptom trajectories predict glycemic control.
Methods: YYA diagnosed with T1D between 2002-2005, ages 10 to 21 years at baseline,
who were enrolled in the SEARCH study, who provided a baseline and at least one
follow-up measure of depressive symptoms using the Center for Epidemiologic Studies –
Depression (CES-D) scale and a measure of glycemic control at the most recent followup visit, which occurred on average eight years after baseline were included (n = 571,
50.1% female, 75.1% non-Hispanic white). Group-based trajectory modeling was used in
this sample to identify five depressive symptom trajectories, described above. ANCOVA
and logistic regression models were performed to assess whether these depressive
symptom trajectories predicted continuous and categorical measures of glycemic control,
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measured by Hemoglobin A1c (HbA1c). High-risk glycemic control was defined as
HbA1c > 9%.
Results: The mean follow-up HbA1c was 9.1% and 48% of the sample exhibited highrisk glycemic control. After adjustment for all covariates, mean HbA1c was statistically
significantly higher among those with stable minimal depressive symptoms and
decreasing mild to minimal symptoms compared to those with little to no symptoms. The
odds of high-risk glycemic control were also increased among those with stable minimal
and decreasing mild to minimal symptoms compared to those with little to no symptoms.
Conclusions: Among YYA with T1D, depressive symptom trajectories predict glycemic
control; however, contrary to expectations, those reporting the greatest burden of
depressive symptoms did not have significantly worse glycemic control compared to
those with little to no symptoms after adjustment for potential confounders. Future
research should focus on examining the role of psychiatric medications in the association
between depressive symptoms and glycemic control and should collect information about
other mental health constructs, including diabetes distress to gain a better understanding
of why those who report minimal depressive symptoms experience worse glycemic
control compared to those who report little to no depressive symptoms.
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Introduction
Type 1 diabetes (T1D) is one of the most frequently diagnosed chronic illnesses
among youth, and the incidence has been increasing in recent years.2 T1D has many
potentially serious short-term and long-term complications such as severe hypoglycemia,
retinopathy, nephropathy, and cardiovascular disease, many of which can be delayed or
prevented through managing blood glucose levels and maintaining optimal glycemic
control, which is defined as Hemoglobin A1c (HbA1c) < 7.5% for youth less than 18
years of age and < 7.0% for adults.13,32,140 However, most youth and young adults (YYA)
with T1D do not meet recommendations regarding glycemic control – according to one
study using data from the SEARCH for Diabetes in Youth (SEARCH) study, 56% do not
meet recommendations, and 17% have HbA1c greater than 9.5%, which is considered
high risk glycemic control.39 Thus, it is important to examine predictors of glycemic
control to identify potential targets for intervention to improve glycemic control and thus
reduce the risk of future complications.
One such potential target for intervention is depression. According to data from
the SEARCH study, approximately 14% of youth with type 1 and type 2 diabetes
between the ages of 10 and 21 years have mild depressed mood and 8.6% have moderate
to severely depressed mood.4 Most research suggests that the prevalence of depression
among YYA with T1D is much higher than the prevalence among their healthy
counterparts.93 The co-occurrence of T1D and depressive symptoms may negatively
impact clinical outcomes in this population, potentially through reduced adherence to
diabetes self-management among those experiencing depressive symptoms, particularly

82

infrequent blood glucose monitoring that subsequently results in nonoptimal glycemic
control, which is associated with future risk of diabetes complications listed above.141,142
Previous research suggests that depressive symptoms are typically associated with
poor glycemic control. A systematic review identified fifteen studies assessing the
association between depressive symptoms and glycemic control in individuals with T1D
under the age of 25, ten of which identified a statistically significant association such that
increased depressive symptoms were associated with worse glycemic control.103 Another
systematic review identified eleven studies among youth with T1D, including five studies
from the previous review, with mean ages between around 13 and 17 years and all eleven
of these studies demonstrated a statistically significant association between depressive
symptoms and poor glycemic control.104
Although most evidence suggests that increased depressive symptoms are
associated with poor glycemic control, the previous research in this area has several
limitations, one of which is the use of cross-sectional data that obscures the temporal
relationship between depressive symptoms and glycemic control.103,104 Additionally,
those studies that have used longitudinal data to examine this association have typically
used overall sample means for HbA1c and depressive symptoms. This approach provides
an average over subgroups in the population who experience unique trajectories of
depressive symptoms over time and thus does not take into account duration and change
in symptoms over time.45,106,143
In Chapter 4, we identified five depressive symptom trajectories over a five-year
follow-up period using data from YYA between the ages of 10 and 21 enrolled in the
SEARCH study. The majority of participants exhibited little to no depressive symptoms
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(63.2%) or minimal symptoms (22.2%) throughout follow-up. A small proportion had
mild depressive symptoms at baseline that decreased to minimal over follow-up (6.7%),
others had mild symptoms that increased to moderate (4.6%), and finally some had
chronic moderate symptoms (3.3%). Thus, using the overall sample mean of depressive
symptoms to examine associations with glycemic control ignores the variation in
symptom experiences among these subgroups of participants.
The purpose of this study is to assess the association between the depressive
symptom trajectories identified in the SEARCH study and glycemic control measured at
the end of follow-up. Findings will contribute to gaining a better understanding of the
nature of the relationship between depressive symptoms and glycemic control, taking into
consideration subgroups of the population with similar level, duration, and change in
symptoms over time.
Methods
Design
The SEARCH for Diabetes in Youth (SEARCH) study is an observational, multicenter, population-based study that has identified incident cases of non-gestational
diabetes diagnosed among youth less than 20 years of age since 2002.118 SEARCH 1
(2000-2005) identified prevalent and incident cases of diagnosed diabetes and included
baseline study visits. SEARCH 2 (2005-2010) included 12-, 24-, and 60-month follow-up
visits among incident cases diagnosed during 2002-2005. SEARCH 3 continued to collect
incident cases and established a cohort, which included incident cases diagnosed between
2002-2005 with a minimum of a baseline visit and 5 years of diabetes duration as well as
incident cases from 2008 and 2012. The present analysis only includes incident cases
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between 2002-2005 because these are the only participants who completed the 12-, 24-,
and 60-month follow-up visits (Figure 5.1a). Five clinical centers in the United States
contributed participants for the cohort study: South Carolina (all counties), Ohio
(Cincinnati and eight surrounding counties), Colorado (all counties), Southern California
(members of Kaiser Permanente Medical Care Program Health Plan in Southern
California, except San Diego), and Washington (four counties surrounding Seattle).119
Population
The present analysis was limited to participants with T1D diagnosed by a
physician between the years 2002-2005 who were at least ten years old at baseline, were
included in the SEARCH cohort, and provided a measure of HbA1c at the cohort visit.
This sample included the 571 participants with T1D who were between the ages of 10
and 21 years at the baseline visit and met the above criteria. These participants completed
up to five visits: baseline, 12-month, 24-month, and 60-months, and the cohort visit. All
participants less than 10 years of age were excluded because these participants did not
complete the CES-D questionnaire.
Data Collection
IRB approval was obtained for data collection at each study site prior to the
initiation of study procedures. Participants provided informed consent (if ≥18 years old)
or assent (if <18 years old) along with parental consent before data collection.
Participants completed in-person study visits, in which they completed questionnaires,
physical exams, and laboratory tests. Questionnaires included data on demographics,
medical history, and physical and mental health. Physical exams and laboratory tests
assessed chronic complications of diabetes, glycemic control, and other relevant risk
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factors associated with diabetes. Questionnaires involving information on age, sex, age at
diagnosis, history of diabetic ketoacidosis, insulin use, prescription medications, and
race/ethnicity were filled out by either the participant or his/her legal guardian, depending
on the age of the participant. A parent or guardian completed these questionnaires on
behalf of participants under the age of 18. All information about depressive symptoms
and health behaviors was provided by the participant regardless of age.
Measures
Depressive Symptom Trajectories. Depressive symptoms were assessed at each
study visit in participants ≥ 10 years of age using the Center for Epidemiologic Studies
Depression (CES-D) scale.72 The CES-D is a 20-item scale which was designed to
measure the current level of depressive symptomatology in the general population.72
Items on the scale reflect symptoms assessed in the diagnosis of depression, focusing on
depressed mood,72 including statements such as “I felt depressed,” “I felt that everything
I did was an effort,” and “I thought my life had been a failure.”72 Participants reported the
frequency with which symptoms occurred in the past week, with responses ranging from
0 (rarely or none of the time) to 3 (most or all of the time).72 The sum of all item
responses ranges from 0 to 60, with higher scores indicating more depressive
symptoms.72 Traditionally, a cut-off of 16 is used to distinguish between depressed and
non-depressed individuals in adult populations.72,73 In adolescent populations, at cut-off
of 24 was found to be more appropriate for identifying depressed mood as defined by the
DSM.121 The accepted categories for assessing depressed mood in adolescents based on
CES-D score are as follows: minimal (0-15), mild (16-23), and moderate/severe (2460).121 The main analysis was conducted using the continuous CES-D score; thus these
cutoffs were used for interpretation only. The CES-D was initially validated in an adult
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sample (Cronbach’s alpha = 0.85) and was subsequently validated in an adolescent
population (Cronbach’s alpha = 0.84-0.87 in various samples).72,73 In the present sample,
the Cronbach’s alpha = 0.86.
Depressive symptom trajectories were modeled using group-based trajectory
modeling (GBTM). The model selection procedure is described in detail in Chapter 4.
Five depressive symptom trajectory groups based on symptoms assessed at baseline, 12-,
24-, and 60-month follow-up visits were identified: little to no depressive symptoms at
any timepoint (63.2%), minimal depressive symptoms (22.2%), decreasing from mild to
minimal over time (6.7%), increasing from mild to moderate over time (4.6%), and
chronic, moderate symptoms (3.3%; see Figure 4.2).
Glycemic Control. Hemoglobin A1c (HbA1C) measured at the cohort visit was
used as the standard measure of glycemic control over the past three months. Whole
blood samples collected during the study visit were analyzed for HbA1C by the
Northwest Lipid Metabolism and Diabetes Research Laboratories in Seattle, WA, using
an automated nonporous ion-exchange high-performance liquid chromatography system
(model G-7; Tosoh Bioscience, Montgomeryville, Pennsylvania) 39. Glycemic control
was then characterized both using the continuous measure (%) and as a categorical
variable based on the ADA and International Society for Pediatric and Adolescent
Diabetes (ISPAD) 2014 Guidelines for HbA1c : for ages <18 years, 1) <7.5% is optimal,
2) 7.5-9.0% is suboptimal, and (3) >9.0% is high risk 32,124; for ages ≥18 years, 1) <7.0%
is optimal, 2) 7.0-9.0% is suboptimal, and 3) >9.0% is high risk 32,39,124. Because there
were very few participants with optimal glycemic control at the cohort visit (Table C2),
the optimal and suboptimal categories were combined, as previously analyzed in
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SEARCH data,144 resulting in a binary variable: optimal/suboptimal vs. high-risk (see
Table C2).
Covariates. Age at diagnosis was determined by calculating the difference
between date of birth and date of diabetes diagnosis. Self- or parent-reported sex was
collected from the initial patient questionnaire. Self- or parent-reported race/ethnicity was
categorized as non-Hispanic white, non-Hispanic black, Hispanic, and other, with nonHispanic white serving as the reference group. Parental education was defined as the
highest education level achieved by either parent/guardian and categorized as high school
degree or less, some college, and college graduate, with college graduate as the reference
group. Household income was categorized as less than $25,000, $25,000-49,999,
$50,000- 74,999, and $75,000 and greater, with less than $25,000 as the reference group.
Insurance type was categorized as private, government-funded, and other/none, with
private as the reference group. Family structure was categorized as two-parent household
and single-parent household/other structure, with two-parent household as the reference
group. Insulin regimen was categorized as insulin pump, basal/bolus injections, and other
regimen, with insulin pump as the reference category. Body mass index was calculated
based on the weight and height of the participant collected during the physical exam at
the study visit as kg/m2, was converted to a z-score to standardize the interpretation of
BMI at different ages, and compared to the 2000 Centers for Disease Control and
Prevention standards.125 Participants reported all medication they were currently taking,
and any medications that belonged to antidepressant, antianxiety, or
antipsychotic/antimanic classes were categorized as psychiatric medications.4 Physical
activity was assessed by the number of days of exercise reported in the past seven days.
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Participants were asked to report the number of days in the previous week in which they
exercised for at least 20 minutes. Number of days with physical activity per week was
used as a continuous variable. Tobacco use was assessed by whether the participant
reported ever trying cigarette smoking. Diet quality was assessed using the Dietary
Approach to Stop Hypertension (DASH) diet score, as calculated from a one-week food
frequency questionnaire, in which participants indicated whether they had consumed and
the frequency with which they consumed 85 listed food items.126 These 85 food items
were divided into eight food groups: grains, vegetables, fruits, dairy, meats,
nuts/seeds/legumes, fats/oils, and sweets which were used to create the DASH diet score,
which ranges from 0 to 80. Higher scores indicated greater adherence to the DASH
diet.126
Statistical Analysis
Group-based trajectory modeling (GBTM), was used to identify latent trajectories
of depressive symptoms among YYA with T1D, utilizing the CES-D scale total score as
the measure of depressive symptoms, measured at the baseline, 12-month, 24-month, and
60-month visits. Duration of diabetes in months was used as the time scale to model
depressive symptom trajectories. GBTM is a statistical approach which allows for the
identification of subgroups of individuals within a population that follow approximately
the same trajectory on a particular outcome over time.127–129 This analysis was conducted
using the PROC TRAJ procedure in SAS (v.9.4, Cary, NC), which was developed to
conduct GBTM as described by Nagin.130–132 This procedure applies a semi-parametric,
group-based modeling strategy using mixture models.131 The model selection procedure
is described in detail in Chapter 4. Five depressive symptom trajectory groups were
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identified: little to no symptoms (63.25), stable minimal (22.2%), decreasing from mild to
minimal (6.7%), increasing from mild to moderate (4.6%), and chronic moderate (3.3%;
see Figure 4.2).
Descriptive statistics were calculated for the study sample and by depressive
symptom trajectory group for glycemic control measured at the outcome visit and all
baseline covariates. In order to assess the association between depressive symptom
trajectory group and glycemic control, two primary analyses were performed. First, an
ANCOVA model was assessed, with depressive symptom trajectory group predicting a
continuous measure of HbA1c assessed at the cohort visit. A crude model was assessed,
followed by adjusted models: Adjustment 1 included demographic characteristics: age at
diagnosis, sex, race/ethnicity, and study site. Adjustment 2 included the previous
covariates in addition to socioeconomic and behavioral characteristics assessed at
baseline: parental education, household income, family structure, health insurance status,
BMI, tobacco use, and physical activity. Adjustment 3 included the previous covariates in
addition to and insulin regimen, and adjustment 4 additionally included use of
antidepressant medications. This process was repeated to assess the association between
depressive symptom trajectory group and categorical glycemic control, using logistic
regression to predict levels of glycemic control. Glycemic control was categorized into
two levels: optimal/suboptimal, and high-risk, as described above, with
optimal/suboptimal as the reference group.
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Results
Baseline Characteristics
Participant characteristics at baseline for the entire sample and by depressive
symptom trajectory group are displayed in Table 5.1. The average age at the baseline visit
was 13.5 years and the average age at diabetes diagnosis was 12.7 years. The sample was
50.1% female, 75.1% non-Hispanic white, 12.1% non-Hispanic black, and 10.9%
Hispanic. On average, the sample had a relatively high socioeconomic status: 47.4%
reported parental education of bachelor’s degree or higher, 38.9% had a household
income of ≥$75,000, 82% used private health insurance, and 67.4% lived in a two-parent
household. The mean HbA1c was 7.6%, and 15.8% had high-risk glycemic control. The
majority of participants did not use an insulin pump (91%) and only 3.5% were taking
psychiatric medications. The average BMI z-score was 0.6, 14.6% had tried cigarette
smoking at least one time, and participants reported exercising on average 3.5 days per
week.
Glycemic Control at Follow-up Visit
At the cohort visit, which occurred a mean of 8.2 years after the baseline visit, the
mean (SD) HbA1c was 9.1% (2.0) and 48% had high-risk glycemic control (Table 5.2).
The highest mean HbA1c occurred in the decreasing mild to minimal depressive
symptom group (9.8%) and the lowest occurred in the little to no symptom group (8.8%).
Similarly, the highest proportion of high-risk glycemic control occurred in the decreasing
mild to minimal group (64.5%) and the lowest occurred in the little to no symptom group
(41.2%).
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Adjusted Associations between Depressive Symptom Trajectories and Continuous
HbA1c
After adjusting for age at diabetes diagnosis, sex, race/ethnicity, and study site,
the stable minimal, decreasing mild to minimal, and increasing mild to moderate
depressive symptom trajectory groups had statistically significantly higher mean HbA1c
levels compared to the little to no depressive symptoms group (Table 5.2). After
additionally adjusting for parental education, household income, family structure, health
insurance status, BMI, tobacco use, and physical activity, the differences in mean HbA1c
between both the stable minimal and decreasing mild to minimal groups and the little to
no symptoms group remained statistically significant. Adjusting for insulin regimen and
use of psychiatric medications did not alter these findings. Further adjustment for diet
quality also did not alter the results. Although the adjusted mean HbA1c in the chronic
moderate group was greater than the adjusted mean for the little to no symptom group in
every model, these differences were not statistically significant.
Adjusted Associations between Depressive Symptom Trajectories and Categories of
Glycemic Control
After adjusting for age at diabetes diagnosis, sex, race/ethnicity, and study site,
the odds of high-risk glycemic control were statistically significantly elevated for the
stable minimal (OR = 1.89, 95% CI = 1.23-2.90) and decreasing mild to minimal (OR =
2.30, 95% CI = 1.04-5.12) compared to the little to no symptoms group (Table 5.3).
These two groups had similar odds ratios which remained statistically significant after
additional adjustment for parental education, household income, family structure, health
insurance status, BMI, tobacco use, physical activity, insulin regimen, and use of
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psychiatric medications. There were no statistically significant associations for odds of
high-risk glycemic between the little to no symptoms group and the increasing mild to
moderate and chronic moderate groups.
Discussion
In a cohort of YYA with T1D, we observed that depressive symptom trajectories
predict glycemic control measured on average eight years after baseline. Those with
stable minimal depressive symptoms and those with mild symptoms that decrease to
minimal over time had on average higher HbA1c and greater odds of high-risk glycemic
control compared to those with little to no depressive symptoms. Although those with
symptoms that increased from mild to moderate and those with chronic moderate
symptoms also had higher HbA1c and greater odds of high-risk glycemic control
compared to those with little to no symptoms, these differences were not statistically
significant after adjustment for covariates.
To our knowledge, only one study has examined the association between
depressive symptom trajectories and glycemic control among individuals with T1D,101
identifying three depressive symptom trajectories among adults between the ages of 17
and 40 years: no depression, improving depressive symptoms over time, and worsening
depressive symptoms over time. Compared to the group with no depressive symptoms
(7.2%), those with worsening depressive symptoms had significantly higher mean HbA1c
(8.2%) after five years of follow-up.101 There was no difference in HbA1c after five years
between the improving symptom group and the no symptom group.101 The results from
the prior study conducted in young adults with T1D differ from those in this younger
population of YYA, which show that there is no significant difference in HbA1c between
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those with little to no depressive symptoms and those with increasing symptoms over
time and that there is a significant difference between those with improving symptoms
and those with little to no symptoms. The previous study measured depressive symptoms
with a different scale – the Symptom Checklist 90-R questionnaire, which to our
knowledge has not been evaluated against the CES-D scale with regard to diagnostic
validity. The study also modeled trajectories using growth mixture modeling rather than
GBTM, followed participants for an average of five years, as opposed to eight years in
the present analysis, and assessed depressive symptoms at up to six visits as opposed to
four in the present analysis.101 Thus, age of participants, the measure of depressive
symptoms, analytic method, length of follow-up, and frequency of symptom assessment
may all contribute to differences in results between these analyses.
Previous research, mostly cross-sectional in nature, supports that increased
depressive symptoms are typically associated with worse glycemic control among YYA
with T1D.103,104 However, previous longitudinal research using data from the SEARCH
study, which examined the association between changes in overall mean CES-D score
over six years and glycemic control found no association between these measures.45
Although the present analysis suggests that those with little to no depressive symptoms
over time have the lowest HbA1c at follow-up compared to all other groups in terms of
crude mean HbA1c and the lowest proportion with high-risk glycemic control, after
adjustment for potential confounders, only those who experience stable minimal
depressive symptoms and those who experience mild symptoms that decrease to minimal
over time have significantly higher mean HbA1c and proportion with high-risk glycemic
control compared to those with little to no symptoms. Contrary to expectations, those
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with the greatest burden and duration of depressive symptoms did not demonstrate worse
HbA1c compared to those with a lesser burden of symptoms in adjusted models. These
results suggest a more complicated relationship between depressive symptoms and
glycemic control rather than a gradient such that increasingly severe or persistent
depressive symptoms predict increasingly poor glycemic control.
Of particular interest is the finding that those with stable minimal depressive
symptoms have significantly greater odds of high-risk glycemic control compared to
those with little no symptoms. The stable minimal depressive symptom group comprises
individuals who do not report clinically significant depressive symptoms at any
timepoint. Previous research has shown that among YYA with T1D, depressive symptom
scales correlate with other distinct but related mental health metrics, such as diabetes
distress, which is emotional distress specifically related to diabetes diagnosis and selfmanagement.145 It is possible that those participants who report minimal depressive
symptoms are not clinically depressed, but may be experiencing other mental health
challenges, including diabetes distress, which is associated with poor glycemic control.145
One potential avenue for further research to elucidate the association between
depressive symptoms and glycemic control is to examine more thoroughly the role of
psychiatric medications in the relationship between depressive symptoms and poor
clinical outcomes. In our sample, the greatest proportion of psychiatric medications were
present in the chronic moderate and increasing mild to moderate symptom groups. We
chose to adjust for the use of psychiatric medicine as a potential confounder in one of our
adjusted models, which produced similar results as the models that did not include
psychiatric medications. However, removing all participants who reported taking
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psychiatric medications did alter the results somewhat, such that glycemic control among
the decreasing from mild to minimal group no longer significantly differed from that of
the little to no symptoms group (Tables C3 and C4). Although not statistically significant,
the odds of high-risk glycemic control among the chronic moderate compared to the little
to no symptom groups increased. Thus, psychiatric medications may have a role in the
relationship between depressive symptoms and glycemic control and are a promising
avenue for future research. Currently available research suggests that antidepressants may
slightly lower HbA1c among adults with type 2 diabetes and comorbid depression, but
little research has been conducted in younger populations with T1D.146
This study has several limitations. There is no available information on diagnoses
of clinical depression or whether participants received any type of therapy for mental
health conditions. This limits our conception of depressive symptoms to the CES-D scale,
which only provides an estimate of potentially clinically significant depressive
symptoms. There are also no measures of related mental health constructs, such as
anxiety and diabetes distress. Additionally, the sample size was limited, particularly in
the increasing mild to moderate and chronic moderate symptom groups. This limits the
power of the analysis to identify statistically significant differences in glycemic control
among these groups. Another potential limitation is the rate of loss to follow-up in this
sample, as 27% of the sample did not contribute at least two CES-D scale measures and
47% did not complete a cohort visit with a measure of HbA1c. Additionally, those
participants who were included had on average higher family income and parental
education and were more likely to use private health insurance. This limits our inferences
to those participants who were willing and able to consistently participate in follow-up
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visits, and therefore may not be generalizable to the general population of YYA with
T1D. An additional limitation is that we do not have measures of depressive symptoms
prior to diabetes diagnosis. It is possible that some individuals experienced depressive
symptoms prior to diagnosis, and these symptoms either remained chronic, increased
following diagnosis, or decreased following diagnosis. It is also possible that some
individuals did not experience clinically significant depressive symptoms prior to
diagnosis, but began to experience symptoms following diagnosis, which may have
remained chronic, increased, or decreased over time. If future research were to obtain
measures of depressive symptoms prior to T1D diagnosis, etiology of the different
trajectories could be further examined. Knowing the CES-D score prior to diagnosis
would provide insight into whether clinically significant symptoms are situational,
resulting from the experience of being diagnosed with a chronic illness, or reflect preexisting, chronic depression. This would also further inform the meaning of the
association between depressive symptom trajectories and a prospective measure of
glycemic control.
Strengths of this study include the longitudinal design with multiple measures of
depressive symptoms across up to five years of follow-up and a subsequent measure of
HbA1c after an average of eight years of follow-up. The SEARCH study is a diverse
cohort of youth with T1D, with a relatively large sample size. Additionally, the SEARCH
study has collected measures of depressive symptoms longitudinally, with up to four
measures contributing to trajectories in the present study. Another strength of this study is
the use of GBTM, an advanced statistical method, which provides a data-driven approach
to model depressive symptom trajectories. This method allows for the identification of
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meaningful subgroups within a population, rather than examining the mean change in an
outcome over time. The use of simply the mean number of depressive symptoms over
time may mask meaningful differences within the study population, whereas the use of
GBTM allows for the identification of distinct patterns, which are differentially
associated with glycemic control.
In conclusion, we found that among YYA with T1D, depressive symptom
trajectories are associated with glycemic control measured on average eight years after
baseline. Specifically, those reporting stable minimal depressive symptoms and those
reporting decreasing symptoms from mild to minimal had significantly higher mean
HbA1c and odds of high-risk glycemic control compared to those who reported little to
no depressive symptoms. Contrary to expectations, those reporting chronic moderate or
increasing from mild to moderate symptoms did not have significantly worse glycemic
control compared to those with little to no symptoms after adjustment for potential
confounders. Future research should focus on examining the role of psychiatric
medications in the association between depressive symptoms and glycemic control and
should collect information about other mental health constructs, including diabetes
distress to gain a better understanding of why those who report minimal depressive
symptoms experience worse glycemic control compared to those who report little to no
depressive symptoms.
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Table 5.1: Baseline Characteristics for the Study Sample and by Depressive Symptom Trajectory Group
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Baseline CES-D* score
Age at baseline visit (years), mean (SD)
Age at diagnosis, mean (SD)
Female, n (%)
Race/Ethnicity, n (%)
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Parental Education, n (%)
High school degree or less
Some college
Bachelor’s degree or more
Family Income, n (%)
<$25,000
$25,000-$49,000
$50,000-$74,999
≥$75,000
Not Reported/Don’t Know
Health Insurance, n (%)

Total
(n= 571)
9.9 (8.1)
13.5 (2.4)
12.7 (2.4)
286 (50.1)

Little to
None
(n= 359)
6.0 (4.2)
13.5 (2.5)
12.6 (2.5)
172 (47.9)

Stable
Minimal
(n= 136)
12.2 (4.5)
13.4 (2.3)
12.6 (2.3)
68 (50.0)

Decreasing
Mild to
Minimal
(n= 31)
26.7 (7.8)
13.4 (2.5)
12.5 (2.5)
18 (58.1)

Increasing
Mild to
Moderate
(n= 23)
15.1 (5.7)
13.8 (2.4)
12.8 (2.5)
14 (60.9)

Chronic
Moderate
(n= 22)
31.0 (4.9)
13.9 (2.3)
13.0 (2.3)
14 (63.6)

429 (75.1)
69 (12.1)
62 (10.9)
11 (1.9)

291 (81.1)
28 (7.8)
33 (9.2)
7 (2.0)

87 (64.0)
27 (19.9)
20 (14.7)
2 (1.5)

19 (61.3)
10 (32.3)
1 (3.2)
1 (3.2)

16 (70.0)
2 (8.7)
4 (17.4)
1 (4.4)

16 (72.7)
2 (9.1)
4 (18.2)
.1)
0 (0)

97 (17.1)
202 (35.6)
269 (47.4)

46 (12.9)
113 (31.7)
198 (55.5)

32 (23.7)
60 (44.4)
43 (31.9)

6 (19.4)
12 (38.7)
13 (41.9)

8 (34.8)
8 (34.8)
7 (30.4)

5 (22.7)
9 (40.9)
8 (36.4)

70 (12.3)
113 (19.9)
125 (22.0)
221 (38.9)
39 (6.9)

30 (8.4)
59 (16.5)
79 (22.1)
166 (46.5)
23 (6.4)

23 (17.0)
35 (25.9)
28 (20.7)
41 (30.4)
8 (5.9)

10 (32.3)
6 (19.4)
7 (22.6)
4 (12.9)
4 (12.9)

4 (17.4)
9 (39.1)
5 (21.7)
4 (17.4)
1 (4.4)

3 (13.6)
4 (18.2)
6 (27.3)
6 (27.3)
3 (13.6)
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Private
465 (82.0) 310 (86.8) 103 (76.9)
19 (61.3)
15 (65.2)
18 (81.8)
Government-funded
84 (14.8)
39 (10.9)
24 (17.9)
10 (32.3)
7 (30.4)
4 (18.2)
Other/None
18 (3.2)
8 (2.2)
7 (5.2)
2 (6.5)
1 (4.4)
0 (0)
Family Structure, n (%)
Two-parent
383 (67.4) 256 (71.5)
88 (65.2)
17 (54.8)
9 (40.9)
13 (59.1)
Single-parent or Other
185 (32.6) 102 (28.5)
47 (34.8)
14 (45.2)
13 (59.1)
9 (40.9)
Baseline Diabetes Duration (months), mean
9.4 (6.4)
9.4 (6.5)
9.1 (5.9)
10.5 (6.9)
11.1 (6.7)
9.8 (7.2)
(SD)
Baseline HbA1c* (%), mean (SD)
7.6 (1.6)
7.5 (1.5)
7.6 (1.7)
8.4 (2.4)
7.7 (1.3)
7.6 (1.6)
Baseline Glycemic Control***, n (%)
Optimal
288 (53.6) 186 (55.0)
68 (53.1)
11 (37.9)
12 (52.2)
11 (57.9)
Suboptimal
164 (30.5) 109 (32.3)
35 (27.3)
10 (34.5)
5 (21.7)
5 (26.3)
High Risk
85 (15.8)
43 (12.7)
25 (19.5)
8 (27.6)
6 (26.1)
3 (15.8)
Insulin Regimen, n (%)
Insulin Pump
50 (9.0)
32 (9.1)
10 (7.6)
4 (12.9)
1 (4.4)
3 (14.3)
Basal/bolus injections
196 (35.2) 118 (33.6)
52 (39.7)
15 (48.4)
7 (30.4)
4 (19.1)
Other regimen
311 (55.8) 201 (57.3)
69 (52.7)
12 (38.7)
15 (65.2)
14 (66.7)
Use of psychiatric medications, n (%)
20 (3.5)
8 (2.2)
4 (2.9)
2 (6.5)
3 (13.0)
3 (13.6)
BMI z-score, mean (SD)
0.6 (1.0)
0.5 (0.9)
0.8 (1.0)
0.8 (1.2)
0.3 (1.0)
0.8 (1.0)
Ever tried cigarette smoking, n (%)
83 (14.6)
33 (9.2)
26 (19.3)
10 (32.3)
6 (27.3)
8 (36.4)
Number of days exercised in past week, mean
3.5 (2.2)
3.4 (2.1)
3.8 (2.4)
4.0 (2.3)
2.6 (2.0)
2.3 (1.91)
(SD)
DASH Diet Score,**** mean (SD)
42.6 (8.8)
42.7 (8.7)
42.0 (9.1)
40.0 (8.2)
45.6 (9.7)
44.3 (7.0)
*Center for Epidemiologic Studies – Depression, **Hemoglobin A1c, ***1) for ages < 18 years, <7.5% is optimal, 2) 7.5-9.0% is
suboptimal, and (3) >9.0% is high risk; for ages ≥18 years, 1) <7.0% is optimal, 2) 7.0-9.0% is suboptimal, and 3) >9.0% is high risk,
****Dietary Approach to Stop Hypertension

Table 5.2: Unadjusted and Adjusted Estimates from ANOVA and ANCOVA for Continuous HbA1c by Depressive Symptom
Trajectory Group
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Little to None
(REF)
Mean (SE)

Stable
Minimal
Mean (SE), p

Decreasing Mild to
Minimal
Mean (SE), p

Increasing Mild to
Moderate
Mean (SE), p

Unadjusted

8.75 (0.10)

9.65 (0.17), <0.001

9.79 (0.35), 0.01

9.63 (0.41), 0.04

9.25 (0.42), 0.25

Adjustment 1

9.10 (0.19)

9.82 (0.22), <0.001

9.92 (0.37), 0.02

9.98 (0.42), 0.03

9.65 (0.45), 0.20

Adjustment 2

9.37 (0.26)

9.90 (0.28), 0.01

10.08 (0.40), 0.05

9.90 (0.48), 0.23

9.66 (0.48), 0.51

Adjustment 3

9.25 (0.28)

9.81 (0.28), 0.01

10.04 (0.41), 0.03

9.78 (0.49), 0.23

9.54 (0.49), 0.52

Adjustment 4

9.23 (0.36)

9.80 (0.36), 0.01

10.03 (0.45), 0.03

9.77 (0.52), 0.23

9.52, 0.52, 0.52

Chronic Moderate
Mean (SE), p

Adjustment 1 – age at diagnosis, sex, race/ethnicity, site; Adjustment 2 - age at diagnosis, sex, race/ethnicity, site, parental education,
household income, family structure, and health insurance status, BMI, tobacco use, physical activity; Adjustment 3 - age at diagnosis,
sex, race/ethnicity, site parental education, household income, family structure, and health insurance status, BMI, tobacco use,
physical activity, insulin regimen; Adjustment 4 - age at diagnosis, sex, race/ethnicity, site parental education, household income,
family structure, and health insurance status, BMI, tobacco use, physical activity, insulin regimen, psychiatric medications

Table 5.3: Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals for High-Risk Glycemic Control from
Logistic Regression
Little to None
(REF)

Stable
Minimal

Decreasing Mild to
Minimal

Increasing Mild to
Moderate

Chronic Moderate
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Unadjusted

-----

2.10 (1.41 – 3.14)

2.59 (1.21 – 5.57)

1.85 (0.79 – 4.34)

1.71 (0.72 – 4.06)

Adjustment 1

-----

1.89 (1.23 – 2.90)

2.30 (1.04 – 5.12)

1.95 (0.77 – 4.95)

1.76 (0.70 – 4.44)

Adjustment 2

-----

1.59 (1.01 – 2.52)

2.48 (1.05 – 5.85)

1.73 (0.62 – 4.88)

1.42 (0.52 – 3.92)

Adjustment 3

-----

1.72 (1.09 – 2.72)

2.74 (1.15 – 6.55)

1.64 (0.60 – 4.51)

1.62 (0.59 – 4.44)

Adjustment 4

-----

1.74 (1.10 – 2.76)

2.86 (1.19 – 6.88)

1.80 (0.64 – 5.08)

1.80 (0.65 – 5.00)

Adjustment 1 – age at diagnosis, sex, race/ethnicity, site; Adjustment 2 - age at diagnosis, sex, race/ethnicity, site, parental education,
household income, family structure, and health insurance status, BMI, tobacco use, physical activity; Adjustment 3 - age at diagnosis,
sex, race/ethnicity, site parental education, household income, family structure, and health insurance status, BMI, tobacco use,
physical activity, insulin regimen; Adjustment 4 - age at diagnosis, sex, race/ethnicity, site parental education, household income,
family structure, and health insurance status, BMI, tobacco use, physical activity, insulin regimen, psychiatric medications

a. Design of the SEARCH cohort study:
Incident cases:
2001

2002

2003

Baseline Baseline
Visit
Visit

2004

2005

2006

2007

Baseline Baseline Baseline
Visit
Visit
Visit

2008
Baseline
Visit

12-, 24, and 60-month follow-up visits

Minimum of baseline visit and 5 years
diabetes duration

Cohort
Visit

b. Sample Selection
1,203 Registered incident cases ages 10 and up at the
baseline visit (2002-2005) diagnosed with type 1
diabetes and completed baseline visit
305 excluded (completed < 2 CES-D measures)
898 with type 1 diabetes, baseline visit, and ≥2 CESD measures
19 excluded (did not complete baseline CES-D)
879 with type 1 diabetes, baseline visit, and ≥2 CESD measures including baseline included in trajectory
analysis
308 excluded (did not provide Hemoglobin A1c at
cohort visit)
571 with type 1 diabetes, baseline visit, ≥2 CES-D
measures including baseline, and HbA1c at cohort
visit included in present analysis
Figure 5.1: SEARCH Study Design and Sample Recruitment
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CHAPTER 6
LONGITUDINAL TRAJECTORIES OF DEPRESSIVE SYMPTOMS AND
ARTERIAL STIFFNESS AMONG YOUTH AND YOUNG ADULTS WITH TYPE 1
DIABETES IN THE SEARCH FOR DIABETES IN YOUTH STUDY3

Melanie W. Sutherland, Angela D. Liese, Matthew Lohman, Kate Flory, Monique
Brown. Not yet submitted.
3
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Abstract
Purpose: Type 1 diabetes (T1D) has many potentially serious long-term complications,
including macrovascular disease. A precursor to macrovascular disease that begins to
change among youth and young adults (YYA) is arterial stiffness. One potential risk
factor for increased arterial stiffness among YYA with T1D is depression, which has
been established as a risk factor for cardiovascular disease incidence and mortality and
increased arterial stiffness in the general population. In a previous study, we identified
five distinct trajectories, or patterns of depressive symptoms over time among YYA with
T1D enrolled in the SEARCH for Diabetes in Youth (SEARCH) study: little to no
symptoms (63.2%), persistent minimal (22.2%), increasing from mild to moderate
(4.6%), decreasing from mild to minimal (6.7%), and chronic moderate (3.3%). The
purpose of this study is to assess whether these depressive symptom trajectories predict
arterial stiffness among YYA with T1D.
Methods: YYA diagnosed with T1D between 2002-2005, ages 10 to 21 years at baseline,
who were enrolled in the SEARCH study, who provided a baseline and at least one
follow-up measure of depressive symptoms using the Center for Epidemiologic Studies –
Depression (CES-D) scale and a measure of arterial stiffness at the most recent follow-up
visit, which occurred on average eight years after baseline were included (n = 537, 49.5%
female, 76% non-Hispanic white). Arterial stiffness was assessed using pulse wave
velocity (PWV). Group-based trajectory modeling was used in this sample to identify
five depressive symptom trajectories, described above. ANCOVA models were
performed to assess whether depressive symptom trajectories predicted three measures of
PWV: carotid-femoral, carotid-radial, and carotid-foot.
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Results: The mean (SD) carotid-femoral PWV was 5.93 m/s (1.21), the highest mean
carotid-femoral PWV occurred in the stable minimal depressive symptom (6.15 m/s) and
decreasing mild to minimal depressive symptom groups (6.13 m/s) and the lowest
occurred in the little to no symptom group (5.84 m/s). After adjustment for all covariates,
there were no significant differences in mean carotid-femoral, carotid-radial, or carotidfoot PWV among the depressive symptom trajectory groups. Adjusted mean carotidfemoral PWV was highest in the stable minimal symptoms group (6.33 m/s) and lowest
in the chronic moderate symptom group (5.97 m/s).
Conclusions: Contrary to expectations, those reporting chronic moderate or increasing
from mild to moderate symptoms did not have significantly higher PWV compared to
those with little to no symptoms after adjustment for potential confounders. Based on our
results, depressive symptoms are not a modifiable risk factor for macrovascular disease
among YYA with T1D. Given the lack of association found in our study and the fact that
prior research has demonstrated mixed findings concerning the association between
depressive symptoms and various measures of subclinical cardiovascular disease,
additional non-invasive, subclinical measures of macrovascular disease, such as
augmentation index, carotid intima-media thickness, flow-mediated vasodilation, and
coronary artery calcium, should be collected in YYA with T1D to determine whether
depressive symptom trajectories are associated with other markers of cardiovascular risk
among YYA with T1D.
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Introduction
Type 1 diabetes (T1D) is one of the most frequently diagnosed chronic illnesses
among youth and young adults (YYA), and has many potentially serious long-term
complications, including macrovascular disease, which refers to diseases affecting large
blood vessels such as heart attacks and strokes.3 In order to reduce the risk of
macrovascular disease among those with T1D, it is important to identify modifiable risk
factors in this population to create opportunities for prevention and early intervention.
The most well-studied risk factors include hyperglycemia, dyslipidemia, and
hypertension, all of which are elevated in YYA with T1D compared to nondiabetic
peers.147 A less-examined risk factor for macrovascular disease with T1D is
depression,4,93 which has been established as a risk factor for cardiovascular disease
incidence and mortality in the general population.114
Subclinical changes in vascular function which predict future cardiovascular risk,
such as stiffening of the arteries, begin to occur early in life, however, overt
cardiovascular disease is rare in younger populations.54 Arterial stiffness is a measure of
vascular dysfunction in the large arteries, and is conceptualized as the speed with which a
pulse pressure wave moves through a segment of an artery.22,50,53 Arterial stiffness
predicts incidence of cardiovascular disease in YYA with T1D, and thus has been used as
a marker of macrovascular risk in this population.66,148
Previous research has established that depressive symptoms are associated with
increased arterial stiffness among adults without diabetes.115 A recent systematic review
and meta-analysis identified eight studies which examined this association and found that
seven of the eight studies, including a total of 913 individuals with depressive symptoms
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and 4648 controls with no depressive symptoms indicated a slightly increased arterial
stiffness among those with depressive symptoms, as measured by pulse wave velocity.115
Previous research has also demonstrated an association between depressive symptoms
and arterial stiffness in otherwise healthy YYA.113 In a sample of 157 YYA aged 16 – 21,
a positive association was found between increased depressive symptoms, as measured
by the CES-D and arterial stiffness, as measured by pulse wave velocity, adjusting for
age, race, sex, BMI, parent education, smoking status, physical activity, systolic blood
pressure, and heart rate.113
To our knowledge, no existing research examines the association between
depressive symptoms and arterial stiffness longitudinally in YYA and no studies of this
association have been conducted among YYA with T1D. The purpose of this study is to
examine whether longitudinal depressive symptom trajectories are associated with
arterial stiffness, as measured by pulse wave velocity (PWV), among YYA with T1D. In
Chapter 4, we identified five depressive symptom trajectories over a five-year follow-up
period using data from YYA between the ages of 10 and 21 enrolled in the SEARCH for
Diabetes in Youth (SEARCH) study. Most participants exhibited little to no depressive
symptoms (63.2%) or minimal symptoms (22.2%) throughout follow-up. A small
proportion had mild depressive symptoms at baseline that decreased to minimal over
follow-up (6.7%), others had mild symptoms that increased to moderate (4.6%), and
finally some had chronic moderate symptoms (3.3%). We will examine whether these
depressive symptom trajectories predict arterial stiffness at follow-up to determine
whether depression is a potentially modifiable risk factor for macrovascular outcomes
among YYA with T1D.
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Methods
Design
The SEARCH for Diabetes in Youth (SEARCH) study is an observational, multicenter, population-based study that has identified incident cases of non-gestational
diabetes diagnosed among youth less than 20 years of age since 2002.118 SEARCH 1
(2000-2005) identified prevalent and incident cases of diagnosed diabetes and included
baseline study visits. SEARCH 2 (2005-2010) included 12-, 24-, and 60-month follow-up
visits among incident cases diagnosed during 2002-2005 and recruited additional incident
cases to baseline visits in 2006 and 2008. SEARCH 3 (2010-2015) continued to collect
incident cases and established a cohort, which included incident cases diagnosed between
2002-2005 with a minimum of a baseline visit and 5 years of diabetes duration as well as
incident cases from 2008 and 2012. The present analysis only includes incident cases
between 2002-2005 because these are the only participants who completed the 12-, 24-,
and 60-month follow-up visits (Figure 6.1a). Five clinical centers in the United States
contributed participants for the cohort study: South Carolina (all counties), Ohio
(Cincinnati and eight surrounding counties), Colorado (all counties), Southern California
(members of Kaiser Permanente Medical Care Program Health Plan in Southern
California, except San Diego), and Washington (four counties surrounding Seattle).119
Population
The present analysis was limited to participants with type 1 diabetes diagnosed by
a physician between the years 2002-2005 who were at least ten years old at baseline,
were included in the SEARCH cohort, and provided a measure of pulse wave velocity
(PWV) at the cohort visit. This sample included the 537 participants with T1D who were
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between the ages of 10 and 21 years at the baseline visit and met the above criteria. For
the purposes of this analysis, only individuals with T1D diagnosed by a physician
between the years 2002-2005 were included. These participants completed up to five
visits: baseline, 12-month, 24-month, and 60-months, and the cohort visit. All
participants less than 10 years of age were excluded because these participants did not
complete the CES-D questionnaire.
Data Collection
IRB approval was obtained for data collection at each study site prior to the
initiation of study procedures. Participants provided informed consent (if ≥18 years old)
or assent (if <18 years old) along with parental consent before data collection.
Participants completed in-person study visits, including questionnaires, physical exams,
and laboratory tests. Questionnaires included data on demographics, medical history,
medication use, and physical and mental health. Physical exams and laboratory tests
assessed chronic complications of diabetes, glycemic control, and other relevant risk
factors associated with diabetes. A parent or guardian completed these questionnaires on
behalf of participants under the age of 18. All information about depressive symptoms
and health behaviors was provided by the participant regardless of age.
Measures
Depressive symptom trajectories. Depressive symptoms were assessed at each
study visit in participants ≥ 10 years of age using the Center for Epidemiologic Studies
Depression (CES-D) scale via self-report.72 The CES-D is a 20-item scale which was
designed to measure the current level of depressive symptomatology in the general
population.72 Items on the scale reflect symptoms assessed in the diagnosis of depression,
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focusing on depressed mood,72 including statements such as “I felt depressed,” “I felt that
everything I did was an effort,” and “I thought my life had been a failure.”72 Participants
reported the frequency with which symptoms occurred in the past week, with responses
ranging from 0 (rarely or none of the time) to 3 (most or all of the time).72 The sum of all
item responses ranges from 0 to 60, with higher scores indicating more depressive
symptoms.72 Traditionally, a cut-off of 16 is used to distinguish between depressed and
non-depressed individuals in adult populations.72,73 In adolescent populations, at cut-off
of 24 was found to be more appropriate for identifying depressed mood as defined by the
DSM.121 The accepted categories for assessing depressed mood in adolescents based on
CES-D score are as follows: minimal (0-15), mild (16-23), and moderate/severe (2460).121 The main analysis was conducted using the continuous CES-D score, thus these
cutoffs were used for interpretation only. The CES-D was initially validated in an adult
sample (Cronbach’s alpha = 0.85) and was subsequently validated in an adolescent
population (Cronbach’s alpha = 0.84-0.87 in various samples).72,73 In the present sample,
the Cronbach’s alpha = 0.86.
Depressive symptom trajectories were modeled using group-based trajectory
modeling (GBTM). The model selection procedure is described in detail in Chapter 4.
Five depressive symptom trajectory groups based on symptoms assessed at baseline, 12-,
24-, and 60-month follow-up visits were identified: little to no depressive symptoms at
any timepoint (63.2%), minimal depressive symptoms (22.2%), decreasing from mild to
minimal over time (6.7%), increasing from mild to moderate over time (4.6%), and
chronic, moderate symptoms (3.3%; see Figure 4.2).
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Arterial Stiffness. The measure of arterial stiffness used in this analysis is Pulse Wave
Velocity (PWV), which was assessed at the SEARCH cohort visit. PWV measures the
speed at which the cardiac ejection reaches the periphery. The SEARCH study collected
data on three measures of PWV: carotid-femoral, carotid-radial, and carotid-foot, all three
of which were examined as outcomes in this study. PWV was measured using the
SphygmoCor CPVH System from AtCor Medical (Lisle, IL) according to the
manufacturer’s instructions. All measurements were performed three times and the
average of the three measures was recorded. First, the participant laid down in a
comfortable position. Then, using a tape measure, the distance between the suprasternal
notch to the umbilicus was measured to obtain the distal distance between those two
points. Next, the distance between the umbilicus and the strongest pulse at the femoral
artery was measured to obtain the distal femoral distance. Next, the distance between the
femoral artery and the point with the strongest pulse on the top of the foot was measured
to obtain the distal foot distance. Next, the distance between the suprasternal notch to the
radial artery on the thumb’s side of the patient’s wrist was measured to obtain the distal
distance between these two points. Finally, the distance between the carotid and the
suprasternal notch was obtained as a measure of the proximal distance for all measures.
Using a tonometer, which is a device used to obtain arterial blood pressure waveforms,
the waveform from the proximal site (carotid) and waveforms from each of the distal
sites (femoral, radial, and foot) were obtained. The PWV was calculated as the difference
between the carotid-to-distal path length divided by the difference in R-wave-towaveform foot times. The R wave-to-waveform foot time is a measure of the duration of
one cardiac cycle. PWV was considered as a continuous variable in all analyses.
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Although the carotid-femoral measure is considered the “gold standard” measure
of arterial stiffness and is the only measure of PWV with extensive validation and
demonstration of an association with increased risk of future cardiovascular events,22 all
three measures of PWV were considered as outcomes in this study to evaluate whether
there are differences in the association between depressive symptom trajectories and the
three measures of PWV.
Covariates. Age at diagnosis was determined by calculating the difference between date
of birth and date of diabetes diagnosis. Self- or parent-reported sex was collected from
the initial patient questionnaire. Self- or parent-reported race/ethnicity was categorized as
non-Hispanic white, non-Hispanic black, Hispanic, and other, with non-Hispanic white
serving as the reference group. Parental education was defined as the highest education
level achieved by either parent/guardian and categorized as high school degree or less,
some college, and college graduate, with college graduate as the reference group.
Household income was categorized as less than $25,000, $25,000-49,999, $50,00074,999, and $75,000 and greater, with less than $25,000 as the reference group. Insurance
type was categorized as private, government-funded, and other/none, with private as the
reference group. Family structure was categorized as two-parent household and singleparent household/other structure, with two-parent household as the reference group.
Insulin regimen was categorized as insulin pump, basal/bolus injections, and other
regimen, with insulin pump as the reference category. Body mass index was calculated
based on the weight and height of the participant collected during the physical exam at
the study visit as kg/m2, was converted to a z-score to standardize the interpretation of
BMI at different ages, and compared to the 2000 Centers for Disease Control and
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Prevention standards.125 Participants reported all medication they were currently taking,
and any medications that belonged to antidepressant, antianxiety, or
antipsychotic/antimanic classes were categorized as psychiatric medications.4 Physical
activity was assessed by the number of days of exercise reported in the past seven days.
Participants were asked to report the number of days in the previous week in which they
exercised for at least 20 minutes. Number of days with physical activity per week was
used as a continuous variable. Tobacco use was assessed by whether the participant
reported ever having tried cigarette smoking. Diet quality was assessed using the Dietary
Approach to Stop Hypertension (DASH) diet score, as calculated from a one-week food
frequency questionnaire, in which participants indicated whether they had consumed and
the frequency with which they consumed 85 listed food items.126 These 85 food items
were divided into eight food groups: grains, vegetables, fruits, dairy, meats,
nuts/seeds/legumes, fats/oils, and sweets which were used to create the DASH diet score,
which ranges from 0 to 80. Higher scores indicated greater adherence to the DASH
diet.126
Statistical Analysis
Group-based trajectory modeling (GBTM), was used to identify latent trajectories
of depressive symptoms among YYA with T1D, utilizing the CES-D scale total score as
the measure of depressive symptoms, measured at the baseline, 12-month, 24-month, and
60-month visits. Duration of diabetes in months was used as the time scale to model
depressive symptom trajectories. GBTM is a statistical approach which allows for the
identification of subgroups of individuals within a population that follow approximately
the same trajectory on a particular outcome over time.127–129 This analysis was conducted
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using the PROC TRAJ procedure in SAS (v.9.4, Cary, NC), which was developed to
conduct GBTM as described by Nagin.130–132 This procedure applies a semi-parametric,
group-based modeling strategy using mixture models.131 The model selection procedure
is described in detail in Chapter 4. Five depressive symptom trajectory groups were
identified: little to no symptoms (63.2), stable minimal (22.2%), decreasing from mild to
minimal (6.7%), increasing from mild to moderate (4.6%), and chronic moderate (3.3%;
see Figure 4.2).
Descriptive statistics were calculated for the study sample and by depressive
symptom trajectory group for arterial stiffness measured at the outcome visit and all
baseline covariates. In order to assess the association between depressive symptom
trajectory group and arterial stiffness, an ANCOVA model was assessed, with depressive
symptom trajectory group predicting PWV assessed at the cohort visit. A crude model
was assessed, followed by adjusted models: Adjustment 1 included demographic
characteristics: age at diagnosis, sex, race/ethnicity, and study site. Adjustment 2
included the previous covariates in addition to socioeconomic and behavioral
characteristics assessed at baseline: parental education, household income, family
structure, health insurance status, BMI, tobacco use, and physical activity. Adjustment 3
included the previous covariates in addition to and insulin regimen, and adjustment 4
additionally included use of antidepressant medications. This process was repeated to
assess the association between depressive symptom trajectory group and each of the three
measures of PWV – carotid-femoral, carotid-radial, and carotid-foot.
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Results
Baseline Characteristics
Participant characteristics at baseline for the entire sample and by depressive
symptom trajectory group are displayed in Table 6.1. The average age at the baseline visit
was 13.4 years and the average age at diabetes diagnosis was 12.6 years. The average
duration of follow-up between the baseline and cohort visits was 8.2 years (data not
shown). The sample was 49.5% female, 76.0% non-Hispanic white, 12.3% non-Hispanic
black, and 9.7% Hispanic. The sample had a relatively high socioeconomic status: 46.4%
reported parental education of bachelor’s degree or higher, 39.0% had a household
income of ≥$75,000, 82.2% used private health insurance, and 67.4% lived in a twoparent household. The mean HbA1c was 7.6%, and 15.8% had high-risk glycemic
control. Most participants did not use an insulin pump (91%) and only 3.5% were taking
psychiatric medications. The average BMI z-score was 0.6, 14.6% had tried cigarette
smoking at least one time, and participants reported exercising on average 3.5 days per
week.
Arterial Stiffness at Follow-up Visit
At the cohort visit, the mean (SD) carotid-femoral PWV was 5.93 m/s (1.21). The
highest mean carotid-femoral PWV occurred in the stable minimal depressive symptom
(6.15 m/s) and decreasing mild to minimal depressive symptom groups (6.13 m/s) and the
lowest occurred in the little to no symptom group (5.84 m/s). The mean (SD) carotidradial PWV was 7.70 m/s (1.46) and the lowest was in the little to no symptom group
(7.61) and the highest was in the decreasing mild to minimal group (8.06). The mean
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(SD) carotid-foot PWV was 8.46 m/s (1.40) and the highest mean was in the decreasing
mild to minimal group (8.72) and the lowest was in the chronic moderate symptom group
(8.08).
Adjusted Associations between Depressive Symptom Trajectories and Arterial
Stiffness
After adjusting for age at diabetes diagnosis, sex, race/ethnicity, and study site,
the stable minimal depressive symptom trajectory group had a non-statistically
significantly higher mean carotid-femoral PWV compared to the little to no depressive
symptoms group (Table 6.2). After additionally adjusting for parental education,
household income, family structure, health insurance status, BMI, tobacco use, and
physical activity, there were no differences in mean carotid-femoral PWV between the
little to no symptoms group and any other group. Additionally adjusting for insulin
regimen, use of psychiatric medications, and diet quality did not alter these findings.
There were no significant differences in mean carotid-radial or carotid-foot PWV
between the depressive symptom trajectory groups in the unadjusted and adjusted
models.
Discussion
Among a cohort of YYA with T1D, we found no evidence of an association
between depressive symptom trajectories and arterial stiffness measured on average 8.2
years after baseline. Although not statistically significantly different, the fully adjusted
mean carotid-femoral PWV, the gold-standard measure of arterial stiffness, was highest
in the stable minimal, decreasing mild to minimal and increasing mild to moderate
depressive symptom trajectory groups and lowest in the chronic moderate symptom
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group. The fully adjusted mean carotid-femoral and carotid-foot PWV was lowest in the
chronic moderate depressive symptom group compared to all other trajectory groups.
This pattern did not hold for carotid-radial PWV, for which the little to no depressive
symptom group had the lowest fully adjusted mean PWV. To our knowledge, this is the
first study to examine the association between depressive symptoms and arterial stiffness
in YYA with T1D.
A previous cross-sectional study conducted in YYA without T1D found that
depressive symptoms were statistically significantly associated with increased carotidfemoral PWV; however, the magnitude of the difference in PWV between low, moderate,
and high depressive symptoms was similar to the magnitude of the difference in carotidfemoral PWV seen in the current study and may not be clinically significant.113
According to results of a meta-analysis of published literature on the association between
carotid-femoral PWV and cardiovascular events in adults, a 1 m/s increase in PWV is
associated with a 14% increased risk of cardiovascular events (including cardiovascular
death, myocardial infarction, stroke, revascularization, and aortic syndromes) overall.53 In
both the cross-sectional study conducted in YYA without T1D and the present
investigation among YYA with T1D, differences in carotid-femoral PWV between
depressive symptom levels were less than 1 m/s.113
Prior research in adult populations without T1D has consistently shown that
depressive symptoms are related to increased PWV in case-control and cross-sectional
studies; however, the effect size is typically small, with differences between depressed
and non-depressed groups ranging from 0.3 to 1.8 m/s.115 Thus, the small magnitude of
differences in carotid-femoral PWV by depressive symptom trajectory group in the
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present investigation are similar to the magnitudes of differences in PWV based on levels
of depressive symptoms found in adult populations.115 However, the pattern of mean
PWV by depressive symptom trajectory group in this study does not support a gradient of
increased risk of arterial stiffness with increasing burden of depressive symptoms.
Rather, those with stable minimal, decreasing mild to minimal, and increasing mild to
moderate depressive symptoms experienced the highest carotid-femoral PWV.
In addition to PWV, prior research has examined the association between
depressive symptoms and other measures of subclinical cardiovascular disease risk,
including carotid intima-media thickness and flow-mediated vasodilation.115 A systematic
review and meta-analysis examining these associations found that increased depressive
symptoms, as measured by a diagnosis of clinical depression or scoring above validated
cut-points on depressive symptom inventories such as the CES-D scale and the Beck
Depression Inventory were associated with increased carotid intima-media thickness and
decreased flow-mediated vasodilation, both of which indicate increased risk of
cardiovascular disease.115 Additionally, depressive symptoms have been associated with
increased carotid intima-media thickness, which is a measure of subclinical
atherosclerosis.149 However, evidence is mixed concerning the association between
depressive symptoms and other measures of subclinical cardiovascular disease, such as
coronary artery calcium.150 A systematic review found that although most studies showed
a positive association between depressive symptoms and coronary artery calcium, many
showed no association, and several showed a negative association.150 Thus, although
prior evidence supports an association between depressive symptoms and increased risk
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of subclinical cardiovascular disease, this association differs by measure of subclinical
disease.
Many pathophysiologic, behavioral, and genetic factors have been proposed as
mechanisms linking depressive symptoms to cardiovascular disease, such as vascular
inflammation, sleep disorders, reduced physical activity, smoking, and presence of
certain genes that are associated with both depressive symptoms and cardiovascular
disease.115 Additionally, research conducted with data from the SEARCH study has
shown that cardiovascular risk factors, such as cholesterol, blood pressure, smoking,
high-risk glycemic control, and BMI, are associated with arterial stiffness in YYA with
T1D.151,152 Future research might consider the association between depressive symptoms
and these other risk factors for cardiovascular disease to gain a better understanding of
this relationship, specifically among YYA with T1D who are at increased risk of both
depressive symptoms and cardiovascular disease compared to their nondiabetic peers.
This study has several strengths, including a relatively large sample size of YYA
with T1D who have been followed prospectively over time, the use of a data-driven
approach, GBTM, to model trajectories of depressive symptoms, and the use of multiple
measures of PWV, including carotid-femoral PWV, which is the gold-standard measure
of arterial stiffness.22 In terms of limitations, our study did not ascertain whether
participants have received a diagnosis of clinical depression, time of onset of depressive
symptoms relative to the date of diabetes diagnosis, and did not collect information about
depression treatment other than through medications. There was also a large degree of
loss to follow-up during the average 8.2 years between the baseline visit and the cohort
visit, with only 44.6% of those eligible at baseline providing a measure of arterial
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stiffness. Additionally, those participants who were included had on average higher
family income and parental education and were more likely to use private health
insurance. Thus, these results cannot be generalized to all YYA with T1D. Additionally,
measures of arterial stiffness, including PWV, have not been used extensively in research
among pediatric and adolescent populations, and no standard range of PWV has been
established. Thus, it is difficult to evaluate clinically significant differences in PWV
measures. Finally, this study is limited by the small sample sizes in the trajectory groups
representing the greatest burden of depressive symptoms (n = 30, 22, and 19 for
decreasing mild to minimal, increasing mild to moderate, and chronic moderate,
respectively). Future research should include longer follow-up periods for the assessment
of arterial stiffness in YYA and attempt to recruit a larger sample size, particularly for
individuals who experience the greatest burden of depressive symptoms.
In conclusion, we found that depressive symptom trajectories are not associated
longitudinally with three measures of PWV among YYA with T1D. To our knowledge,
this is the first study to examine the association between depressive symptoms and
arterial stiffness in YYA with T1D, and the first study to assess this association using
depressive symptom trajectories as opposed to a single measure of depressive symptoms
Given the lack of association found in our study and the fact that prior research has
demonstrated mixed findings concerning the association between depressive symptoms
and various measures of subclinical cardiovascular disease, additional non-invasive,
subclinical measures of macrovascular disease, such as augmentation index, carotid
intima-media thickness, flow-mediated vasodilation, and coronary artery calcium, should
be collected in YYA with T1D to determine whether depressive symptoms are associated
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with other markers of cardiovascular risk in this population. Additionally, length of
follow-up among this sample should be increased to determine whether cardiovascular
changes become more common with age and whether these potential changes are related
to depressive symptom burden over time. The ultimate goal of this research should be to
determine whether depression is a modifiable risk factor of cardiovascular disease that
can be intervened upon early in the disease process to improve future health outcomes.
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Table 6.1: Baseline Characteristics for the Study Sample and by Depressive Symptom Trajectory Group
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Baseline CES-D* score
Age at baseline visit (years), mean (SD)
Age at diagnosis, mean (SD)
Female, n (%)
Race/Ethnicity, n (%)
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Parental Education, n (%)
High school degree or less
Some college
Bachelor’s degree or more
Family Income, n (%)
<$25,000
$25,000-$49,000
$50,000-$74,999
≥$75,000
Not Reported/Don’t Know
Health Insurance, n (%)

Total
(n= 537)
9.8 (8.1)
13.4 (2.4)
12.6 (2.4)
266 (49.5)

Little to
None
(n= 343)
6.0 (4.3)
13.5 (2.4)
12.6 (2.5)
164 (47.8)

Stable
Minimal
(n= 123)
12.0 (4.5)
13.3 (2.3)
12.5 (2.4)
59 (48.0)

Decreasing
Mild to
Minimal
(n= 30)
26.8 (7.9)
13.4 (2.5)
12.5 (2.5)
17 (56.7)

Increasing
Mild to
Moderate
(n= 22)
14.9 (5.8)
13.6 (2.4)
12.7 (2.5)
13 (59.1)

Chronic
Moderate
(n= 19)
31.2 (5.2)
14.0 (2.3)
13.1 (2.1)
13 (68.4)

408 (76.0)
66 (12.3)
52 (9.7)
11 (2.1)

279 (81.3)
28 (8.2)
29 (8.5)
7 (2.0)

81 (65.9)
24 (19.5)
16 (13.0)
2 (1.6)

18 (60.0)
10 (33.3)
1 (3.3)
1 (3.3)

15 (68.2)
2 (9.1)
4 (18.2)
1 (4.6)

15 (79.0)
2 (10.5)
2 (10.5)
.1)
0 (0)

91 (17.0)
195 (36.5)
248 (46.4)

44 (12.9)
111 (32.6)
186 (54.6)

28 (23.0)
57 (46.7)
37 (30.3)

6 (20.0)
11 (36.7)
13 (43.3)

8 (36.4)
8 (36.4)
6 (27.3)

5 (26.3)
8 (42.1)
6 (31.6)

66 (12.4)
104 (19.5)
117 (21.9)
208 (39.0)
39 (7.3)

29 (8.5)
52 (15.3)
76 (22.3)
161 (47.2)
23 (6.7)

20 (16.4)
33 (27.1)
25 (20.5)
36 (29.5)
8 (6.6)

10 (33.3)
6 (20.0)
6 (20.0)
4 (13.3)
4 (13.3)

4 (18.2)
9 (40.9)
5 (22.7)
3 (13.6)
1 (4.5)

3 (15.8)
4 (21.1)
5 (26.3)
4 (21.1)
3 (15.8)
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Private
Government-funded
Other/None
Family Structure, n (%)
Two-parent
Single-parent or Other
Baseline Diabetes Duration (months), mean
(SD)
Baseline HbA1c** (%), mean (SD)
Baseline Glycemic Control***, n (%)
Optimal
Suboptimal
High Risk
Insulin Regimen, n (%)
Insulin Pump
Basal/bolus injections
Other regimen
Use of psychiatric medications, n (%)
BMI z-score, mean (SD)
Ever tried cigarette smoking, n (%)
Number of days exercised in past week, mean
(SD)
DASH**** Diet Score, mean (SD)

438 (82.2)
77 (14.5)
18 (3.4)

297 (87.1)
36 (10.6)
8 (2.3)

94 (77.7)
20 (16.5)
7 (5.8)

18 (60.0)
10 (33.3)
2 (6.7)

14 (63.6)
7 (31.8)
1 (4.6)

15 (79.0)
4 (21.1)
0 (0)

360 (67.4)
174 (32.6)
9.4 (6.3)
7.6 (1.6)

245 (71.6)
97 (28.4)
9.3 (6.4)
7.5 (1.5)

78 (63.9)
44 (36.1)
9.1 (6.1)
7.6 (1.7)

17 (56.7)
13 (43.3)
9.8 (6.0)
8.5 (2.4)

8 (38.1)
13 (61.9)
11.0 (6.8)
7.8 (1.3)

12 (63.2)
7 (36.8)
9.6 (6.9)
7.8 (1.6)

265 (52.9)
157 (31.3)
79 (15.8)

174 (54.4)
105 (32.8)
41 (12.8)

62 (53.9)
32 (27.8)
21 (18.3)

10 (35.7)
10 (35.7)
8 (28.6)

11 (50.0)
5 (22.7)
6 (27.3)

8 (50.0)
5 (31.3)
3 (18.8)

48 (9.2)
189 (36.1)
287 (54.8)
19 (3.5)
0.6 (1.0)
78 (14.6)
3.5 (2.2)
41.7 (8.5)

32 (9.6)
114 (34.0)
189 (56.4)
7 (2.0)
0.5 (0.9)
32 (9.4)
3.5 (2.1)
41.8 (8.6)

9 (7.6)
49 (41.5)
60 (50.9)
4 (3.3)
0.8 (1.0)
25 (20.5)
3.9 (2.4)
40.8 (8.6)

3 (10.0)
15 (50.0)
12 (40.0)
2 (6.7)
0.8 (1.2)
9 (30.0)
3.9 (2.4)
38.6 (7.4)

1 (4.6)
7 (31.8)
14 (63.6)
3 (13.6)
0.3 (1.0)
5 (23.8)
2.7 (2.0)
47.8 (6.8)

3 (15.8)
4 (21.1)
12 (63.2)
3 (15.8)
0.9 (1.0)
7 (36.8)
2.6 (1.9)
42.5 (7.3)

*Center for Epidemiologic Studies – Depression, **Hemoglobin A1c, ***1) for ages < 18 years, <7.5% is optimal, 2) 7.5-9.0% is
suboptimal, and (3) >9.0% is high risk; for ages ≥18 years, 1) <7.0% is optimal, 2) 7.0-9.0% is suboptimal, and 3) >9.0% is high risk,
****Dietary Approach to Stop Hypertension

Table 6.2: Unadjusted and Adjusted Estimates from ANOVA and ANCOVA for Carotid-Femoral Pulse Wave Velocity by
Depressive Symptom Trajectory Group, n= 528

125

Little to None
(REF)
Mean (SE)

Stable
Minimal
Mean (SE), p

Decreasing Mild to
Minimal
Mean (SE), p

Increasing Mild to
Moderate
Mean (SE), p

Chronic Moderate
Mean (SE), p

Unadjusted

5.84 (0.07)

6.15 (0.11), 0.02

6.13 (0.22), 0.20

5.99 (0.26), 0.57

5.87 (0.29), 0.92

Adjustment 1

6.18 (0.12)

6.41 (0.14), 0.07

6.43 (0.23), 0.27

6.29 (0.26), 0.66

6.10 (0.30), 0.78

Adjustment 2

6.26 (0.16)

6.41 (0.17), 0.23

6.36 (0.25), 0.65

6.36 (0.29), 0.71

6.02 (0.32), 0.43

Adjustment 3

6.24 (0.18)

6.39 (0.18), 0.25

6.34 (0.25), 0.66

6.34 (0.30), 0.72

6.02 (0.32), 0.47

Adjustment 4

6.17 (0.23)

6.33 (0.23), 0.24

6.28 (0.29), 0.64

6.29 (0.32), 0.68

5.97 (0.34), 0.49

Adjustment 1 – age at diagnosis, sex, race/ethnicity, site; Adjustment 2 - age at diagnosis, sex, race/ethnicity, site, parental education,
household income, family structure, and health insurance status, BMI, tobacco use, physical activity; Adjustment 3 - age at diagnosis,
sex, race/ethnicity, site parental education, household income, family structure, and health insurance status, BMI, tobacco use,
physical activity, insulin regimen; Adjustment 4 - age at diagnosis, sex, race/ethnicity, site parental education, household income,
family structure, and health insurance status, BMI, tobacco use, physical activity, insulin regimen, psychiatric medications

Table 6.3: Unadjusted and Adjusted Estimates from ANOVA and ANCOVA for Carotid-Radial Pulse Wave Velocity by
Depressive Symptom Trajectory Group, n= 535
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Little to None
(REF)
Mean (SE)

Stable
Minimal
Mean (SE), p

Decreasing Mild to
Minimal
Mean (SE), p

Increasing Mild to
Moderate
Mean (SE), p

Chronic Moderate
Mean (SE), p

Unadjusted

7.61 (0.08)

7.86 (0.13), 0.11

8.06 (0.27), 0.11

7.67 (0.31), 0.86

7.72 (0.33), 0.75

Adjustment 1

8.01 (0.14)

8.13 (0.16), 0.42

8.23 (0.27), 0.40

7.88 (0.31), 0.66

8.21 (0.34), 0.54

Adjustment 2

8.02 (0.20)

8.15 (0.21), 0.43

8.17 (0.30), 0.58

7.84 (0.36), 0.59

8.20 (0.38), 0.62

Adjustment 3

8.14 (0.21)

8.26 (0.22), 0.46

8.26 (0.31), 0.67

7.97 (0.36), 0.61

8.27 (0.38), 0.71

Adjustment 4

8.15 (0.27)

8.26 (0.27), 0.47

8.27 (0.34), 0.67

7.98 (0.39), 0.61

8.27 (0.27), 0.72

Adjustment 1 – age at diagnosis, sex, race/ethnicity, site; Adjustment 2 - age at diagnosis, sex, race/ethnicity, site, parental education,
household income, family structure, and health insurance status, BMI, tobacco use, physical activity; Adjustment 3 - age at diagnosis,
sex, race/ethnicity, site parental education, household income, family structure, and health insurance status, BMI, tobacco use,
physical activity, insulin regimen; Adjustment 4 - age at diagnosis, sex, race/ethnicity, site parental education, household income,
family structure, and health insurance status, BMI, tobacco use, physical activity, insulin regimen, psychiatric medications

Table 6.4: Unadjusted and Adjusted Estimates from ANOVA and ANCOVA for Carotid-Foot Pulse Wave Velocity by
Depressive Symptom Trajectory Group, n= 510
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Little to None
(REF)
Mean (SE)

Stable
Minimal
Mean (SE), p

Decreasing Mild to
Minimal
Mean (SE), p

Increasing Mild to
Moderate
Mean (SE), p

Chronic Moderate
Mean (SE), p

Unadjusted

8.49 (0.08)

8.39 (0.13), 0.50

8.72 (0.26), 0.39

8.43 (0.31), 0.85

8.08 (0.33), 0.23

Adjustment 1

8.65 (0.14)

8.50 (0.16), 0.31

8.73 (0.27), 0.77

8.69 (0.32), 0.91

8.41 (0.34), 0.46

Adjustment 2

8.59 (0.21)

8.49 (0.21), 0.53

8.80 (0.30), 0.44

8.67 (0.37), 0.81

8.59 (0.21), 0.60

Adjustment 3

8.65 (0.22)

8.55 (0.22), 0.54

8.86 (0.31), 0.45

8.74 (0.38), 0.80

8.42 (0.39), 0.52

Adjustment 4

8.91 (0.28)

8.79 (0.28), 0.49

9.09 (0.34), 0.51

8.92 (0.40), 0.96

8.63 (0.41), 0.44

Adjustment 1 – age at diagnosis, sex, race/ethnicity, site; Adjustment 2 - age at diagnosis, sex, race/ethnicity, site, parental education,
household income, family structure, and health insurance status, BMI, tobacco use, physical activity; Adjustment 3 - age at diagnosis,
sex, race/ethnicity, site parental education, household income, family structure, and health insurance status, BMI, tobacco use,
physical activity, insulin regimen; Adjustment 4 - age at diagnosis, sex, race/ethnicity, site parental education, household income,
family structure, and health insurance status, BMI, tobacco use, physical activity, insulin regimen, psychiatric medications

a. Design of the SEARCH cohort study:
Incident cases:
2001

2002

2003

2004

2005

Baseline Baseline Baseline Baseline
Visit
Visit
Visit
Visit

2006
Baseline
Visit

2007

2008
Baseline
Visit

12-, 24, and 60-month follow-up visits

Minimum of baseline visit and 5 years
diabetes duration

Cohort
Visit

b. Sample Selection
1,203 Registered incident cases ages 10 and up at
the baseline visit (2002-2005) diagnosed with
type 1 diabetes and completed baseline visit
305 excluded (completed < 2 CES-D
measures)
898 with type 1 diabetes, baseline visit, and ≥2
CES-D measures
19 excluded (did not complete baseline CES-D)
879 with type 1 diabetes, baseline visit, and ≥2
CES-D measures including baseline included in
trajectory analysis

342 excluded (did not provide pulse wave
velocity at cohort visit)
537 with type 1 diabetes, baseline visit, ≥2 CES-D
measures including baseline, and > 1 measure of
pulse wave velocity at cohort visit included in
present analysis

Figure 6.1: SEARCH Study Design and Sample Recruitment
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CHAPTER 7
SUMMARY OF FINDINGS
The aims of this research were to identify longitudinal trajectories of depressive
symptoms experienced by YYA with T1D, to understand the baseline characteristics
associated with these trajectories, and to assess the effects of depressive symptom
trajectories on two health outcomes: glycemic control and arterial stiffness. We
conducted this research with the goals of characterizing the burden of depressive
symptoms in this population, examining factors that may be used to identify those at
greatest risk for experiencing clinically significant symptoms, and understanding health
outcomes of experiencing depressive symptoms among YYA with T1D.
Using data from YYA recently diagnosed with T1D who were enrolled in the
SEARCH for Diabetes in Youth Study between 2002-2005, we identified five depressive
symptom trajectories with GBTM based on CES-D scores collected at up to four
timepoints over a five-year period: little to no symptoms (63.2%), persistent minimal
(22.2%), increasing from mild to moderate (4.6%), decreasing from mild to minimal
(6.7%), and chronic moderate symptoms (3.3%). After adjustment for all covariates,
female gender, experiencing at least one severe hypoglycemic and/or diabetic
ketoacidosis episode, and living in a single-parent home were more common among
those who experienced clinically significant depressive symptoms compared to those who
experienced little to no depressive symptoms. Next, we found that depressive symptom
trajectories predicted
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glycemic control measured on average eight years after baseline, such that those with
stable minimal and decreasing mild to minimal symptoms had the greatest odds of highrisk glycemic control compared to those with little to no symptoms. Contrary to
expectations, those with the greatest burden of depressive symptoms (increasing mild to
moderate and chronic moderate) did not have statistically significantly greater odds of
high-risk glycemic control compared to those with little to no symptoms. Finally, we
found that there was no statistically significant association between depressive symptom
trajectories and arterial stiffness, as measured by three forms of PWV: carotid-femoral,
carotid-radial, and carotid-foot, on average eight years after baseline.
An important factor in interpreting these results is the timing of depressive
symptom measurement in relation to diabetes diagnosis. All participants were recently
diagnosed with T1D at the baseline measure of depressive symptoms; thus, we do not
have information about depressive symptom levels prior to diagnosis. It is possible that
some individuals experienced depressive symptoms prior to diagnosis, and these
symptoms either remained chronic, increased following diagnosis, or decreased following
diagnosis. It is also possible that some individuals did not experience clinically
significant depressive symptoms prior to diagnosis, but began to experience symptoms
following diagnosis, which may subsequently have become chronic, increased, or
decreased over time. Because we do not have this information, it is difficult to consider
etiologic origins of the five identified depressive symptom trajectories. Therefore, all
results must be interpreted with the caveat that our trajectories capture a snapshot of the
mental health history of each person - albeit a lengthy snapshot – that does not
necessarily include the point of onset of depressive symptoms.
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Although the results in relation to glycemic control and arterial stiffness were not
as we expected, the pattern of results was similar for both outcomes. We anticipated that
those with the greatest burden of depressive symptoms – increasing mild to moderate and
chronic moderate – would have both the greatest odds of high-risk glycemic control and
the greatest mean carotid-femoral PWV compared to those with a lesser burden of
depressive symptoms. Instead, we found that for both glycemic control and arterial
stiffness, those with stable minimal and those with decreasing mild to minimal depressive
symptoms demonstrated worse health outcomes, compared to those with little to no
symptoms, although the differences were not statistically significant for arterial stiffness.
This similar pattern of results for both outcomes supports the need for further research to
examine why these groups, which do not reflect clinically significant depressive
symptoms across time, experience potentially worse health outcomes compared to those
groups that do report clinically significant symptoms.
Limitations
This research has several limitations. The SEARCH study does not have data
concerning whether participants are seeing a psychologist or are receiving any type of
therapy for depression. Thus, we could not account for this form of treatment in the
analyses. Additionally, the SEARCH study also does not contain a measure of anxiety,
which is associated with depression, glycemic control, and arterial stiffness.8,117 The
measure of depressive symptoms were limited to that reflected in the CES-D, which is a
self-report screening tool used to measure experiences of depressive symptoms.72 Thus,
we did not have information about diagnoses of clinical depression, but were only able to
use the CES-D to identify those who may be at increased risk for clinical depression
based on the number and frequency of reported symptoms.72 Furthermore, because there
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was no measure of alcohol consumption at the baseline visit, we were unable to adjust for
this potential confounder in the analyses. Another potential limitation is the rate of loss to
follow-up in this sample. Previous studies utilizing data from the SEARCH cohort study
have reported that those with lower socioeconomic status are less likely to return for
follow-up visits, and we found this to be the case in the current analyses.45 Thus, our
results are not generalizable to the general SEARCH baseline population.
Strengths
Despite the above limitations, this study has many strengths. The SEARCH study
is a diverse cohort of youth with T1D, with a relatively large sample size. Additionally,
the SEARCH study has collected measures of depressive symptoms longitudinally, with
up to four measures contributing to trajectories in the present study. Because most prior
research investigating depressive symptoms in YYA with T1D has been cross-sectional
in nature, this investigation contributes to the literature examining the course of
depressive symptoms in this population as well as the association between depressive
symptoms and glycemic control. The use of longitudinal data enhanced the ability to
make causal inferences about the nature of the association between depressive symptoms
and both glycemic control and arterial stiffness compared to the existing literature
examining these questions.
Another strength of this study is the use of GBTM, an advanced statistical
method, which provides a data-driven approach to model depressive symptom
trajectories. This method allows for the identification of meaningful subgroups of
depressive symptoms within the population, rather than examining the mean change in
depressive symptoms over time. The use of simply the mean number of depressive
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symptoms over time may mask meaningful differences within the study population,
whereas the use of GBTM allows for the identification of distinct patterns, which were
differentially associated with both baseline predictors and glycemic control.
Another strength of this study was the use of multiple measures of PWV,
including the “gold standard” measure of carotid-femoral PWV in addition to two
peripheral measures (carotid-radial and carotid-foot) that are less documented in the
literature. The use of three measures allows for the assessment of similarities or
differences in associations between depressive symptom trajectories and each of the three
measures, which will contribute to the literature on arterial stiffness in adolescent
populations. We did not find any differences in the association between depressive
symptom trajectories and PWV among the three measures.
Public Health Implications
This study has implications for improving the understanding of the course,
predictors, and health outcomes of depressive symptoms among YYA with T1D. YYA
with T1D are at increased risk of a number of health outcomes, involving both physical
and mental health.13,20 Describing trajectories in the course of depressive symptoms over
time in this population contributes to the understanding of the burden of depressive
symptoms, and provides potential avenues for identifying those who are at greatest risk
for experiencing persistently high depressive symptoms during adolescence and emerging
adulthood. We found that most YYA with T1D do not experience clinically significant
depressive symptoms during the first five years following diabetes diagnosis; however,
around 8% reported either increasing mild to moderate symptoms or chronic moderate
symptoms during this timeframe. Therefore, it is important that YYA with T1D are
screened for depression during visits with their health provider and that appropriate
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resources are available to treat depression in this population. Particularly, we found that
females, those living in single-parent homes, those experiencing severe hypoglycemic
and/or diabetic ketoacidosis episodes are most likely to experience clinically significant
depressive symptoms. Additionally, those with lower socioeconomic status and those
with no health insurance were more likely to experience slightly elevated depressive
symptoms that did not reach clinical significance. Finally, those who reported having
tried cigarette smoking were more likely to report depressive symptoms at any level.
Thus, these groups of YYA with T1D should be closely monitored for the development
of depressive symptoms as they are at greatest risk for experiencing such symptoms.
This study also contributes to the understanding of health outcomes associated
with varied trajectories of depressive symptoms, particularly glycemic control and
arterial stiffness. Contrary to expectations, we found that those who experienced the
greatest burden of depressive symptoms over time did not have the worst highest mean
HbA1c or arterial stiffness. Rather, those with slightly elevated depressive symptoms that
either remained stable or decreased over time demonstrated the greatest odds of high-risk
glycemic control and there were no statistically significant differences in arterial
stiffness. Therefore, YYA with T1D who report slightly elevated depressive symptoms
should be followed closely by healthcare providers to ensure that diabetes selfmanagement guidelines are being followed to reduce the likelihood of high-risk glycemic
control in this population.
Recommendations for Future Research
In order to further investigate the burden of depressive symptoms among YYA
with T1D and to gain a better understanding of health outcomes associated with
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depressive symptoms, future research should focus on several key areas. First, collecting
data on depression and other mental health disorders experienced prior to diagnosis of
diabetes would help to differentiate between those who were already experiencing
depression prior to diabetes diagnosis and those who developed depressive symptoms
following diagnosis. This information would contribute to a better understanding of the
etiologic origins of depression in YYA with T1D and allow for the identification of those
whose depressive symptoms are triggered by diabetes diagnosis rather than preexisting.
Future research should also consider additional factors that may be influenced by
depressive symptoms, such as diabetes self-management adherence, emergency room
utilization and hospital visits, hypertension, and other diabetes complications such as
neuropathy, retinopathy, and kidney disease. It will be useful to understand whether the
pattern of results seen for glycemic control and arterial stiffness are similar for other
health outcomes, such that those who report mild to minimal depressive symptoms
experience worse outcomes compared to those who report moderate to severe depressive
symptoms. Finally, due to a lack of longitudinal research on depression and other mental
health comorbidities in YYA with T1D, further research should continue to investigate
how mental health comorbidities change over time in this population, including relevant
constructs such as depressive symptoms, anxiety, diabetes distress, and quality of life.
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APPENDIX A:
MODEL SELECTION FOR MINIMUM OF THREE CES-D MEASURES
Table A.1: Model Selection Procedure
n=586
Classes

BIC

AIC

1

-6787.48

-6780.92

2

-6567.38

-6554.26

3

-6494.76

-6475.08

4

-6474.49

-6448.25

5

-6467.51

-6434.71

6

-6474.98

-6435.62

Table A.2: Sample Size by Visit
Visit

N with CESD

Baseline
12 mo
24 mo
60 mo

586 (99.0)
515 (87.0)
489 (82.6)
415 (70.1)

N with visit, no
CESD
6 (1.0)
0
2 (0.3)
2 (0.3)

N with no visit

Table A.3: Accuracy of Trajectory Group Classification
Group

n

1
2
3
4
5

315
47
173
33
18

Average Posterior
Probability
0.88
0.77
0.73
0.78
0.96

Odds of Correct
Classification
7.33/1.07 = 6.85
3.35/0.092 = 36.4
2.70/.43 = 6.28
3.55/.071 = 50
24/.033 = 727
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0
77 (13.0)
101 (17.1)
175 (29.6)

Figure A.1: Predicted Depressive Symptom Trajectories
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APPENDIX B:
SUPPLEMENTAL TABLES FOR CHAPTER FOUR
Table B.1: Comparison of Included vs. Excluded Participants

Age at baseline visit (years), mean (sd)
Age at diagnosis (years), mean (sd)
Female, n (%)
Race/Ethnicity, n (%)
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Parental Education, n (%)
Less than high school
High school degree
Some college
Bachelor’s degree or more
Family Income, n (%)
<$25,000
$25,000-$49,000
$50,000-$74,999
≥$75,000
Not reported/Don’t Know
Health Insurance, n (%)
Private
Government-funded
Other
None
Family Structure
Two-parent
Single-parent
Other Structure

152

Included
(n = 879)
13.6 (2.40)

Excluded
(n = 324)
14.0 (2.5)

p-value

418 (47.6)

152 (46.9)

0.84

671 (76.3)
94 (10.7)
94 (10.7)
20 (2.3)

227 (70.1)
46 (14.2)
39 (12.0)
12 (3.7)

0.11

35 (4.0)
122 (13.9)
304 (34.7)
414 (47.3)

22 (7.1)
60 (19.4)
107 (34.5)
121 (39.0)

0.01

112 (12.8)
176 (20.1)
184 (21.1)
348 (39.8)

42 (13.5)
76 (24.4)
57 (18.3)
90 (28.9)

< 0.001

710 (81.4)
134 (15.4)
11 (1.3)
17 (1.9)

225 (72.1)
72 (23.1)
12 (3.9)
3 (0.9)

0.002

583 (66.6)
264 (30.2)
28 (3.2)

190 (61.1)
106 (34.1)
15 (4.8)

0.14

0.01

Table B.2: Missing Data Patterns

Pattern
1
2
3
4
5
6
7

n
229
177
103
91
77
95
107

%
Baseline
26.05
10.36
20.14
9.12
11.72
9.32
10.35
9.42
8.76
9.34
10.81
10.14
12.17
9.88

Mean CES-D Score
12 Month 24 Month
9.38
8.64
9.64
9.47
9.38 .
9.42 .
.
10.05
.
8.92
.
.

60 Month
9.33
.
9.66
.
9.27
.
10.93

Table B.3: Bayesian Information Criteria for Two through Six-Class Models
Classes

BIC

AIC

1

-8847.68

-8840.51

2

-8564.96

-8550.63

3

-8483.25

-8461.74

4

-8491.12

-8462.45

5

-8425.67

-8389.83

6

-8424.70

-8381.69

Table B.4: Average Posterior Probability and Odds of Correct Classification by
Trajectory Class Assignment
Class

n

1
2
3
4
5

577
186
49
37
30

Average Posterior
Probability
0.92
0.74
0.76
0.78
0.92
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Odds of Correct
Classification
6.7
10.0
44
74
336

Table B.5: Unadjusted odds ratios and 95% confidence intervals from multinomial logistic regression of baseline
characteristics predicting depressive symptom trajectory group

Age at baseline visit
Age at diagnosis
Sex (Female vs. Male)
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Race/Ethnicity (ref = NonHispanic White)
Non-Hispanic Black
Hispanic
Other
Parental Education (ref =
college graduate)
High School or Less
Some College
Family Income (ref =
<$25,000)
$25,000-$49,000
$50,000-$74,999
≥$75,000
Not Reported/Don’t Know
Health Insurance (ref=private)
Government-funded
Other/None
Family Structure (ref = two-

Little to
None
1.00
1.00
1.00

Stable
Minimal
0.97 (0.90 - 1.04)
0.97 (0.90 - 1.04)
1.42 (1.02 – 1.97)

Decreasing Mild
to Minimal
0.92 (0.81 - 1.04)
0.91 (0.80 - 1.04)
2.05 (1.13 – 3.73)

Increasing Mild to
Moderate
1.02 (0.89 - 1.17)
1.00 (0.87 - 1.14)
1.53 (0.78 – 3.00)

Chronic Moderate
1.13 (0.98 - 1.30)
1.12 (0.97 - 1.29)
2.60 (1.20 – 5.65)

1.00
1.00
1.00

1.99 (1.20 - 3.32)
1.92 (1.16 - 3.18)
1.03 (0.33 - 3.19)

3.44 (1.67 - 7.08)
0.83 (0.24 - 2.79)
1.00 (0.13 - 7.86)

1.09 (0.32 - 3.73)
2.44 (1.01 - 5.91)
1.27 (0.16 - 10.05)

1.35 (0.39 - 4.69)
2.59 (1.00 - 6.72)
-----

1.00
1.00

2.69 (1.70 – 4.27)
2.52 (1.72 - 3.70)

1.94 (0.90 - 4.17)
1.45 (0.75 -2.83)

3.69 (1.49 - 9.17)
3.05 (1.37 - 6.81)

2.96 (1.13 – 7.72)
2.15 (0.91 - 5.09)

1.00
1.00
1.00
1.00

0.89 (0.51 - 1.56)
0.55 (0.31 - 0.97)
0.41 (0.24 - 0.69)
0.41 (0.17 - 1.00)

0.26 (0.10 - 0.63)
0.29 (0.13, 0.65)
0.10 (0.04 - 0.23)
0.45 (0.15 - 1.34)

1.09 (0.42 - 2.87)
0.38 (0.12 - 1.18)
0.23 (0.08 - 0.67)
0.44 (0.09 - 2.25)

0.82 (0.22 - 3.03)
0.89 (0.26 - 3.07)
0.41 (0.12 - 1.41)
1.54 (0.36 - 6.58)

1.00
1.00

1.70 (1.09 - 2.67)
3.27 (1.66 - 6.47)
3.19 (1.33 – 7.66) 7.44 (2.43 – 22.79)

3.09 (1.46 - 6.55)
1.79 (0.22 - 14.38)

1.46 (0.54 - 3.95)
1.86 (0.23 – 15.00)
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parent)
Single-Parent/Other
Baseline Diabetes Duration
(months)
Baseline HbA1c (%)
Baseline Glycemic Control
(ref = optimal)
Suboptimal
High Risk
Severe hypoglycemic episode
in past 6 mos (ref = no)
DKA episodes in past 6 mos
(ref = no)
Frequency of blood glucose
monitoring (ref = <1/day)
3 times per day
≥4 times per day
Insulin Regimen (ref = pump)
Basal/bolus injections
Other regimen
Use of psychiatric
medications (ref = no)
BMI z-score
Ever tried cigarette (ref = no)
Days exercised in past week

1.22 (0.86 - 1.74)
1.00 (0.97 - 1.02)

2.97 (1.65 - 5.37)
1.01 (0.96 - 1.05)

3.81 (1.90 - 7.62)
1.04 (0.99 - 1.09)

1.85 (0.88 – 3.90)
1.02 (0.97 - 1.08)

1.00

1.13 (1.02 - 1.25)

1.31 (1.12 - 1.52)

1.19 (1.00 - 1.43)

1.13 (0.90 - 1.42)

1.00
1.00

1.23 (0.83 - 1.82)
2.06 (1.30 - 3.27)
1.66 (0.89 - 3.11)

1.57 (0.77 - 3.23)
3.52 (1.66 - 7.48)
1.14 (0.34 - 3.89)

1.22 (0.56 - 2.70)
2.67 (1.16 - 6.13)
1.00 (0.23 - 4.36)

0.82 (0.31 - 2.20)
1.97 (0.72 - 5.37)
5.34 (2.13 - 13.41)

1.15 (0.75 - 1.78)

1.31 (0.63 - 2.72)

0.99 (0.40 - 2.44)

3.41 (1.59 - 7.32)

1.86 (0.84 – 4.13)
1.11 (0.57 – 2.16)

0.69 (0.17 – 2.73)
0.73 (0.27 – 1.94)

1.15 (0.24 – 5.41)
0.91 (0.27 – 3.11)

6.02 (0.71 – 50.8)
1.82 (0.24 – 13.91)

1.13 (0.62 - 2.06)
0.83 (0.46 - 1.49)
1.45 (0.54 - 3.86)

1.43 (0.47 - 4.37)
1.02 (0.34 - 3.04)
1.85 (0.41 - 8.43)

2.58 (0.32 - 20.81)
4.23 (0.56 - 31.81)
6.78 (2.28 - 20.19)

0.76 (0.20 - 2.98)
0.98 (0.28 - 3.43)
10.85 (3.80 – 31.0)

1.28 (1.07 - 1.54)
1.79 (1.12 - 2.87)
0.99 (0.92 - 1.06)

1.41 (1.02 - 1.96)
3.21 (1.61 - 6.39)
1.02 (0.90 - 1.16)

1.01 (0.71 - 1.45)
3.42 (1.57 - 7.44)
0.80 (0.68 - 0.93)

1.37 (0.90 - 2.09)
5.14 (2.33 - 11.33)
0.81 (0.68 - 0.96)

1.00
1.00

1.00
1.00

1.00
1.00
1.00
1.00
1.00
1.00

APPENDIX C:
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Table C.1: Comparison of Included and Excluded Participants

Age at baseline visit (years), mean (sd)
Age at diagnosis (years), mean (sd)
Depressive Symptom Trajectory Group
Little to No Symptoms
Stable Minimal
Decreasing Mild to Minimal
Increasing Mild to Moderate
Chronic Moderate
Female, n (%)
Race/Ethnicity, n (%)
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Parental Education, n (%)
High school degree or less
Some college
Bachelor’s degree or more
Family Income, n (%)
<$25,000
$25,000-$49,000
$50,000-$74,999
≥$75,000
Not reported/Don’t Know
Health Insurance, n (%)
Private
Government-funded
Other/None

Excluded
(n = 308)
13.7 (2.4)
12.9 (2.4)

Included
(n = 571)
13.5 (2.4)
12.7 (2.4)

218 (70.8)
50 (16.2)
18 (5.8)
14 (4.6)
8 (2.6)
132 (42.9)

359 (62.9)
136 (23.8)
31 (5.4)
23 (4.0)
22 (3.9)
286 (50.1)

242 (78.6)
25 (8.1)
32 (10.4)
9 (2.9)

429 (75.1)
69 (12.1)
62 (10.9)
11 (1.9)

p-value
0.11
0.19
0.08

0.04
0.24

0.61
60 (19.5)
102 (33.2)
145 (47.2)

97 (17.1)
202 (35.6)
269 (47.4)

42 (13.7)
63 (20.6)
59 (19.3)
127 (41.5)
15 (4.9)

70 (12.3)
113 (19.9)
125 (22.0)
221 (38.9)
39 (6.9)

0.62

0.82
245 (80.3)
50 (16.4)
10 (3.3)
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465 (82.0)
84 (14.8)
18 (3.2)

Family Structure
Two-parent
Single-parent/Other structure

0.49
200 (65.2)
107 (34.9)

157

383 (67.4)
185 (32.6)

Table C.2: Glycemic Control for the Sample and by Depressive Symptom Trajectory Group
HbA1c*, mean
(SD)

Glycemic Control, n (%)
Optimal

Total

Suboptimal

High Risk

158

9.08 (2.01)

81 (14.2)

216 (37.8)

274 (48.0)

Little to None

8.75 (1.87)

66 (18.4)

145 (40.4)

148 (41.2)

Stable Minimal

9.65 (2.05)

6 (4.4)

49 (36.0)

81 (59.6)

Decreasing Mild to Minimal

9.79 (2.62)

6 (19.4)

5 (16.1)

20 (64.5)

Increasing Mild to Moderate

9.63 (1.86)

0 (0)

10 (43.5)

13 (56.5)

Chronic Moderate

9.25 (2.10)

3 (13.6)

7 (31.8)

12 (54.6)

*Hemoglobin A1c

Table C.3: Unadjusted and Adjusted Estimates from ANOVA and ANCOVA for Continuous HbA1c by Depressive Symptom
Trajectory Group Excluding Those Using Psychiatric Medications
Little to None
(REF)
Mean (SE)

Stable
Minimal
Mean (SE), p

Decreasing Mild to
Minimal
Mean (SE), p

Increasing Mild to
Moderate
Mean (SE), p

Unadjusted

8.75 (0.10)

9.70 (0.17), <0.001

9.70 (0.36), 0.01

9.80 (0.44), 0.02

9.39 (0.45), 0.17

Adjustment 1

9.10 (0.19)

9.86 (0.22), <0.01

9.79 (0.37), 0.06

10.05 (0.44), 0.03

9.68 (0.48), 0.21

Adjustment 2

9.36 (0.27)

9.92 (0.28), 0.01

9.93 (0.41), 0.14

9.98 (0.50), 0.21

9.78 (0.51), 0.38

Adjustment 3

9.26 (0.28)

9.84 (0.29), 0.01

9.90 (0.42), 0.10

9.87 (0.52), 0.21

9.67 (0.52), 0.40

Chronic Moderate
Mean (SE), p

159

Adjustment 1 – age at diagnosis, sex, race/ethnicity, site; Adjustment 2 - age at diagnosis, sex, race/ethnicity, site, parental education,
household income, family structure, and health insurance status, BMI, tobacco use, physical activity; Adjustment 3 - age at diagnosis,
sex, race/ethnicity, site parental education, household income, family structure, and health insurance status, BMI, tobacco use,
physical activity, insulin regimen

Table C.4: Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals for High-Risk Glycemic Control from
Logistic Regression Excluding Those Using Psychiatric Medications
Little to None
(REF)

Stable
Minimal

Decreasing Mild to
Minimal

Increasing Mild to
Moderate

Chronic Moderate

Unadjusted

-----

2.16 (1.44 – 3.25)

2.30 (1.05 – 5.01)

2.11 (0.84 – 5.28)

2.41 (0.93 – 6.26)

Adjustment 1

-----

1.94 (1.25 – 3.01)

1.97 (0.87 – 4.45)

2.08 (0.76 – 5.73)

2.42 (0.86 – 6.78)

Adjustment 2

-----

1.60 (1.00 – 2.55)

2.06 (0.86 – 4.96)

1.88 (0.60 – 5.88)

2.38 (0.74 – 7.62)

Adjustment 3

-----

1.71 (1.07 – 2.72)

2.26 (0.92 – 5.50)

1.78 (0.58 – 5.41)

2.66 (0.84 – 8.40)
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Adjustment 1 – age at diagnosis, sex, race/ethnicity, site; Adjustment 2 - age at diagnosis, sex, race/ethnicity, site, parental education,
household income, family structure, and health insurance status, BMI, tobacco use, physical activity; Adjustment 3 - age at diagnosis,
sex, race/ethnicity, site parental education, household income, family structure, and health insurance status, BMI, tobacco use,
physical activity, insulin regimen

APPENDIX D:
SUPPLEMENTAL TABLE FOR CHAPTER 6
Table D.1: Comparison of Included and Excluded Participants

Age at baseline visit (years), mean (sd)
Age at diagnosis (years), mean (sd)
Depressive Symptom Trajectory Group
Little to No Symptoms
Stable Minimal
Decreasing Mild to Minimal
Increasing Mild to Moderate
Chronic Moderate
Female, n (%)
Race/Ethnicity, n (%)
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Parental Education, n (%)
High school degree or less
Some college
Bachelor’s degree or more
Family Income, n (%)
<$25,000
$25,000-$49,000
$50,000-$74,999
≥$75,000
Not reported/Don’t Know
Health Insurance, n (%)
Private
Government-funded
Other/None

Excluded
(n = 342)
13.8 (2.4)
12.9 (2.4)

Included
(n = 537)
13.4 (2.4)
12.6 (2.4)

234 (68.4)
63 (18.4)
19 (5.6)
15 (4.4)
11 (3.2)
152 (44.4)

343 (63.9)
123 (22.9)
30 (5.6)
22 (4.1)
19 (3.5)
266 (49.5)

263 (76.9)
28 (8.2)
42 (12.3)
9 (2.6)

408 (76.0)
66 (12.3)
52 (9.7)
11 (2.1)

p-value
0.05
0.10
0.60

0.14
0.17

0.35
66 (19.4)
109 (32.0)
166 (48.7)

91 (17.0)
195 (36.5)
248 (46.4)

46 (13.5)
72 (21.2)
67 (19.7)
140 (41.2)
15 (4.9)

66 (12.4)
104 (19.5)
117 (21.9)
208 (39.0)
39 (6.9)

0.40

0.62
272 (80.2)
57 (16.8)
10 (3.0)

161

438 (82.2)
77 (14.5)
18 (3.4)

Family Structure
Two-parent
Single-parent/Other structure

0.54
223 (65.4)
118 (34.6)

162

360 (67.4)
174 (32.6)

